,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,179,1,1,,113379,4173,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
1,188,1,1,,102189,4173,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in CD2F1 (CDF1) mice,Other,,
2,192,1,1,,113379,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
3,194,1,1,,113379,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
4,200,1,1,,113379,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
5,210,1,1,,113379,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
6,212,1,1,,113379,4173,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
7,222,1,1,,113379,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in C57BL/6 mice,Other,,
8,256,1,1,,113379,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
9,270,1,1,,113379,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
10,274,1,1,,113379,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6D2F1 (BDF1) mice,Other,,
11,288,1,1,,113379,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
12,328,1,1,,113379,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
13,330,1,1,,102189,4173,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
14,330,1,1,,113379,4173,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
15,357,2,1,,855672,4173,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
16,357,2,1,,11112343,4173,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
17,361,1,2,,855672,4173,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
18,364,1,3,,855672,4173,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
19,368,2,3,,855672,4173,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
20,371,1,1,,855672,4173,Inactive,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
21,373,1,4,,855672,4173,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
22,374,2,3,,855672,4173,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
23,375,2,3,,855672,4173,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
24,377,1,3,,10321393,4173,Inactive,42741659.0,5243.0,,,MDR-1,Other,,
25,410,1,5,,11112343,4173,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
26,411,2,1,,855672,4173,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
27,411,2,1,,11112343,4173,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
28,421,1,3,,17389815,4173,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
29,422,1,5,,855672,4173,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
30,425,3,2,,855672,4173,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
31,426,1,2,,17389815,4173,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
32,427,1,1,,17389815,4173,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
33,429,1,5,,855672,4173,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
34,429,1,5,,855672,4173,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
35,430,2,4,,855672,4173,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
36,431,2,4,,855672,4173,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
37,432,2,4,,855672,4173,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
38,433,1,1,,17389815,4173,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
39,434,1,2,,17389815,4173,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
40,435,1,2,,17389815,4173,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
41,436,2,1,,855672,4173,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
42,438,1,4,,855672,4173,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
43,440,3,3,,855672,4173,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
44,441,3,3,,855672,4173,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
45,444,1,1,,855672,4173,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
46,444,1,1,,11112343,4173,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
47,445,3,1,,11112343,4173,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
48,445,3,1,,17389815,4173,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
49,446,1,1,,855672,4173,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
50,446,1,1,,11112343,4173,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
51,447,1,1,,11112343,4173,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
52,448,1,2,,11112343,4173,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
53,449,1,5,,855672,4173,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
54,450,1,2,,855672,4173,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
55,450,1,2,,11112343,4173,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
56,451,1,2,,11112343,4173,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
57,453,2,2,,855672,4173,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
58,454,1,7,,855672,4173,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
59,455,1,7,,855672,4173,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
60,456,1,7,,855672,4173,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
61,457,1,7,,855672,4173,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
62,460,2,2,,855672,4173,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
63,461,1,7,,855672,4173,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression,Screening,,
64,483,1,6,,855672,4173,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
65,485,1,8,,855672,4173,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
66,485,1,8,,26719631,4173,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
67,487,1,2,,855672,4173,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
68,488,2,1,,855672,4173,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
69,501,2,2,,855672,4173,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
70,518,2,6,,855672,4173,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
71,521,2,5,,855672,4173,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
72,522,1,2,,855672,4173,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
73,524,1,3,,855672,4173,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
74,525,1,3,,855672,4173,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
75,526,1,1,,11112343,4173,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
76,527,3,1,,855672,4173,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
77,528,1,4,,855672,4173,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
78,529,1,4,,855672,4173,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
79,530,1,1,,11112343,4173,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
80,530,1,1,,17389815,4173,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
81,538,2,2,,855672,4173,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
82,539,1,2,,855672,4173,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
83,540,1,1,,17389815,4173,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
84,541,1,1,,17389815,4173,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
85,542,1,1,,17389815,4173,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
86,543,1,1,,17389815,4173,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
87,544,2,1,,17389815,4173,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
88,545,1,1,,17389815,4173,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
89,546,1,1,,17389815,4173,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
90,552,1,3,,855672,4173,Inactive,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
91,555,1,2,,855672,4173,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
92,556,1,3,,855672,4173,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
93,559,2,2,,855672,4173,Inactive,147728.0,,,,RNA polymerase,Screening,,
94,560,1,2,,855672,4173,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
95,561,1,3,,855672,4173,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
96,565,1,4,,855672,4173,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
97,567,1,4,,855672,4173,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
98,568,1,7,,855672,4173,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
99,568,1,7,,855672,4173,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
100,570,1,4,,855672,4173,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
101,571,1,4,,855672,4173,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
102,572,1,5,,855672,4173,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
103,573,1,4,,855672,4173,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
104,574,1,3,,855672,4173,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
105,575,1,4,,855672,4173,Inactive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
106,576,1,2,,855672,4173,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
107,577,1,1,,855672,4173,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
108,580,1,5,,855672,4173,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
109,581,2,2,,855672,4173,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
110,583,2,6,,855672,4173,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
111,584,1,3,,11112343,4173,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
112,584,1,3,,17389815,4173,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
113,585,1,4,,11112343,4173,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
114,585,1,4,,17389815,4173,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
115,587,1,5,,855672,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
116,587,1,5,,11112343,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
117,588,1,4,,855672,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
118,588,1,4,,11112343,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
119,589,1,3,,855672,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
120,589,1,3,,11112343,4173,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
121,590,1,3,,855672,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
122,590,1,3,,11112343,4173,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
123,591,1,4,,855672,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
124,591,1,4,,11112343,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
125,592,1,6,,855672,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
126,592,1,6,,11112343,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
127,593,1,4,,855672,4173,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
128,593,1,4,,11112343,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
129,594,1,4,,855672,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
130,594,1,4,,11112343,4173,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
131,595,1,3,,11112343,4173,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
132,595,1,3,,17389815,4173,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
133,596,1,2,,11112343,4173,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
134,596,1,2,,17389815,4173,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
135,597,1,3,,855672,4173,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
136,597,1,3,,11112343,4173,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
137,598,1,4,,855672,4173,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
138,601,1,4,,855672,4173,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
139,602,1,4,,855672,4173,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
140,603,1,2,,11112343,4173,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
141,603,1,2,,17389815,4173,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
142,604,1,3,,855672,4173,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
143,605,1,2,,11112343,4173,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
144,605,1,2,,17389815,4173,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
145,606,1,3,,855672,4173,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
146,606,1,3,,855672,4173,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
147,607,1,3,,11112343,4173,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
148,609,1,2,,855672,4173,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
149,614,1,6,,855672,4173,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
150,615,1,6,,855672,4173,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
151,618,2,6,,855672,4173,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
152,620,2,5,,855672,4173,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
153,622,1,2,,855672,4173,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
154,623,1,3,,855672,4173,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
155,624,1,2,,855672,4173,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
156,625,1,2,,855672,4173,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
157,626,1,3,,855672,4173,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
158,628,2,4,,855672,4173,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
159,629,1,3,,855672,4173,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
160,630,1,1,,855672,4173,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
161,631,1,4,,855672,4173,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
162,631,1,4,,855672,4173,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
163,631,1,4,,26719631,4173,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
164,631,1,4,,26719631,4173,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
165,633,1,3,,855672,4173,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
166,639,1,2,,855672,4173,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
167,641,1,4,,855672,4173,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
168,645,1,4,,855672,4173,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
169,648,1,3,,855672,4173,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
170,654,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
171,655,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
172,656,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
173,657,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
174,658,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
175,659,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
176,660,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
177,661,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
178,662,1,1,,11112343,4173,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
179,662,1,1,,17389815,4173,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
180,663,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
181,664,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
182,665,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
183,666,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
184,667,1,1,,17389815,4173,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
185,680,1,10,,855672,4173,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
186,684,1,12,,855672,4173,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
187,686,1,1,,855672,4173,Inactive,,,,,Zebrafish Lipid Metabolism Assay---Primary Screen,Screening,,
188,687,1,17,,855672,4173,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
189,701,1,17,,855672,4173,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
190,708,1,4,,855672,4173,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
191,709,1,2,,855672,4173,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
192,719,1,3,,855672,4173,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
193,731,1,5,,855672,4173,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
194,731,1,5,,855672,4173,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
195,731,1,5,,26719631,4173,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
196,731,1,5,,26719631,4173,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
197,746,1,1,,855672,4173,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
198,750,1,3,,855672,4173,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
199,751,1,3,,855672,4173,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
200,757,1,4,,855672,4173,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
201,758,1,4,,855672,4173,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
202,759,1,4,,855672,4173,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
203,760,1,4,,855672,4173,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
204,761,1,4,,855672,4173,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
205,764,1,4,,855672,4173,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
206,770,1,1,,855672,4173,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
207,771,1,2,,855672,4173,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
208,772,1,2,,855672,4173,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
209,774,1,2,,855672,4173,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
210,775,1,3,,855672,4173,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
211,781,1,1,,855672,4173,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
212,781,1,1,,26719631,4173,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
213,782,1,2,,855672,4173,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
214,782,1,2,,855672,4173,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
215,782,1,2,,26719631,4173,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
216,782,1,2,,26719631,4173,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
217,793,1,2,,855672,4173,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
218,795,1,1,,855672,4173,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
219,797,1,1,,855672,4173,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
220,798,2,12,,855672,4173,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
221,799,1,5,,855672,4173,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
222,800,2,11,,855672,4173,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
223,803,1,4,,855672,4173,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
224,804,1,3,,855672,4173,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
225,813,1,4,,855672,4173,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
226,817,1,1,,855672,4173,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
227,818,1,2,,855672,4173,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
228,827,1,2,,855672,4173,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
229,828,1,5,,855672,4173,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
230,834,1,3,,855672,4173,Inactive,,,,,C. albicans biofilm killing,Screening,,
231,841,1,1,,855672,4173,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
232,847,1,2,,855672,4173,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
233,861,1,1,,855672,4173,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
234,862,1,2,,855672,4173,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
235,868,1,3,,855672,4173,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
236,871,1,2,,855672,4173,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
237,873,1,13,,855672,4173,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
238,875,1,2,,11112343,4173,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
239,875,1,2,,17389815,4173,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
240,878,1,2,,855672,4173,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
241,880,2,1,,855672,4173,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
242,880,2,1,,855672,4173,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
243,880,2,1,,11112343,4173,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
244,880,2,1,,11112343,4173,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
245,880,2,1,,17389815,4173,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
246,880,2,1,,17389815,4173,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
247,880,2,1,,26719631,4173,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
248,880,2,1,,26719631,4173,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
249,880,2,1,,26746949,4173,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
250,880,2,1,,26746949,4173,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
251,881,2,2,,11112343,4173,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
252,881,2,2,,17389815,4173,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
253,883,1,3,,11112343,4173,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
254,884,1,2,,11112343,4173,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
255,884,1,2,,17389815,4173,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
256,885,1,2,,11112343,4173,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
257,885,1,2,,17389815,4173,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
258,886,1,2,,11112343,4173,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
259,886,1,2,,11112343,4173,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
260,886,1,2,,17389815,4173,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
261,886,1,2,,17389815,4173,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
262,887,1,2,,11112343,4173,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
263,887,1,2,,17389815,4173,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
264,889,1,3,,11112343,4173,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
265,889,1,3,,17389815,4173,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
266,891,1,2,,11112343,4173,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
267,892,1,2,,11112343,4173,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
268,892,1,2,,17389815,4173,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
269,893,1,2,,11112343,4173,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
270,893,1,2,,11112343,4173,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
271,893,1,2,,17389815,4173,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
272,893,1,2,,17389815,4173,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
273,894,2,1,,855672,4173,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
274,894,2,1,,11112343,4173,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
275,894,2,1,,17389815,4173,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
276,894,2,1,,26746949,4173,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
277,898,1,1,,855672,4173,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
278,899,1,2,,11112343,4173,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
279,900,1,3,,11112343,4173,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
280,900,1,3,,17389815,4173,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
281,901,1,2,,11112343,4173,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
282,902,1,2,,11112343,4173,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
283,902,1,2,,17389815,4173,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
284,910,1,2,,17389815,4173,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
285,912,1,2,,11112343,4173,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
286,912,1,2,,17389815,4173,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
287,914,1,3,,855672,4173,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
288,914,1,3,,11112343,4173,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
289,915,1,3,,855672,4173,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
290,915,1,3,,11112343,4173,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
291,920,1,2,,855672,4173,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
292,921,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
293,923,1,2,,11112343,4173,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
294,923,1,2,,17389815,4173,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
295,924,1,2,,11112343,4173,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
296,924,1,2,,17389815,4173,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
297,925,1,2,,11112343,4173,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
298,925,1,2,,17389815,4173,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
299,926,1,2,,11112343,4173,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
300,926,1,2,,17389815,4173,Inconclusive,38016895.0,7253.0,15.8489,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
301,927,1,3,,11112343,4173,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
302,927,1,3,,17389815,4173,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
303,930,1,2,,17389815,4173,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
304,932,1,4,,855672,4173,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
305,938,1,2,,11112343,4173,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
306,938,1,2,,17389815,4173,Inactive,38016895.0,7253.0,15.8489,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
307,940,1,2,,855672,4173,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
308,940,1,2,,26611824,4173,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
309,946,1,2,,17389815,4173,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
310,947,1,2,,17389815,4173,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
311,948,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
312,950,1,1,,855672,4173,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
313,950,1,1,,26719631,4173,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
314,951,1,1,,855672,4173,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
315,951,1,1,,26719631,4173,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
316,952,1,1,,855672,4173,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
317,952,1,1,,26719631,4173,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
318,955,1,2,,17389815,4173,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
319,960,1,2,,17389815,4173,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
320,961,1,2,,17389815,4173,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
321,962,1,2,,17389815,4173,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
322,963,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
323,964,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
324,965,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
325,966,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
326,967,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
327,968,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
328,969,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
329,970,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
330,971,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
331,972,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
332,973,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
333,974,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
334,975,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
335,976,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
336,977,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
337,978,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
338,979,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
339,980,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
340,981,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
341,982,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
342,983,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
343,984,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
344,985,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
345,986,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
346,987,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
347,988,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
348,989,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
349,993,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
350,994,1,2,,17389815,4173,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
351,995,1,2,,11112343,4173,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
352,995,1,2,,17389815,4173,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
353,1001,2,2,,855672,4173,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
354,1001,2,2,,26719631,4173,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
355,1006,1,6,,855672,4173,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
356,1006,1,6,,26719631,4173,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
357,1007,1,1,,855672,4173,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
358,1007,1,1,,26719631,4173,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
359,1008,1,2,,855672,4173,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
360,1008,1,2,,26719631,4173,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
361,1009,1,2,,855672,4173,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
362,1009,1,2,,26719631,4173,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
363,1012,1,4,,855672,4173,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
364,1012,1,4,,26719631,4173,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
365,1016,1,4,,855672,4173,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
366,1016,1,4,,26719631,4173,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
367,1018,2,5,,855672,4173,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
368,1018,2,5,,26719631,4173,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
369,1019,1,4,,855672,4173,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
370,1019,1,4,,26719631,4173,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
371,1020,1,5,,855672,4173,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
372,1020,1,5,,26719631,4173,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
373,1021,1,1,,855672,4173,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
374,1021,1,1,,26719631,4173,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
375,1022,1,1,,855672,4173,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
376,1022,1,1,,26719631,4173,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
377,1027,1,3,,855672,4173,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
378,1027,1,3,,26719631,4173,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
379,1030,2,1,,855672,4173,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
380,1030,2,1,,11112343,4173,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
381,1030,2,1,,17389815,4173,Active,30582681.0,216.0,7.9433,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
382,1030,2,1,,26746949,4173,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
383,1032,1,2,,855672,4173,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
384,1032,1,2,,855672,4173,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
385,1032,1,2,,26719631,4173,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
386,1032,1,2,,26719631,4173,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
387,1040,1,2,,855672,4173,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
388,1040,1,2,,26719631,4173,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
389,1046,1,6,,855672,4173,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
390,1048,1,1,,855672,4173,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
391,1048,1,1,,855672,4173,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
392,1048,1,1,,26719631,4173,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
393,1048,1,1,,26719631,4173,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
394,1049,1,1,,855672,4173,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
395,1049,1,1,,855672,4173,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
396,1049,1,1,,26719631,4173,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
397,1049,1,1,,26719631,4173,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
398,1051,1,1,,855672,4173,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
399,1051,1,1,,855672,4173,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
400,1051,1,1,,26719631,4173,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
401,1051,1,1,,26719631,4173,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
402,1063,1,1,,855672,4173,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
403,1066,1,2,,855672,4173,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
404,1066,1,2,,26719631,4173,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
405,1085,1,1,,855672,4173,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
406,1085,1,1,,26719631,4173,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
407,1135,1,3,,855672,4173,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
408,1135,1,3,,26719631,4173,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
409,1136,1,3,,855672,4173,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
410,1136,1,3,,26719631,4173,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
411,1189,1,5,,48414062,4173,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
412,1194,1,3,,48414062,4173,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
413,1195,1,2,,48416271,4173,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
414,1199,1,3,,48414062,4173,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
415,1203,1,3,,855672,4173,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
416,1203,1,3,,26719631,4173,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
417,1205,1,4,,48414062,4173,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
418,1208,1,3,,48414062,4173,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
419,1209,2,2,,855672,4173,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
420,1209,2,2,,26719631,4173,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
421,1214,1,4,,855672,4173,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
422,1214,1,4,,26719631,4173,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
423,1216,1,5,,855672,4173,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
424,1216,1,5,,26719631,4173,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
425,1217,1,4,,855672,4173,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
426,1217,1,4,,26719631,4173,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
427,1220,2,2,,855672,4173,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
428,1220,2,2,,26719631,4173,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
429,1222,1,6,,855672,4173,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
430,1222,1,6,,26719631,4173,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
431,1229,1,3,,855672,4173,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
432,1229,1,3,,26719631,4173,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
433,1235,1,2,,855672,4173,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
434,1236,1,1,,855672,4173,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
435,1236,1,1,,26719631,4173,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
436,1239,1,3,,855672,4173,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
437,1239,1,3,,855672,4173,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
438,1242,1,1,,855672,4173,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
439,1251,1,1,,855672,4173,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
440,1251,1,1,,26719631,4173,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
441,1273,1,1,,855672,4173,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
442,1274,1,2,,855672,4173,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
443,1274,1,2,,26719631,4173,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
444,1276,1,1,,855672,4173,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
445,1285,1,1,,855672,4173,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
446,1296,1,1,,855672,4173,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
447,1304,1,2,,855672,4173,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
448,1304,1,2,,26719631,4173,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
449,1321,1,2,,855672,4173,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
450,1321,1,2,,26719631,4173,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
451,1325,1,2,,855672,4173,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
452,1325,1,2,,26719631,4173,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
453,1326,1,4,,855672,4173,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
454,1332,1,1,,49698715,4173,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
455,1359,1,4,,855672,4173,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
456,1359,1,4,,26719631,4173,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
457,1362,1,2,,855672,4173,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
458,1362,1,2,,26719631,4173,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
459,1376,1,2,,855672,4173,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
460,1377,1,1,,855672,4173,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
461,1379,1,2,,855672,4173,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
462,1379,1,2,,11112343,4173,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
463,1379,1,2,,26746949,4173,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
464,1381,1,1,,855672,4173,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
465,1385,2,2,,855672,4173,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
466,1415,1,2,,855672,4173,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
467,1415,1,2,,855672,4173,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
468,1415,1,2,,26719631,4173,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
469,1415,1,2,,26719631,4173,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
470,1416,1,2,,855672,4173,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
471,1416,1,2,,26719631,4173,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
472,1422,1,1,,855672,4173,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
473,1422,1,1,,26611824,4173,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
474,1423,1,2,,855672,4173,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
475,1423,1,2,,855672,4173,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
476,1423,1,2,,26719631,4173,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
477,1423,1,2,,26719631,4173,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
478,1424,1,1,,855672,4173,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
479,1424,1,1,,26719631,4173,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
480,1430,1,1,,855672,4173,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
481,1434,2,3,,855672,4173,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
482,1434,2,3,,855672,4173,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
483,1434,2,3,,26719631,4173,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
484,1434,2,3,,26719631,4173,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
485,1439,1,1,,855672,4173,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
486,1439,1,1,,855672,4173,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
487,1439,1,1,,26719631,4173,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
488,1439,1,1,,26719631,4173,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
489,1440,1,1,,855672,4173,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
490,1440,1,1,,855672,4173,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
491,1440,1,1,,26719631,4173,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
492,1440,1,1,,26719631,4173,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
493,1441,1,1,,855672,4173,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
494,1441,1,1,,855672,4173,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
495,1441,1,1,,26719631,4173,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
496,1441,1,1,,26719631,4173,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
497,1443,1,3,,855672,4173,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
498,1443,1,3,,26719631,4173,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
499,1445,1,1,,855672,4173,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
500,1445,1,1,,26719631,4173,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
501,1446,1,3,,855672,4173,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
502,1446,1,3,,26719631,4173,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
503,1448,1,3,,855672,4173,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
504,1448,1,3,,26719631,4173,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
505,1452,1,1,,855672,4173,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
506,1452,1,1,,11112343,4173,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
507,1452,1,1,,17389815,4173,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
508,1454,1,1,,11112343,4173,Inconclusive,66932916.0,5594.0,8.9125,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
509,1454,1,1,,26719631,4173,Inconclusive,66932916.0,5594.0,15.8489,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
510,1454,1,1,,26746949,4173,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
511,1456,1,1,,855672,4173,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
512,1456,1,1,,26719631,4173,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
513,1457,1,1,,855672,4173,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
514,1457,1,1,,11112343,4173,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
515,1457,1,1,,17389815,4173,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
516,1457,1,1,,26746949,4173,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
517,1458,1,1,,855672,4173,Unspecified,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
518,1458,1,1,,11112343,4173,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
519,1458,1,1,,17389815,4173,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
520,1458,1,1,,26746949,4173,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
521,1460,1,3,,855672,4173,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
522,1460,1,3,,26719631,4173,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
523,1460,1,3,,26746949,4173,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
524,1461,1,2,,855672,4173,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
525,1461,1,2,,26719631,4173,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
526,1463,1,1,,855672,4173,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
527,1463,1,1,,26719631,4173,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
528,1463,1,1,,26746949,4173,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
529,1465,1,1,,855672,4173,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
530,1466,1,2,,855672,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
531,1466,1,2,,26719631,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
532,1467,1,3,,11112343,4173,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
533,1467,1,3,,26719631,4173,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
534,1467,1,3,,26746949,4173,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
535,1468,1,1,,855672,4173,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
536,1468,1,1,,26719631,4173,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
537,1468,1,1,,26746949,4173,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
538,1469,1,1,,855672,4173,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
539,1469,1,1,,11112343,4173,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
540,1469,1,1,,17389815,4173,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
541,1469,1,1,,26719631,4173,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
542,1469,1,1,,26746949,4173,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
543,1471,2,1,,11112343,4173,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
544,1471,2,1,,17389815,4173,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
545,1471,2,1,,26746949,4173,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
546,1476,2,1,,855672,4173,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
547,1476,2,1,,11112343,4173,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
548,1476,2,1,,17389815,4173,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
549,1476,2,1,,26746949,4173,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
550,1477,1,1,,855672,4173,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
551,1477,1,1,,11112343,4173,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
552,1477,1,1,,17389815,4173,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
553,1477,1,1,,26719631,4173,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
554,1477,1,1,,26746949,4173,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
555,1478,2,1,,855672,4173,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
556,1478,2,1,,11112343,4173,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
557,1478,2,1,,17389815,4173,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
558,1478,2,1,,26746949,4173,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
559,1479,1,2,,855672,4173,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
560,1479,1,2,,11112343,4173,Inconclusive,189491771.0,7068.0,7.0795,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
561,1479,1,2,,17389815,4173,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
562,1479,1,2,,26719631,4173,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
563,1479,1,2,,26746949,4173,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
564,1481,1,2,,855672,4173,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
565,1481,1,2,,26719631,4173,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
566,1486,1,3,,855672,4173,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
567,1486,1,3,,26719631,4173,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
568,1487,1,1,,855672,4173,Inconclusive,27436948.0,4000.0,2.5119,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
569,1487,1,1,,11112343,4173,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
570,1487,1,1,,26719631,4173,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
571,1487,1,1,,26746949,4173,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
572,1490,2,1,,855672,4173,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
573,1490,2,1,,11112343,4173,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
574,1490,2,1,,26719631,4173,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
575,1490,2,1,,26746949,4173,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
576,1496,1,4,,855672,4173,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
577,1496,1,4,,855672,4173,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
578,1496,1,4,,26719631,4173,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
579,1496,1,4,,26719631,4173,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
580,1509,1,2,,855672,4173,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
581,1509,1,2,,26719631,4173,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
582,1510,1,3,,855672,4173,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
583,1510,1,3,,26719631,4173,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
584,1511,1,3,,855672,4173,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
585,1515,1,2,,855672,4173,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
586,1515,1,2,,26719631,4173,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
587,1519,1,3,,11112343,4173,Inconclusive,,,0.0141,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
588,1519,1,3,,26746949,4173,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
589,1527,1,3,,855672,4173,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
590,1527,1,3,,26719631,4173,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
591,1529,1,1,,855672,4173,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
592,1529,1,1,,26719631,4173,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
593,1530,1,1,,855672,4173,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
594,1530,1,1,,26719631,4173,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
595,1531,1,1,,855672,4173,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
596,1531,1,1,,26719631,4173,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
597,1532,1,1,,855672,4173,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
598,1533,1,1,,26719631,4173,Inactive,15610402.0,888704.0,,,Rml C and D inhibition 384-well mixture HTS from 1536-well compound plates,Screening,,
599,1533,1,1,,26719631,4173,Inactive,15610601.0,887352.0,,,Rml C and D inhibition 384-well mixture HTS from 1536-well compound plates,Screening,,
600,1554,1,1,,855672,4173,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
601,1556,1,4,,855672,4173,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
602,1556,1,4,,26719631,4173,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
603,1565,2,2,,855672,4173,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
604,1565,2,2,,26719631,4173,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
605,1566,2,3,,855672,4173,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
606,1566,2,3,,26719631,4173,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
607,1578,3,2,,855672,4173,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
608,1578,3,2,,26719631,4173,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
609,1580,1,1,,8149429,4173,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
610,1581,1,1,,8149429,4173,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
611,1582,1,1,,8149429,4173,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
612,1583,1,1,,8149429,4173,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
613,1584,1,1,,8149429,4173,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
614,1585,1,1,,8149429,4173,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
615,1586,1,1,,8149429,4173,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
616,1587,1,1,,8149429,4173,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
617,1588,1,1,,8149429,4173,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
618,1589,1,1,,8149429,4173,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
619,1590,1,1,,8149429,4173,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
620,1593,1,1,,8149429,4173,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
621,1594,1,1,,8149429,4173,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
622,1595,1,1,,8149429,4173,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
623,1596,1,1,,8149429,4173,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
624,1597,1,1,,8149429,4173,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
625,1598,1,1,,8149429,4173,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
626,1599,1,1,,8149429,4173,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
627,1600,1,1,,8149429,4173,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
628,1601,1,1,,8149429,4173,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
629,1602,1,1,,8149429,4173,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
630,1603,1,1,,8149429,4173,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
631,1604,1,1,,8149429,4173,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
632,1605,1,1,,8149429,4173,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
633,1606,1,1,,8149429,4173,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
634,1607,1,1,,8149429,4173,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
635,1608,1,1,,8149429,4173,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
636,1609,1,1,,8149429,4173,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
637,1610,1,1,,8149429,4173,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
638,1611,1,1,,8149429,4173,Unspecified,,,,,Screen for compounds that induce the human heat shock transcriptional response (HSEluc),Other,,
639,1612,1,1,,8149429,4173,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
640,1613,1,1,,8149429,4173,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
641,1614,1,1,,8149429,4173,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
642,1616,1,1,,8149429,4173,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
643,1619,1,2,,855672,4173,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
644,1619,1,2,,26719631,4173,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
645,1621,1,2,,855672,4173,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
646,1625,2,2,,26719631,4173,Inactive,,,,EC50,HCS for Compounds that Up-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
647,1626,1,2,,855672,4173,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
648,1626,1,2,,26719631,4173,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
649,1628,2,2,,26719631,4173,Inactive,,,,IC50,HCS for Compounds that Down-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
650,1631,3,1,,855672,4173,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
651,1631,3,1,,26719631,4173,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
652,1634,3,1,,855672,4173,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
653,1634,3,1,,26719631,4173,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
654,1654,2,2,,855672,4173,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
655,1654,2,2,,26719631,4173,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
656,1656,2,2,,855672,4173,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
657,1656,2,2,,26719631,4173,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
658,1662,1,2,,855672,4173,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
659,1663,1,2,,855672,4173,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
660,1665,2,2,,26719631,4173,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
661,1672,1,3,,855672,4173,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
662,1688,1,1,,855672,4173,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
663,1688,1,1,,26746949,4173,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
664,1700,1,2,,855672,4173,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
665,1700,1,2,,26719631,4173,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
666,1706,1,2,,855672,4173,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
667,1706,1,2,,26719631,4173,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
668,1721,1,2,,855672,4173,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
669,1721,1,2,,26719631,4173,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
670,1722,1,2,,855672,4173,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
671,1722,1,2,,26719631,4173,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
672,1766,1,1,,855672,4173,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
673,1766,1,1,,855672,4173,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
674,1766,1,1,,11112343,4173,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
675,1766,1,1,,11112343,4173,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
676,1766,1,1,,26719631,4173,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
677,1766,1,1,,26719631,4173,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
678,1766,1,1,,26746949,4173,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
679,1766,1,1,,26746949,4173,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
680,1768,1,1,,855672,4173,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
681,1768,1,1,,855672,4173,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
682,1768,1,1,,11112343,4173,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
683,1768,1,1,,11112343,4173,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
684,1768,1,1,,26719631,4173,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
685,1768,1,1,,26719631,4173,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
686,1768,1,1,,26746949,4173,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
687,1768,1,1,,26746949,4173,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
688,1775,1,2,,855672,4173,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
689,1775,1,2,,26719631,4173,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
690,1776,1,2,,855672,4173,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
691,1776,1,2,,26719631,4173,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
692,1777,3,2,,855672,4173,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
693,1777,3,2,,26719631,4173,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
694,1778,3,3,,855672,4173,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
695,1778,3,3,,26719631,4173,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
696,1779,2,2,,855672,4173,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
697,1779,2,2,,26719631,4173,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
698,1789,1,2,,855672,4173,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
699,1789,1,2,,26719631,4173,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
700,1800,1,2,,855672,4173,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
701,1800,1,2,,26719631,4173,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
702,1813,1,2,,855672,4173,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
703,1814,1,2,,855672,4173,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
704,1817,2,2,,855672,4173,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
705,1817,2,2,,26719631,4173,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
706,1822,1,3,,855672,4173,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
707,1822,1,3,,26719631,4173,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
708,1825,1,1,,855672,4173,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
709,1825,1,1,,26719631,4173,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
710,1832,2,1,,855672,4173,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
711,1845,1,2,,855672,4173,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
712,1845,1,2,,26719631,4173,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
713,1850,2,1,,855672,4173,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
714,1851,1,2,,11112343,4173,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
715,1851,1,2,1.0,11112343,4173,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
716,1851,1,2,2.0,11112343,4173,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
717,1851,1,2,3.0,11112343,4173,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
718,1851,1,2,4.0,11112343,4173,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
719,1851,1,2,5.0,11112343,4173,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
720,1861,2,1,,855672,4173,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
721,1861,2,1,,26719631,4173,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
722,1862,1,4,,855672,4173,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
723,1863,2,1,,855672,4173,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
724,1863,2,1,,26719631,4173,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
725,1865,1,1,,855672,4173,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
726,1865,1,1,,11112343,4173,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
727,1865,1,1,,26719631,4173,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
728,1865,1,1,,26746949,4173,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
729,1867,1,4,,855672,4173,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
730,1868,1,4,,855672,4173,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
731,1868,1,4,,26719631,4173,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
732,1870,1,4,,855672,4173,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
733,1873,1,4,,855672,4173,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
734,1875,2,1,,855672,4173,Inconclusive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
735,1885,2,1,,855672,4173,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
736,1887,1,4,,855672,4173,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
737,1899,1,3,,855672,4173,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
738,1903,2,3,,855672,4173,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
739,1903,2,3,,26719631,4173,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
740,1906,1,3,,855672,4173,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
741,1910,1,2,,855672,4173,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
742,1947,1,2,,855672,4173,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
743,1948,1,1,,11112343,4173,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
744,1948,1,1,,17389815,4173,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
745,1948,1,1,,26746949,4173,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
746,1950,1,3,,855672,4173,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
747,1956,1,1,,855672,4173,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
748,1961,2,2,,855672,4173,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
749,1961,2,2,,26719631,4173,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
750,1962,1,2,,855672,4173,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
751,1974,1,2,,855672,4173,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
752,1979,1,1,,855672,4173,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
753,1984,1,3,,855672,4173,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
754,1984,1,3,,26719631,4173,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
755,1986,1,2,,855672,4173,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
756,1986,1,2,,26719631,4173,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
757,1987,1,2,,855672,4173,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
758,1996,2,2,,855672,4173,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
759,2006,3,2,,855672,4173,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
760,2006,3,2,,855672,4173,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
761,2006,3,2,,855672,4173,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
762,2006,3,2,,26719631,4173,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
763,2006,3,2,,26719631,4173,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
764,2006,3,2,,26719631,4173,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
765,2012,3,2,,855672,4173,Active,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
766,2012,3,2,,26719631,4173,Active,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
767,2013,2,2,,855672,4173,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
768,2013,2,2,,26719631,4173,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
769,2014,3,2,,855672,4173,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
770,2014,3,2,,26719631,4173,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
771,2016,1,3,,855672,4173,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
772,2023,1,3,,855672,4173,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
773,2025,1,3,,855672,4173,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
774,2029,1,3,,855672,4173,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
775,2052,2,1,,855672,4173,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
776,2057,1,2,,855672,4173,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
777,2058,3,2,,855672,4173,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
778,2058,3,2,,26719631,4173,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
779,2066,1,4,,855672,4173,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
780,2071,2,2,,855672,4173,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
781,2071,2,2,,26719631,4173,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
782,2073,2,3,,855672,4173,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
783,2073,2,3,,855672,4173,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
784,2073,2,3,,26719631,4173,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
785,2073,2,3,,26719631,4173,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
786,2094,1,2,,855672,4173,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
787,2094,1,2,,855672,4173,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
788,2094,1,2,,855672,4173,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
789,2097,1,2,,855672,4173,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
790,2098,1,1,,855672,4173,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
791,2099,1,1,,855672,4173,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
792,2100,1,1,,855672,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
793,2100,1,1,,26719631,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
794,2101,1,1,,855672,4173,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
795,2101,1,1,,11112343,4173,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
796,2101,1,1,,17389815,4173,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
797,2101,1,1,,26719631,4173,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
798,2101,1,1,,26746949,4173,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
799,2107,1,1,,855672,4173,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
800,2107,1,1,,11112343,4173,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
801,2107,1,1,,17389815,4173,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
802,2107,1,1,,26719631,4173,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
803,2107,1,1,,26746949,4173,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
804,2112,1,1,,855672,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
805,2112,1,1,,11112343,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
806,2112,1,1,,17389815,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
807,2112,1,1,,26719631,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
808,2112,1,1,,26746949,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
809,2120,1,1,,17389815,4173,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
810,2129,1,2,,855672,4173,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
811,2130,1,3,,855672,4173,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
812,2147,1,1,,855672,4173,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
813,2147,1,1,,11112343,4173,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
814,2147,1,1,,26719631,4173,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
815,2147,1,1,,26746949,4173,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
816,2156,2,2,,855672,4173,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
817,2174,1,3,,855672,4173,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
818,2177,1,3,,855672,4173,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
819,2205,1,1,,855672,4173,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
820,2216,1,3,,855672,4173,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
821,2221,1,2,,855672,4173,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
822,2227,1,2,,855672,4173,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
823,2234,1,2,,855672,4173,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
824,2235,1,2,,855672,4173,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
825,2237,1,2,,855672,4173,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
826,2239,1,2,,855672,4173,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
827,2242,1,1,,855672,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
828,2242,1,1,,26719631,4173,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
829,2247,1,2,,855672,4173,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
830,2280,2,3,,855672,4173,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
831,2288,1,1,,855672,4173,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
832,2288,1,1,,26719631,4173,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
833,2289,1,1,,855672,4173,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
834,2289,1,1,,26719631,4173,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
835,2300,1,3,,855672,4173,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
836,2314,1,2,,855672,4173,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
837,2314,1,2,,855672,4173,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
838,2314,1,2,,26719631,4173,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
839,2314,1,2,,26719631,4173,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
840,2315,1,2,,855672,4173,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
841,2315,1,2,,855672,4173,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
842,2315,1,2,,26719631,4173,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
843,2315,1,2,,26719631,4173,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
844,2326,1,1,,855672,4173,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
845,2380,1,2,,855672,4173,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
846,2391,1,1,,855672,4173,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
847,2417,1,1,,855672,4173,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
848,2435,1,2,,855672,4173,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
849,2445,1,2,,855672,4173,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
850,2451,1,2,,855672,4173,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
851,2451,1,2,,11112343,4173,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
852,2451,1,2,,26719631,4173,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
853,2451,1,2,,26746949,4173,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
854,2462,1,1,,855672,4173,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
855,2462,1,1,,855672,4173,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
856,2472,1,2,,855672,4173,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
857,2472,1,2,,11112343,4173,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
858,2472,1,2,,26719631,4173,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
859,2472,1,2,,26746949,4173,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
860,2517,2,1,,855672,4173,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
861,2517,2,1,,11112343,4173,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
862,2517,2,1,,17389815,4173,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
863,2517,2,1,,26719631,4173,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
864,2517,2,1,,26746949,4173,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
865,2520,1,4,,855672,4173,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
866,2521,1,3,,855672,4173,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
867,2523,1,1,,855672,4173,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
868,2524,1,2,,855672,4173,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
869,2528,1,2,,855672,4173,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
870,2528,1,2,,11112343,4173,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
871,2528,1,2,,26719631,4173,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
872,2528,1,2,,26746949,4173,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
873,2540,1,2,,855672,4173,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
874,2544,1,2,,855672,4173,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
875,2546,1,1,,855672,4173,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
876,2546,1,1,,11112343,4173,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
877,2546,1,1,,17389815,4173,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
878,2546,1,1,,26719631,4173,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
879,2546,1,1,,26746949,4173,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
880,2549,1,1,,855672,4173,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
881,2549,1,1,,11112343,4173,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
882,2549,1,1,,17389815,4173,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
883,2549,1,1,,26719631,4173,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
884,2549,1,1,,26746949,4173,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
885,2550,1,3,,855672,4173,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
886,2551,1,1,,855672,4173,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
887,2551,1,1,,11112343,4173,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
888,2551,1,1,,17389815,4173,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
889,2551,1,1,,26719631,4173,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
890,2551,1,1,,26746949,4173,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
891,2553,1,2,,855672,4173,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
892,2557,1,3,,855672,4173,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
893,2563,1,1,,855672,4173,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
894,2599,1,2,,855672,4173,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
895,2606,1,2,,855672,4173,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
896,2629,1,1,,855672,4173,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
897,2642,1,2,,855672,4173,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
898,2648,1,2,,855672,4173,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
899,2650,2,1,,855672,4173,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
900,2661,1,1,,855672,4173,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
901,2662,2,1,,855672,4173,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
902,2662,2,1,,26719631,4173,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
903,2674,1,1,,855672,4173,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
904,2675,1,1,,855672,4173,Inconclusive,41281591.0,4154.0,79.4328,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
905,2675,1,1,,26719631,4173,Inconclusive,41281591.0,4154.0,25.1189,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
906,2676,1,2,,855672,4173,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
907,2676,1,2,,26719631,4173,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
908,2685,1,1,,855672,4173,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
909,2685,1,1,,26719631,4173,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
910,2690,1,2,,855672,4173,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
911,2706,1,1,,855672,4173,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
912,2716,1,1,,855672,4173,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
913,2717,1,2,,855672,4173,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
914,2718,1,1,,855672,4173,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
915,2732,1,1,,855672,4173,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
916,2732,1,1,,26719631,4173,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
917,2751,2,2,,855672,4173,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
918,2796,1,4,,855672,4173,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
919,2797,1,2,,855672,4173,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
920,2805,2,2,,855672,4173,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
921,2806,2,2,,855672,4173,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
922,2825,1,2,,855672,4173,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
923,7783,3,4,,103189534,4173,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
924,8002,5,2,,103189534,4173,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
925,9473,3,4,,103189534,4173,Unspecified,,,,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,Other,8308864.0,
926,9474,3,4,,103189534,4173,Unspecified,,,,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,Other,8308864.0,
927,9480,3,4,,103189534,4173,Unspecified,,,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Other,8308864.0,
928,9641,6,2,,103189534,4173,Unspecified,,,23000.0,IC50,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,Confirmatory,8308864.0,
929,9657,3,4,,103189534,4173,Unspecified,,,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Other,8308864.0,
930,16036,3,4,,103189534,4173,Unspecified,,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,Other,3806622.0,
931,16037,3,4,,103189534,4173,Unspecified,,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,Other,3806622.0,
932,16038,3,4,,103189534,4173,Unspecified,,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,Other,3806622.0,
933,16039,3,4,,103189534,4173,Unspecified,,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,Other,3806622.0,
934,16040,3,4,,103189534,4173,Unspecified,,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,Other,3806622.0,
935,16041,3,4,,103189534,4173,Unspecified,,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,Other,3806622.0,
936,19424,3,4,,103189534,4173,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
937,21136,4,1,,103189534,4173,Unspecified,,,,,Solubility in mMol was measured by UV spectrophotometry.,Other,8308864.0,
938,23240,3,3,,103189534,4173,Unspecified,,,,,Partition coefficient (logP),Other,3806622.0,
939,23442,3,3,,103189534,4173,Unspecified,,,,,Partition coefficient (logP),Other,1995902.0,
940,23681,3,3,,103189534,4173,Unspecified,,,,,Partition coefficient (logP),Other,3959031.0,
941,23734,3,3,,103189534,4173,Unspecified,,,,,Micelle/water partition coefficient (Pmic) of the compound was determined,Other,8691461.0,
942,24912,3,3,,103189534,4173,Unspecified,,,,,Half life for the nitro group loss in xanthine oxidase enzyme assay in 0.2%DMF at 0.1 mM,Other,8289205.0,
943,26380,3,3,,103189534,4173,Inactive,,,,,Dissociation constant (pKa),Other,14971904.0,
944,26535,3,3,,103189534,4173,Unspecified,,,,,Capacity factor (log k'),Other,3959031.0,
945,26811,3,3,,103189534,4173,Unspecified,,,,,Partition coefficient (logP),Other,7392035.0,
946,27167,3,4,,103189534,4173,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
947,27575,3,3,,103189534,4173,Unspecified,,,,,HPLC capacity factor (k),Other,10956200.0,
948,27580,3,3,,103189534,4173,Unspecified,,,,,Partition coefficient (logP),Other,10956200.0,
949,27795,5,4,,103189534,4173,Unspecified,,,,,AUC (area under curve) after oral dosing by gavage needle at 30 mg/kg in C57BL/6NTac female mice; Not checked,Other,12213071.0,
950,27797,5,3,,103189534,4173,Unspecified,,,,,Maximum plasma concentration (Cmax) after oral dosing by gavage needle at 30 mg/kg in C57BL/6NTac female mice; Not checked,Other,12213071.0,
951,28233,3,3,,103189534,4173,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
952,28235,3,3,,103189534,4173,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
953,28236,3,3,,103189534,4173,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
954,28681,3,4,,103189534,4173,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
955,29344,3,3,,103189534,4173,Inactive,,,,,Ionisation constant (pKa),Other,12061889.0,
956,29363,3,3,,103189534,4173,Inconclusive,,,,,Dissociation constant (pKa),Other,10891117.0,
957,29421,3,3,,103189534,4173,Unspecified,,,,,Partition coefficient (logP) (HPLC),Other,10956200.0,
958,29423,3,4,,103189534,4173,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
959,29811,4,3,,103189534,4173,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
960,29925,5,2,,103189534,4173,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
961,30563,4,4,,103189534,4173,Unspecified,,,,,"Antibacterial activity against Actinomyces israelii, activity expressed as inhibitory zone (mm, diameter)",Other,6834379.0,
962,38347,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity was measured against B. fragilis range; Value ranges from 0.39-0.78,Other,10966750.0,
963,40337,6,2,,103189534,4173,Unspecified,,,,,Compound was evaluated for antimicrobial activity against Bacteroides fragilis,Other,9871756.0,
964,40354,3,3,,103189534,4173,Inconclusive,,,,,Relative stability towards beta-lactamase was determined in Bacillus fragilis FP784; Not tested,Other,15109666.0,
965,40356,3,3,,103189534,4173,Inconclusive,,,,,Relative stability towards penicillinase was determined; Not tested,Other,15109666.0,
966,40358,3,3,,103189534,4173,Inconclusive,,,,,Stability towards beta-lactamase was determined in Bacillus fragilis FP784; Not tested,Other,15109666.0,
967,40360,3,3,,103189534,4173,Inconclusive,,,,,Stability towards beta-lactamase was determined in penicillinase; Not tested,Other,15109666.0,
968,40466,5,2,,103189534,4173,Inconclusive,,,,,Stability towards beta-lactamase was determined in Bacillus fragilis FP784; Not tested,Other,15109666.0,
969,40468,5,2,,103189534,4173,Inconclusive,,,,,Stability towards penicillinase was determined; Not tested,Other,15109666.0,
970,41121,4,4,,103189534,4173,Unspecified,,,,,"Antibacterial activity against Bacteroides fragilis, activity expressed as minimum inhibitory zone (mm, diameter)",Other,6834379.0,
971,41271,8,1,,103189534,4173,Active,,,,,Minimum inhibitory concentration measured against Bacteroides fragilis strain,Other,3339605.0,
972,41272,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Bacteroides fragilis (MZ-R)(in vitro),Other,1875335.0,
973,41273,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Bacteroides fragilis(NCTC 10581)(in vitro),Other,1875335.0,
974,41274,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Bacteroides fragilis(NCTC 9343)(in vitro),Other,1875335.0,
975,41275,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Bacteroides fragilis(NCTC 9344)(in vitro),Other,1875335.0,
976,41276,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Bacteroides fragilis (WSI)(in vitro),Other,1875335.0,
977,42862,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity was measured against Clostridium difficile organism; Value ranges from 0.1-0.39,Other,10966750.0,
978,42872,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity was measured against Campylobacter jejuni organism; Value ranges from 0.78-100,Other,10966750.0,
979,43006,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity was measured against Clostridium perfringens organism; Value ranges from 0.78-3.13,Other,10966750.0,
980,44956,7,2,,103189534,4173,Unspecified,,,,,"Antifungal activity against Candida albicans, activity expressed as minimum inhibitory concentration (ug/mL)",Other,6834379.0,
981,46744,6,2,,103189534,4173,Unspecified,,,,,Compound was evaluated for antimicrobial activity against Campylobacter jejuni,Other,9871756.0,
982,47570,3,4,,103189534,4173,Unspecified,,,,,"Antifungal activity against Candida albicans, activity expressed as minimum inhibitory zone (mm, diameter)",Other,6834379.0,
983,50732,6,2,,103189534,4173,Unspecified,,,,,Compound was evaluated for antimicrobial activity against Clostridium difficile,Other,9871756.0,
984,50859,4,4,,103189534,4173,Unspecified,,,,,"Antibacterial activity against Clostridium novyi, activity expressed as inhibitory zone (mm, diameter)",Other,6834379.0,
985,50983,6,2,,103189534,4173,Unspecified,,,,,Compound was evaluated for antimicrobial activity against Clostridium perfringens,Other,9871756.0,
986,51004,8,1,,103189534,4173,Active,,,,,Minimum inhibitory concentration measured against Clostridium perfringens strain,Other,3339605.0,
987,51005,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Clostridium perfringens (NCTC 523)(in vitro),Other,1875335.0,
988,51006,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Clostridium perfringens (NCTC 8237)(in vitro),Other,1875335.0,
989,54254,7,1,,103189534,4173,Unspecified,,,,,Concentration required for 50% decrease in fluorescence of ethidium bromide bound to calf thymus DNA. at 600 nm,Other,,
990,66922,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis was determined,Other,12873498.0,
991,67511,5,2,,103189534,4173,Inconclusive,,,,,Antiprotozoal activity measured as the conc for 95-25% inhibition of Entamoeba histolytica; ND denotes no data,Other,6834379.0,
992,67513,5,2,,103189534,4173,Inconclusive,,,,,Antiprotozoal activity measured as the conc for <25% inhibition of Entamoeba histolytica; ND denotes no data,Other,6834379.0,
993,67515,5,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity measured as the conc for 100% inhibition of Entamoeba histolytica,Other,6834379.0,
994,67520,5,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity measured as the conc for >95% inhibition of Entamoeba histolytica,Other,6834379.0,
995,67522,6,2,,103189534,4173,Active,,,2.03,IC50,In vitro antiamnesic activity against HM-1:1MMS strain of Entamoeba histolytica,Confirmatory,12639559.0,
996,67523,6,2,,103189534,4173,Unspecified,,,,,In vitro antiamnesic activity was evaluated against HK-9 strain of Entamoeba histolytica,Other,11591499.0,
997,67524,6,2,,103189534,4173,Active,,,0.35,IC50,In vitro antiprotozoal activity against Entamoeba histolytica,Confirmatory,11206455.0,
998,67525,6,2,,103189534,4173,Active,,,3.2,IC50,In vitro growth inhibition against Entamoeba histolytica,Confirmatory,14695831.0,
999,67527,6,2,,103189534,4173,Active,,,2.1,IC50,Inhibitory concentration against Entamoeba histolytica (HK-9) for antiamnesic activity,Confirmatory,12419387.0,
1000,67528,6,2,,103189534,4173,Unspecified,,,,,Tested for antiamnesic activity against HK-9 strain of Entamoeba histolytica,Other,11055329.0,
1001,67529,6,2,,103189534,4173,Active,,,0.35,IC50,"The compound was tested in vitro against the protozoa Entamoeba histolytica, for the inhibition of tubulin polymerization in rat brain",Confirmatory,12127542.0,
1002,67621,3,4,,103189534,4173,Unspecified,,,,,Aerobic cytotoxicity against murine mammary carcinoma EMT6 cells in a growth inhibition microassay,Other,8308864.0,
1003,69326,8,1,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration measured against Escherichia coli AB1157 strain (Uvr+ Rec+),Other,3339605.0,
1004,69327,8,1,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration measured against Escherichia coli AB1885 strain (UvrB- Rec+),Other,3339605.0,
1005,69328,8,1,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration measured against Escherichia coli EE128 strain (Uvr+ RecA-),Other,3339605.0,
1006,69329,8,1,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration measured against Escherichia coli EE349 strain (UvrB- Rec+),Other,3339605.0,
1007,69330,8,1,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration measured against Escherichia coli SR58 strain (RecA- UvrB-),Other,3339605.0,
1008,69916,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Escherichia coli K-12 was determined,Other,12873498.0,
1009,70072,4,4,,103189534,4173,Unspecified,,,,,"Antifungal activity against Epidermophyton floccosum, activity expressed as inhibitory zone (mm, diameter)",Other,6834379.0,
1010,70074,7,2,,103189534,4173,Unspecified,,,,,"Antifungal activity against Epidermophyton floccosum, activity expressed as minimum inhibitory concentration (ug/mL)",Other,6834379.0,
1011,72162,3,4,,103189534,4173,Unspecified,,,,,Aerobic cytotoxicity against human melanoma FME cells in a growth inhibition microassay,Other,8308864.0,
1012,72251,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Fusobacterium necrophorum (ATCC 11295)(in vitro),Other,1875335.0,
1013,75265,6,2,,103189534,4173,Active,,,1.22,IC50,In vitro antiprotozoal activity against Giardia lamblia,Confirmatory,11206455.0,
1014,75267,6,2,,103189534,4173,Active,,,1.16,IC50,Inhibitory concentration against G. Lamblia (IMSS-0989) for antigiardial activity,Confirmatory,12419387.0,
1015,75268,6,2,,103189534,4173,Active,,,1.22,IC50,"The compound was tested in vitro against the protozoa Giardia lamblia, for the inhibition of tubulin polymerization in rat brain",Confirmatory,12127542.0,
1016,79590,5,1,,103189534,4173,Unspecified,,,,,Minimum bactericidal concentration against Helicobacter pylori ATCC 43504; range 2-4 ug/mL,Other,12213070.0,
1017,84163,3,3,,103189534,4173,Unspecified,,,,,Value is expressed as the ratio of (Tritrichomonas foetus infected) animals cured / total number(15) infected at day 1 post treatment after 4 days of treatment,Other,4067993.0,
1018,84164,3,3,,103189534,4173,Unspecified,,,,,Value is expressed as the ratio of (Tritrichomonas foetus infected) animals cured / total number(15) infected at day 4 post treatment after 4 days of treatment,Other,4067993.0,
1019,84679,3,3,,103189534,4173,Unspecified,,,,,Lowest active dose which cured hamsters with Entamoeba histolytica hepatic infection was measured,Other,7359534.0,
1020,87806,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori ATCC 43504 was determined,Other,12873498.0,
1021,87807,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP001 was determined,Other,12873498.0,
1022,87808,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP0016 was determined,Other,12873498.0,
1023,87809,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP0017 was determined,Other,12873498.0,
1024,87810,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP0018 was determined,Other,12873498.0,
1025,87926,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP0019 was determined,Other,12873498.0,
1026,87927,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP003 was determined,Other,12873498.0,
1027,87928,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP004 was determined,Other,12873498.0,
1028,87929,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP007 was determined,Other,12873498.0,
1029,87930,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP008 was determined,Other,12873498.0,
1030,87931,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP020 was determined,Other,12873498.0,
1031,87932,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP021 was determined,Other,12873498.0,
1032,87933,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori HP022 was determined,Other,12873498.0,
1033,87942,6,2,,103189534,4173,Unspecified,,,,,Compound was evaluated for antimicrobial activity against Helicobacter pylori,Other,9871756.0,
1034,87945,6,2,,103189534,4173,Unspecified,,,,,Evaluated for antimicrobial activity against Helicobacter pylori,Other,9258352.0,
1035,87946,6,2,,103189534,4173,Unspecified,,,,,Inhibitory activity was determined against 102R strain of Helicobacter pylori,Other,11212121.0,
1036,87947,6,2,,103189534,4173,Unspecified,,,,,Inhibitory activity was determined against NCTC-11637 strain of Helicobacter pylori,Other,11212121.0,
1037,87949,6,2,,103189534,4173,Unspecified,,,,,Minimal concentration needed to inhibitH. pylori strain,Other,11212121.0,
1038,87950,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Helicobacter pylori (Helicobacter pylori) ARHp strain 115,Other,12213071.0,
1039,87951,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Helicobacter pylori (Helicobacter pylori) ARHp strain 206,Other,12213071.0,
1040,87952,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Helicobacter pylori (Helicobacter pylori) ARHp strain 80,Other,12213071.0,
1041,87953,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Helicobacter pylori (Helicobacter pylori) ARHp strain 81,Other,12213071.0,
1042,87954,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory activity against clarithromycin- and metronidazole-resistant strain 15069,Other,15109666.0,
1043,87956,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory activity against clarithromycin- and metronidazole-resistant strain 16021,Other,15109666.0,
1044,87958,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory activity against clarithromycin- and metronidazole-resistant strain 16043,Other,15109666.0,
1045,87965,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration that inhibited macroscopic colony growth of Helicobacter pylori,Other,10425101.0,
1046,88083,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration required to inhibit macroscopic colonial growth of Helicobacter pylori; ranges from(1.56-25),Other,11754586.0,
1047,88227,6,2,,103189534,4173,Unspecified,,,,,The lowest drug concentration that inhibited macroscopic colonial growth against Helicobacter pylori; Value ranges from 1.56-25,Other,10966750.0,
1048,88245,6,2,,103189534,4173,Unspecified,,,,,Minimal concentration needed to inhibit 50% of Helicobacter pylori strain,Other,11212121.0,
1049,88248,6,2,,103189534,4173,Unspecified,,,,,Minimal concentration needed to inhibit 90% of Helicobacter pylori strain,Other,11212121.0,
1050,88249,6,2,,103189534,4173,Unspecified,,,,,In vitro inhibitory activity evaluated against Helicobacter pylori (HP),Other,10021926.0,
1051,96068,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae was determined,Other,12873498.0,
1052,125251,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Morganella morganii was determined,Other,12873498.0,
1053,144206,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity was measured against Neisseria gonorrhoeae organism,Other,10966750.0,
1054,144209,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity was measured against Neisseria meningitidis organism.,Other,10966750.0,
1055,147155,6,2,,103189534,4173,Unspecified,,,,,Compound was evaluated for antimicrobial activity against Neisseria gonorrhoeae,Other,9871756.0,
1056,147159,6,2,,103189534,4173,Unspecified,,,,,Compound was evaluated for antimicrobial activity against Neisseria meningitidis,Other,9871756.0,
1057,157249,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Peptococcus magnus(in vitro),Other,1875335.0,
1058,157253,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Peptococcus prevotti(in vitro),Other,1875335.0,
1059,157257,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Peptostreptococcus anaerobius(in vitro),Other,1875335.0,
1060,160375,4,4,,103189534,4173,Unspecified,,,,,"Antibacterial activity against Propionibacterium acnes, activity expressed as inhibitory zone (mm, diameter)",Other,6834379.0,
1061,160386,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Propionibacterium acnes(NCTC 7337)(in vitro),Other,1875335.0,
1062,160387,6,2,,103189534,4173,Unspecified,,,,,Minimum inhibitory concentration against Propionibacterium acnes(NCTC 737)(in vitro),Other,1875335.0,
1063,172616,3,5,,103189534,4173,Unspecified,,,,,The amount of the unchanged form of compound detected in the urine samples collected at 0-18 hr after the treatment by HPLC technique,Other,3959031.0,
1064,172618,3,5,,103189534,4173,Unspecified,,,,,The amount of unchanged compound detected in urine collected at 0-18 hr after treatment,Other,3959031.0,
1065,172620,3,5,,103189534,4173,Unspecified,,,,,The amount of unchanged compound in urine collected at 0-36 hr after treatment,Other,3959031.0,
1066,172621,3,5,,103189534,4173,Unspecified,,,,,The amount of unchanged compound in urine collected at 0-54 hr after treatment,Other,3959031.0,
1067,172622,3,4,,103189534,4173,Unspecified,,,,,The amount of unchanged compound in urine collected at 0-72 h after treatment,Other,3959031.0,
1068,173917,3,3,,103189534,4173,Unspecified,,,,,Lowest active dose which cured rats with Entamoeba histolytica cecal infection was measured,Other,7359534.0,
1069,189629,3,3,,103189534,4173,Unspecified,,,,,The capillary permeability of radioligand was measured in Rat brain,Other,7392035.0,
1070,194141,3,5,,103189534,4173,Unspecified,,,,,The total 18 hr urinary excretion of the unchanged form of compound in urine was reported as log (percent X 10) of the administered dose by HPLC technique,Other,3959031.0,
1071,194143,3,4,,103189534,4173,Unspecified,,,,,The total 18 hr urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose,Other,3959031.0,
1072,194144,3,4,,103189534,4173,Unspecified,,,,,The total 36 hr urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose,Other,3959031.0,
1073,194145,3,3,,103189534,4173,Unspecified,,,,,The total 54 h urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose,Other,3959031.0,
1074,194146,3,4,,103189534,4173,Unspecified,,,,,The total 72 hr urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose,Other,3959031.0,
1075,200314,3,4,,103189534,4173,Unspecified,,,,,"Antifungal activity against Saccharomyces cerevisiae, activity expressed as inhibitory zone (mm, diameter)",Other,6834379.0,
1076,200690,3,4,,103189534,4173,Unspecified,,,,,Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol,Other,1995902.0,
1077,200885,3,5,,103189534,4173,Unspecified,,,,,Compound was tested for the mutagenicity activity in the Salmonella Typhimurium reverse mutation assay; +++-indicates the levels of mutagenicity as the number of revertant colonies obtained increases 10 times,Other,,
1078,202866,7,2,,103189534,4173,Unspecified,,,,,"Antifungal activity against Saccharomyces cerevisiae, activity expressed as minimum inhibitory concentration (ug/mL).",Other,6834379.0,
1079,205565,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis was determined,Other,12873498.0,
1080,207179,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus 209P JC was determined,Other,12873498.0,
1081,210260,4,4,,103189534,4173,Unspecified,,,,,"Antibacterial activity against Streptococcus pyogenes C, activity expressed as inhibitory zone (mm, diameter)",Other,6834379.0,
1082,210972,5,2,,103189534,4173,Inconclusive,,,,,Percentage viability reduction of Trichinella spiralis muscle larvae after 3 days of incubation; Not determined,Other,12127542.0,
1083,211133,5,2,,103189534,4173,Inconclusive,,,,,Antiprotozoal activity measured as the conc for >95% inhibition of Trichomonas foetus; ND denotes no data,Other,6834379.0,
1084,211134,6,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity measured as the conc for 100% inhibition of Trichomonas foetus,Other,6834379.0,
1085,211135,5,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity measured as the conc for 95-25% inhibition of Trichomonas foetus,Other,6834379.0,
1086,211137,6,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity measured as the conc for <25% inhibition of Trichomonas foetus,Other,6834379.0,
1087,211139,5,1,,103189534,4173,Unspecified,,,,,In vitro anti-trichomonal activity against Trichomonas foetus-Ortho strain-2.,Other,3543363.0,
1088,211142,3,3,,103189534,4173,Unspecified,,,,,The Mutagenicity against Trichomonas foetus relative to Ronidazole.,Other,3543363.0,
1089,211149,6,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity measured as the conc for 100% inhibition of Trichomonas vaginalis,Other,6834379.0,
1090,211150,6,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity measured as the conc for 95-25% inhibition of Trichomonas vaginalis,Other,6834379.0,
1091,211151,5,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity measured as the conc for <25% inhibition of Trichomonas vaginalis,Other,6834379.0,
1092,211152,6,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity measured as the conc for >95% inhibition of Trichomonas vaginalis,Other,6834379.0,
1093,211154,6,2,,103189534,4173,Active,,,1.92,IC50,Inhibitory concentration against Trichomonas vaginalis (tv-43) for anti-trichomonal activity,Confirmatory,12419387.0,
1094,211155,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Trichomonas vaginalis,Other,9083486.0,
1095,214096,4,4,,103189534,4173,Unspecified,,,,,"Antifungal activity against Trichophyton mentagrophytes, activity expressed as inhibitory zone (mm, diameter)",Other,6834379.0,
1096,214101,7,2,,103189534,4173,Unspecified,,,,,"Antifungal activity against Trichophyton mentagrophytes, activity expressed as minimum inhibitory concentration (ug/mL).",Other,6834379.0,
1097,215302,3,4,,103189534,4173,Unspecified,,,,,Aerobic cytotoxicity against UV4 cells in a growth inhibition microassay,Other,8308864.0,
1098,216885,3,4,,103189534,4173,Unspecified,,,,,Concentration required to kill 50 % of the cells after ca. 7 days aerobic exposure.,Other,,
1099,217019,3,4,,103189534,4173,Unspecified,,,,,Enhancement ratio was calculated to determine the radiosensitization as the ratio of radiation dose required to kill similar cells in anoxia to those with the compound; at a concentration of ~5 mM,Other,,
1100,223214,3,5,,103189534,4173,Unspecified,,,,,Inhibition of histamine-stimulated chronotropic response in isolated guinea pig right atrium at 1*10e-6 g/mL; ND is No Data.,Other,11754586.0,
1101,228170,3,5,,103189534,4173,Unspecified,,,,,Inhibition of histamine-stimulated gastric acid secretion in lumen-perfused stomach of anesthetized rats after 1 mg/kg iv administration; ND is No Data.,Other,11754586.0,
1102,228766,9,2,,103189534,4173,Active,,,,,Minimum inhibitory concentration (MIC) of compound expressed as geometric mean of various bacterias.*,Other,,
1103,232822,3,4,,103189534,4173,Unspecified,,,,,Ratio of mean intracellular to extracellular compound concentration determined under hypoxic conditions 30 mins after exposure to compound at C1.6 concentration,Other,8308864.0,
1104,233802,3,3,,103189534,4173,Unspecified,,,,,The ratio of aerobic CT10 to hypoxic CT10,Other,8308864.0,
1105,235834,3,3,,103189534,4173,Unspecified,,,,,Safety index.,Other,3543363.0,
1106,245231,6,2,,103189534,4173,Unspecified,,,,,Minimal inhibitory concentration against metronidazole resistant Helicobacter pylori 8 strain,Other,15664821.0,
1107,245242,6,2,,103189534,4173,Unspecified,,,,,Minimal inhibitory concentration against metronidazole resistant Helicobacter pylori 19 strain,Other,15664821.0,
1108,245243,6,2,,103189534,4173,Unspecified,,,,,Minimal inhibitory concentration against metronidazole resistant Helicobacter pylori 20 strain,Other,15664821.0,
1109,245320,6,2,,103189534,4173,Unspecified,,,,,Minimal inhibitory concentration against metronidazole resistant Helicobacter pylori NCTC 11637 strain,Other,15664821.0,
1110,249262,6,2,,103189534,4173,Unspecified,,,,,Minimal inhibitory concentration against 17 strains of Helicobacter pylori,Other,15664821.0,
1111,249328,6,2,,103189534,4173,Unspecified,,,,,Minimal inhibitory concentration against 17 strains of Helicobacter pylori,Other,15664821.0,
1112,250189,3,4,,103189534,4173,Unspecified,,,,,Viable Mycobacterium tuberculosis in lungs of infected Mice after an 8-day drug treatment; Dose is 150 mg/kg,Other,15456272.0,
1113,250202,3,4,,103189534,4173,Unspecified,,,,,Viable Mycobacterium tuberculosis in spleen of infected Mice after an 8-day drug treatment; Dose is 150 mg/kg,Other,15456272.0,
1114,252979,3,3,,103189534,4173,Unspecified,,,,,In vitro cytocidal activity against Trichomonas vaginalis at a dose of 1 mg/mL after 24 hours,Other,16005626.0,
1115,252980,3,3,,103189534,4173,Unspecified,,,,,In vitro cytocidal activity against Trichomonas vaginalis at a dose of 1 mg/mL after 48 hours,Other,16005626.0,
1116,252981,3,3,,103189534,4173,Unspecified,,,,,In vitro cytocidal activity against Trichomonas vaginalis at a dose of 2 mg/ml after 24 hours,Other,16005626.0,
1117,252982,3,3,,103189534,4173,Unspecified,,,,,In vitro cytocidal activity against Trichomonas vaginalis at a dose of 2 mg/ml after 48 hours,Other,16005626.0,
1118,252984,3,3,,103189534,4173,Unspecified,,,,,In vitro cytocidal activity against Trichomonas vaginalis at a dose of 0.5 mg/ml after 24 hours,Other,16005626.0,
1119,252985,3,3,,103189534,4173,Unspecified,,,,,In vitro cytocidal activity against Trichomonas vaginalis at a dose of 0.5 mg/ml after 48 hours,Other,16005626.0,
1120,260369,6,2,,103189534,4173,Inconclusive,,,,IC50,Antiprotozoal activity against Leishmania donovani MHOM/ET/L82/LV9,Confirmatory,16309903.0,
1121,260370,7,1,,103189534,4173,Inconclusive,,,,,Antiprotozoal activity against Trypanosoma brucei brucei GVR35,Other,16309903.0,
1122,260371,6,2,,103189534,4173,Active,,,5.8,IC50,Antiprotozoal activity against Trichomonas vaginalis CMP,Confirmatory,16309903.0,
1123,263999,6,2,,103189534,4173,Active,,,1.69,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS,Confirmatory,16495051.0,
1124,276338,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori DSMZ 4867,Other,16945527.0,
1125,283190,3,4,,103189534,4173,Active,,,,,Growth inhibition of Escherichia coli CC104 expressing rdxA after 16 hrs relative to Escherichia coli with pBSK,Other,17158936.0,
1126,285159,8,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days,Other,17210775.0,
1127,285160,8,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days,Other,17210775.0,
1128,285161,8,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay,Other,17210775.0,
1129,285162,8,1,,103189534,4173,Active,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days,Other,17210775.0,
1130,285514,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis by agar dilution method,Other,17242152.0,
1131,285515,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium difficile by agar dilution method,Other,17242152.0,
1132,285526,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Propionibacterium acnes,Other,17242152.0,
1133,285551,3,3,,103189534,4173,Inactive,,,,,Bactericidal activity against 5-day old actively replicating Mycobacterium tuberculosis H37Rv in aerobic condition at 8 ug/ml by Wayne dormancy culture model,Other,17242153.0,
1134,285558,3,3,,103189534,4173,Active,,,,,Bactericidal activity against 19-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 1 day by Wayne dormancy culture model,Other,17242153.0,
1135,285559,3,3,,103189534,4173,Active,,,,,Bactericidal activity against 19-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 4 days by Wayne dormancy culture model,Other,17242153.0,
1136,285560,3,3,,103189534,4173,Active,,,,,Bactericidal activity against 19-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 11 days by Wayne dormancy culture model,Other,17242153.0,
1137,285564,3,3,,103189534,4173,Active,,,,,Bactericidal activity against 26-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 1 day by Wayne dormancy culture model,Other,17242153.0,
1138,285565,3,3,,103189534,4173,Active,,,,,Bactericidal activity against 26-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 4 days by Wayne dormancy culture model,Other,17242153.0,
1139,285566,3,3,,103189534,4173,Active,,,,,Bactericidal activity against 26-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 11 days by Wayne dormancy culture model,Other,17242153.0,
1140,285570,3,3,,103189534,4173,Active,,,,,Bactericidal activity against 12-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 1 day by Wayne dormancy culture model,Other,17242153.0,
1141,285571,3,3,,103189534,4173,Active,,,,,Bactericidal activity against 12-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 4 days by Wayne dormancy culture model,Other,17242153.0,
1142,285572,3,3,,103189534,4173,Active,,,,,Bactericidal activity against 12-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 11 days by Wayne dormancy culture model,Other,17242153.0,
1143,286232,6,2,,103189534,4173,Active,,,1.23,IC50,Antiprotozoal activity against Giardia intestinalis IMSS:0696:1 trophozoites after 48 hrs,Confirmatory,17385912.0,
1144,289871,6,4,,103189534,4173,Active,,,1.82,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs,Confirmatory,17156895.0,
1145,296136,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis after 20 hrs by broth microdilution method,Other,17442577.0,
1146,296137,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides thetaiotaomicron after 20 hrs by broth microdilution method,Other,17442577.0,
1147,311534,8,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori ATCC 43504 by agar dilution method,Other,17883259.0,
1148,318681,7,1,,103189534,4173,Unspecified,,,,,Anticarcinogenic activity in rat assessed as induction of tumors per day,Other,18295489.0,
1149,319572,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-sensitive Helicobacter pylori assessed as inhibition zone diameter at 8 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1150,319573,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-sensitive Helicobacter pylori assessed as inhibition zone diameter at 16 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1151,319574,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-sensitive Helicobacter pylori assessed as inhibition zone diameter at 32 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1152,319575,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-resistant Helicobacter pylori assessed as inhibition zone diameter at 8 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1153,319576,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-resistant Helicobacter pylori assessed as inhibition zone diameter at 16 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1154,319577,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-resistant Helicobacter pylori assessed as inhibition zone diameter at 32 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1155,319578,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 0.5 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1156,319579,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 1 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1157,319580,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 2 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1158,319581,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 4 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1159,319582,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 8 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1160,319583,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 16 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1161,319584,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 32 ug/disk after 3-5 days by paper disk diffusion assay,Other,18442909.0,
1162,322087,6,2,,103189534,4173,Active,,,2.0,EC50,Antimicrobial activity against Entamoeba histolytica HM1 IMSS trophozoites after 48 hrs,Confirmatory,17371810.0,
1163,322093,3,4,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Trichomonas vaginalis G3 assessed as parasite death at 1 uM after 24 hrs,Other,17371810.0,
1164,322753,9,5,,103189534,4173,Unspecified,3915660.0,1595.0,200.0,IC50,Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay,Confirmatory,17194716.0,
1165,323659,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus anaerobius,Other,17403999.0,
1166,323660,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus stomatis,Other,17403999.0,
1167,324729,3,3,,103189534,4173,Inactive,,,,,Antimicrobial activity against Fusobacterium nucleatum biofilms assessed as decrease in viable cell count at 2 uM after 30 mins,Other,17325219.0,
1168,325505,3,3,,103189534,4173,Inactive,,,,,Inhibition of Giardia lamblia recombinant nitroreductase 1 (EAA43030.1) expressed in Escherichia coli at 5 uM,Other,17438059.0,
1169,331191,6,2,,103189534,4173,Active,,,0.28600000000000003,IC50,Antiprotozoal activity against Trichomonas vaginalis,Confirmatory,18486471.0,
1170,331192,6,2,,103189534,4173,Active,,,1.286,IC50,Antiprotozoal activity against Giardia lamblia,Confirmatory,18486471.0,
1171,331193,6,2,,103189534,4173,Active,,,0.7709999999999999,IC50,Antiprotozoal activity against Entamoeba histolytica,Confirmatory,18486471.0,
1172,331194,6,2,,103189534,4173,Inconclusive,,,,IC50,Antiprotozoal activity against Leishmania mexicana,Confirmatory,18486471.0,
1173,331195,6,2,,103189534,4173,Inconclusive,,,,IC50,Antiprotozoal activity against Plasmodium berghei,Confirmatory,18486471.0,
1174,341089,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile clinical isolates by agar dilution method,Other,17517836.0,
1175,341722,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori SS1 after 96 hrs,Other,18611050.0,
1176,341723,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-resistant Helicobacter pylori ATCC 43504 after 96 hrs,Other,18611050.0,
1177,346839,8,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against wild type Mycobacterium tuberculosis H37Rv ATCC 27294 after 2 weeks,Other,19209889.0,
1178,346840,7,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against wild type Mycobacterium tuberculosis H37Rv NRP-2 stage after 3 weeks under anaerobic condition,Other,19209889.0,
1179,346841,8,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis with cofactor F420 mutant,Other,19209889.0,
1180,346842,8,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis with deazaflavin-dependent nitroreductase mutant,Other,19209889.0,
1181,346843,7,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis with deazaflavin-dependent nitroreductase mutant under anaerobic condition,Other,19209889.0,
1182,351909,6,3,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay,Confirmatory,18378360.0,
1183,351910,6,2,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by trypan blue exclusion method,Confirmatory,18378360.0,
1184,351911,3,3,,103189534,4173,Unspecified,,,,,"Safety index, ratio of IC50 for human kidney epithelial cells to IC50 for Entamoeba histolytica HM-1:IMSS",Other,18378360.0,
1185,360611,6,2,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS trophozoites after 48 hrs by MTT/PMS assay,Other,11374974.0,
1186,360612,6,2,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against Giardia lamblia IMSS:0989:1 after 48 hrs by MTT/PMS assay,Other,11374974.0,
1187,366938,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-sensitive Helicobacter pylori at 8 ug/disk after 3 to 5 days by filter paper disk diffusion method,Other,18192086.0,
1188,366941,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-resistant Helicobacter pylori at 8 ug/disk after 3 to 5 days by filter paper disk diffusion method,Other,18192086.0,
1189,366948,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori clinical isolates at 8 ug/disk after 3 to 5 days by filter paper disk diffusion method,Other,18192086.0,
1190,366964,6,2,,103189534,4173,Active,,,1.81,IC50,Antiamnesic activity against Entamoeba histolytica HM1:IMSS after 72 hrs by microplate method,Confirmatory,18222017.0,
1191,366965,6,2,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human KB cells after 44 hrs by MTT assay,Confirmatory,18222017.0,
1192,366966,3,3,,103189534,4173,Unspecified,,,,,"Safety index, IC50 for human KB cells to IC50 for Entamoeba histolytica HM1:IMSS",Other,18222017.0,
1193,367002,6,2,,103189534,4173,Active,,,1.81,IC50,Antiamnesic activity against Entamoeba histolytica HM1:IMSS after 72 hrs by microdilution method,Confirmatory,18242785.0,
1194,369333,3,4,,103189534,4173,Unspecified,,,,,Antimicrobial activity against log phase recombinant Mycobacterium tuberculosis H37Rv-lux with plasmid MV361 at 10 ug/ml incubated for 7 days assessed as bacterial count after 4 days,Other,10879539.0,
1195,369334,3,4,,103189534,4173,Unspecified,,,,,Antimicrobial activity against log phase recombinant Mycobacterium tuberculosis H37Rv-lux with plasmid MV361 at 10 ug/ml incubated for 7 days assessed as bacterial count,Other,10879539.0,
1196,371504,6,2,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HMI:IMSS after 72 hrs by microdilution method,Confirmatory,18068273.0,
1197,371505,6,3,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay,Confirmatory,18068273.0,
1198,371506,3,3,,103189534,4173,Unspecified,,,,,"Safety index, ratio of IC50 for human kidney epithelial cells to IC50 for Entamoeba histolytica HMI:IMSS",Other,18068273.0,
1199,373105,7,2,,103189534,4173,Unspecified,,,2630.0,IC50,Antiamnesic activity against Entamoeba histolytica HM1:IMSS after 72 hrs by microdilution method,Confirmatory,18675491.0,
1200,373575,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Ruminococcus sp. CCRI-16110 containing vanD-like gene by agar dilution method,Other,17724150.0,
1201,375861,5,2,,103189534,4173,Active,,,1.4791100000000001,EC50,Antigiardial activity against metronidazole-resistant Giardia lamblia isolate 713 trophozoite after 2 days by bactiter-glo viability assay,Confirmatory,19480409.0,
1202,375862,3,3,,103189534,4173,Unspecified,,,,,Resistance ratio of EC50 for metronidazole-resistant Giardia lamblia isolate 106 to EC50 for metronidazole-sensitive Giardia lamblia isolate 106,Other,19480409.0,
1203,375863,8,1,,103189534,4173,Active,,,2.63,EC50,Antigiardial activity against Giardia lamblia trophozoites isolates after 2 days by bactiter-glo viability assay,Confirmatory,19480409.0,
1204,375864,5,2,,103189534,4173,Unspecified,,,6025.6,IC50,Cytotoxicity against human HeLa cells after 2 days by Alamar blue assay,Confirmatory,19480409.0,
1205,375865,3,4,,103189534,4173,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human HeLa cells to EC50 for Giardia lamblia trophozoites isolates",Other,19480409.0,
1206,375866,3,4,,103189534,4173,Unspecified,,,,,"Antigiardial activity against Giardia lamblia GS/M trophozoites infected in C57BL/6 mouse assessed as reduction in live trophozoite number in small intestine at 10 mg/kg, po administered as 5 doses for 3 days relative to control",Other,19480409.0,
1207,375867,3,4,,103189534,4173,Inactive,,,,,"Antigiardial activity against Giardia lamblia GS/M trophozoites infected in C57BL/6 mouse assessed as reduction in live trophozoite number in small intestine at 2 mg/kg, po administered as 5 doses for 3 days",Other,19480409.0,
1208,375868,3,4,,103189534,4173,Inactive,,,,,"Antigiardial activity against Giardia lamblia GS/M trophozoites infected in C57BL/6 mouse assessed as parasite eradication in small intestine at 10 mg/kg, po administered as 5 doses for 3 days",Other,19480409.0,
1209,375870,5,2,,103189534,4173,Active,,,44.6684,EC50,Antigiardial activity against metronidazole-sensitive Giardia lamblia isolate 713 trophozoite after 2 days by bactiter-glo viability assay,Confirmatory,19480409.0,
1210,375871,5,2,,103189534,4173,Active,,,3.98107,EC50,Antigiardial activity against metronidazole-resistant Giardia lamblia isolate 106 trophozoite after 2 days by bactiter-glo viability assay,Confirmatory,19480409.0,
1211,375872,5,2,,103189534,4173,Active,,,25.704,EC50,Antigiardial activity against metronidazole-sensitive Giardia lamblia isolate 106 trophozoite after 2 days by bactiter-glo viability assay,Confirmatory,19480409.0,
1212,375873,3,3,,103189534,4173,Unspecified,,,,,Resistance ratio of EC50 for metronidazole-resistant Giardia lamblia isolate 713 to EC50 for metronidazole-sensitive Giardia lamblia isolate 713,Other,19480409.0,
1213,377875,6,2,,103189534,4173,Unspecified,,,,,Antifungal activity against Giardia intestinalis ATCC 30888 after 48 hrs by XTT assay,Other,11076565.0,
1214,377877,6,2,,103189534,4173,Inactive,,,,,Antifungal activity against Giardia intestinalis ATCC 30888 assessed as impairment of parasite motility after 2 hrs,Other,11076565.0,
1215,377878,6,2,,103189534,4173,Inactive,,,,,Antifungal activity against Giardia intestinalis ATCC 30888 assessed as impairment of parasite motility after 4 hrs,Other,11076565.0,
1216,377889,3,3,,103189534,4173,Active,,,,,Antimicrobial activity against Trichomonas,Other,11076565.0,
1217,379774,6,2,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against axenically grown trophozoites of Giardia lamblia IMSS:0989:1 after 48 hrs by MTT method,Other,10346950.0,
1218,379775,6,2,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against axenically grown trophozoites of Entamoeba histolytica HM1-IMSS after 48 hrs by MTT method,Other,10346950.0,
1219,379776,3,4,,103189534,4173,Inactive,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT method,Other,10346950.0,
1220,379777,3,4,,103189534,4173,Inactive,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT method,Other,10346950.0,
1221,379778,3,4,,103189534,4173,Inactive,,,,,Cytotoxicity against human A549 cells after 7 days by MTT method,Other,10346950.0,
1222,380452,5,3,,103189534,4173,Inconclusive,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv at 6.25 mg/ml,Other,16562840.0,
1223,380454,7,2,,103189534,4173,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 by standard broth microdilution technique,Other,16562840.0,
1224,380455,7,2,,103189534,4173,Inconclusive,,,,,Antibacterial activity against Streptococcus pyogenes ATCC 19615 by standard broth microdilution technique,Other,16562840.0,
1225,380456,7,2,,103189534,4173,Inconclusive,,,,,Antibacterial activity against Enterococcus faecalis by standard broth microdilution technique,Other,16562840.0,
1226,380457,7,2,,103189534,4173,Inconclusive,,,,,Antibacterial activity against Escherichia coli ATCC 25922 by standard broth microdilution technique,Other,16562840.0,
1227,380458,7,2,,103189534,4173,Inconclusive,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by standard broth microdilution technique,Other,16562840.0,
1228,380459,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis DSM 2151 by standard broth microdilution technique,Other,16562840.0,
1229,380460,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides thetaiotaomicron DSM 2255 by standard broth microdilution technique,Other,16562840.0,
1230,380831,8,1,,103189534,4173,Active,,,,,Antigiardial activity against Giardia intestinalis,Other,10479310.0,
1231,382587,6,2,,103189534,4173,Active,,,1.81,IC50,Antiamnesic activity against Entamoeba histolytica HM1 IMSS after 72 hrs by serial dilution method,Confirmatory,17513021.0,
1232,382588,6,2,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human KB cells after 44 hrs by MTT assay,Confirmatory,17513021.0,
1233,382589,3,3,,103189534,4173,Unspecified,,,,,"Selectivity index, Ratio of IC50 for human KB cells to IC50 for Entamoeba histolytica HM1 IMSS",Other,17513021.0,
1234,386920,3,3,,103189534,4173,Inactive,,,,,Spermicidal activity in liquefied human semen assessed as drug level required to kill 100% sperm in 20 seconds,Other,18061311.0,
1235,386921,6,2,,103189534,4173,Inactive,,,,,Antifungal activity against Candida albicans after 48 hrs by broth microdilution technique,Other,18061311.0,
1236,386922,6,2,,103189534,4173,Inactive,,,,,Antifungal activity against Cryptococcus neoformans after 48 hrs by broth microdilution technique,Other,18061311.0,
1237,386923,6,2,,103189534,4173,Inactive,,,,,Antifungal activity against Sporothrix schenckii after 48 hrs by broth microdilution technique,Other,18061311.0,
1238,386924,6,2,,103189534,4173,Inactive,,,,,Antifungal activity against Trichophyton mentagrophytes after 48 hrs by broth microdilution technique,Other,18061311.0,
1239,386925,6,2,,103189534,4173,Inactive,,,,,Antifungal activity against Aspergillus fumigatus after 48 hrs by broth microdilution technique,Other,18061311.0,
1240,386926,6,2,,103189534,4173,Inactive,,,,,Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by broth microdilution technique,Other,18061311.0,
1241,386927,7,2,,103189534,4173,Unspecified,,,,,Antitrichomonas activity against Trichomonas vaginalis after 48 hrs by trypan blue staining,Other,18061311.0,
1242,393131,6,2,,103189534,4173,Active,,,1.226,IC50,Antiprotozoal activity against Giardia intestinalis IMSS:0981:1 trophozoites after 48 hrs,Confirmatory,19186059.0,
1243,393132,6,2,,103189534,4173,Active,,,0.23600000000000002,IC50,Antiprotozoal activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs,Confirmatory,19186059.0,
1244,394719,6,2,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution method,Confirmatory,18187238.0,
1245,394720,6,3,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay,Confirmatory,18187238.0,
1246,394721,3,3,,103189534,4173,Unspecified,,,,,"Selectivity index, ratio of IC50 for human kidney epithelial cells to IC50 for Entamoeba histolytica HM-1:IMSS trophozoites",Other,18187238.0,
1247,396583,6,2,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution assay,Confirmatory,18068873.0,
1248,409946,3,9,,103189534,4173,Inactive,113980.0,4129.0,,,Inhibition of human recombinant MAOB at 100 uM by fluorimetric method,Other,18834112.0,
1249,409951,3,9,,103189534,4173,Inactive,113980.0,4129.0,,,Inhibition of human liver MAOB,Other,18834112.0,
1250,416727,6,2,,103189534,4173,Active,,,2.7460000000000004,IC50,Antitrichomonas activity against Trichomonas vaginalis TVR87 after 48 hrs by trypan blue staining,Confirmatory,18590939.0,
1251,416728,3,3,,103189534,4173,Unspecified,,,,,"Specificity index, ratio of IC50 for human THP1 cells to IC50 for Trichomonas vaginalis TVR87",Other,18590939.0,
1252,416729,6,2,,103189534,4173,Unspecified,,,1460.0,IC50,Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide-based flow cytometry,Confirmatory,18590939.0,
1253,416730,3,4,,103189534,4173,Unspecified,,,,,Induction of mutagenicity in Salmonella Typhimurium YG1042 assessed as number of revertant per ug after 48 hrs,Other,18590939.0,
1254,416731,3,4,,103189534,4173,Unspecified,,,,,Induction of mutagenicity in Salmonella Typhimurium TA100 assessed as number of revertant per ug after 48 hrs,Other,18590939.0,
1255,416732,3,4,,103189534,4173,Unspecified,,,,,Induction of mutagenicity in Salmonella Typhimurium YG1042 assessed as number of revertant per nmol after 48 hrs,Other,18590939.0,
1256,416733,3,4,,103189534,4173,Unspecified,,,,,Induction of mutagenicity in Salmonella Typhimurium TA100 assessed as number of revertant per nmol after 48 hrs,Other,18590939.0,
1257,416736,3,4,,103189534,4173,Unspecified,,,,,Ratio of number of revertant per nmol of drug for Salmonella Typhimurium YG1042 to number of revertant per nmol of drug for Salmonella Typhimurium TA100,Other,18590939.0,
1258,417443,6,3,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against HEK cells after 44 hrs by MTT assay,Confirmatory,18384916.0,
1259,417444,3,3,,103189534,4173,Unspecified,,,,,"Safety index, ratio of IC50 for HEK cells to IC50 for Entamoeba histolytica HM-1:IMSS",Other,18384916.0,
1260,417445,6,2,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by trypan blue exclusion assay,Confirmatory,18384916.0,
1261,424319,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister pneumosintes by agar dilution method,Other,17923492.0,
1262,424320,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister micraerophilus by agar dilution method,Other,17923492.0,
1263,424321,6,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister pneumosintes assessed as susceptibility breakpoint by CLSI method,Other,17923492.0,
1264,424322,6,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister micraerophilus assessed as susceptibility breakpoint by CLSI method,Other,17923492.0,
1265,424323,5,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister pneumosintes assessed as susceptibility breakpoint by CA-SFM method,Other,17923492.0,
1266,424324,5,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister micraerophilus assessed as susceptibility breakpoint by CA-SFM method,Other,17923492.0,
1267,424327,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister propionicifaciens by agar dilution method,Other,17923492.0,
1268,424328,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister invisus by agar dilution method,Other,17923492.0,
1269,424329,6,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister propionicifaciens assessed as susceptibility breakpoint by CLSI method,Other,17923492.0,
1270,424330,6,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister invisus assessed as susceptibility breakpoint by CLSI method,Other,17923492.0,
1271,424331,5,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister propionicifaciens assessed as susceptibility breakpoint by CA-SFM method,Other,17923492.0,
1272,424332,5,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Dialister invisus assessed as susceptibility breakpoint by CA-SFM method,Other,17923492.0,
1273,425075,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1274,425076,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1275,425077,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Bacteroides ovatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1276,425078,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Bacteroides vulgatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1277,425079,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Bacteroides distasonis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1278,425080,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Prevotella bivia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1279,425081,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Prevotella disiens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1280,425082,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1281,425083,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Prevotella nigrescens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1282,425084,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Prevotella melaninogenica isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1283,425085,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Prevotella denticola isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1284,425086,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Prevotella corporis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1285,425087,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Prevotella buccae isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1286,425088,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1287,425089,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1288,425090,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas levii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1289,425091,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1290,425092,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium necrophorum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1291,425093,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium varium isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1292,425094,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Fusobacterium mortiferum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1293,425095,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1294,425096,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Micromonas micros isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1295,425097,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus anaerobius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1296,425098,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus prevotii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1297,425099,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus tetradius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1298,425100,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1299,425101,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1300,425102,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1301,425103,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium innocuum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1302,425104,8,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium ramosum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1303,425105,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium bifermentans isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1304,425106,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium clostridioforme isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1305,425107,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium sordellii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1306,425108,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium paraputrificum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1307,425109,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium cadaveris isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method,Other,17938185.0,
1308,425110,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis,Other,17938185.0,
1309,425111,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis,Other,17938185.0,
1310,425112,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis,Other,17938185.0,
1311,425113,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis,Other,17938185.0,
1312,425114,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis,Other,17938185.0,
1313,425115,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis,Other,17938185.0,
1314,425116,7,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis,Other,17938185.0,
1315,425652,7,2,,103189534,4173,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
1316,425653,7,2,,103189534,4173,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
1317,426304,6,2,,103189534,4173,Active,,,0.29,IC50,Antiparasitic activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs by Hill culture method,Confirmatory,19208443.0,
1318,426305,6,2,,103189534,4173,Unspecified,,,68.0,CC50,Cytotoxicity against MDCK cells after 72 hrs by MTT assay,Confirmatory,19208443.0,
1319,426309,6,2,,103189534,4173,Active,,,5.36,IC50,Antiparasitic activity against Giardia intestinalis IMSS:0696 trophozoites after 48 hrs by Hill culture method,Confirmatory,19208443.0,
1320,426310,6,2,,103189534,4173,Active,,,0.77,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 48 hrs by Hill culture method,Confirmatory,19208443.0,
1321,433017,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1322,433018,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides caccae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1323,433019,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides ovatus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1324,433020,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides stercoris isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1325,433149,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides thetaiotaomicron isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1326,433150,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides uniformis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1327,433151,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides vulgatus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1328,433152,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Parabacteroides distasonis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1329,433153,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Parabacteroides merdae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1330,433154,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Porphyromonas asaccharolyticus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1331,433155,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Porphyromonas somerae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1332,433156,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella bivia isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1333,433157,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium perfringens isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1334,433158,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium aminovalericum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1335,433159,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium cadaveris isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1336,433160,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium clostridioforme isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1337,433161,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium innocuum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1338,433162,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium malenominatum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1339,433163,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium sphenoides isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1340,433164,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Propionibacterium acnes isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1341,433165,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Anaerococcus prevotii isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1342,433166,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Anaerococcus tetradius isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1343,433167,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Finegoldia magna isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1344,433168,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptoniphilus asaccharolyticus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1345,433169,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus anaerobius isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1346,433170,7,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus micros isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1347,433198,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1348,433199,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides caccae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1349,433200,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides ovatus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1350,433201,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides stercoris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1351,433202,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides thetaiotaomicron isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1352,433351,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides uniformis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1353,433352,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides vulgatus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1354,433353,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Parabacteroides distasonis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1355,433354,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Parabacteroides merdae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1356,433355,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Porphyromonas asaccharolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1357,433356,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Porphyromonas somerae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1358,433357,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella bivia isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1359,433358,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium perfringens isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1360,433359,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium aminovalericum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1361,433360,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium cadaveris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1362,433361,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium clostridioforme isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1363,433362,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium innocuum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1364,433363,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium malenominatum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1365,433364,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium sphenoides isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1366,433365,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Propionibacterium acnes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1367,433366,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Anaerococcus prevotii isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1368,433367,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Anaerococcus tetradius isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1369,433368,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Finegoldia magna isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1370,433369,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptoniphilus asaccharolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1371,433370,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus anaerobius isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1372,433371,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus micros isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1373,433375,10,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Anaerococcus vaginalis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1374,433376,3,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Anaerococcus vaginalis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method,Other,18070958.0,
1375,434955,1,2,,855672,4173,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1376,434962,1,2,,855672,4173,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1377,434973,1,3,,855672,4173,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1378,434989,1,1,,855672,4173,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1379,435003,1,3,,855672,4173,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1380,435005,1,1,,855672,4173,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
1381,435022,2,2,,855672,4173,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1382,435030,1,2,,855672,4173,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1383,435030,1,2,,855672,4173,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1384,440729,3,5,,103189534,4173,Active,,,,,Antimycobacterial activity against 30 day old non-replicating dormant cultures of Mycobacterium tuberculosis H37Rv assessed as reduction of bacterial viability measured after 11 days by resazurin reduction assay,Other,19827833.0,
1385,440732,3,5,,103189534,4173,Active,,,,,Antimycobacterial activity against 30 day old non-replicating dormant cultures of Mycobacterium tuberculosis H37Rv assessed as revival of bacterial viability exposed for 11 days measured after 30 days post exposure by resazurin reduction assay,Other,19827833.0,
1386,444050,7,1,,103189534,4173,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
1387,444051,6,2,,103189534,4173,Unspecified,,,,,Total clearance in human,Other,20070106.0,
1388,444052,6,2,,103189534,4173,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
1389,444053,6,2,,103189534,4173,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
1390,444054,6,1,,103189534,4173,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
1391,444055,3,3,,103189534,4173,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
1392,444056,3,3,,103189534,4173,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
1393,444057,3,3,,103189534,4173,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
1394,444058,6,2,,103189534,4173,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
1395,449728,1,2,,855672,4173,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1396,449739,1,2,,855672,4173,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
1397,449762,1,2,,855672,4173,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1398,449763,1,3,,855672,4173,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1399,449768,1,1,,855672,4173,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1400,450072,8,1,,103189534,4173,Unspecified,,,,,Antigiardial activity against Giardia lamblia WB (ATCC 30957) trophozoites after 24 hrs by trypan blue assay,Other,19683930.0,
1401,454072,4,3,,103189534,4173,Inactive,,,,,Inhibition of Helicobacter pylori ATCC 43504 urease assessed as ammonia production at 1 mM after 3 hrs by indophenol method,Other,19804978.0,
1402,463073,1,2,,855672,4173,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1403,463075,1,1,,855672,4173,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1404,463079,1,2,,855672,4173,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1405,463082,1,1,,855672,4173,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1406,463104,1,2,,855672,4173,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1407,463111,1,1,,855672,4173,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1408,463115,1,1,,855672,4173,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1409,463141,1,2,,855672,4173,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1410,463165,1,1,,855672,4173,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1411,463187,1,1,,855672,4173,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1412,463189,1,1,,855672,4173,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1413,463190,1,2,,855672,4173,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1414,463193,1,1,,855672,4173,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1415,463195,1,2,,855672,4173,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1416,463210,1,2,,855672,4173,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1417,463212,1,1,,855672,4173,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1418,463254,1,1,,855672,4173,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1419,463254,1,1,,26719631,4173,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1420,467622,5,2,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM1:IMSS trophozoites after 72 hrs by microdilution method,Confirmatory,19589625.0,
1421,467623,5,2,,103189534,4173,Unspecified,,,116.0,IC50,Toxicity in rat H9c2 cells after 48 hrs by MTT assay,Confirmatory,19589625.0,
1422,467624,3,4,,103189534,4173,Unspecified,,,,,"Safety index, ratio of IC50 for rat H9c2 cells to IC50 for Entamoeba histolytica HM1:IMSS trophozoites",Other,19589625.0,
1423,467900,3,4,,103189534,4173,Unspecified,,,,,Sperimcidal activity against human spermatozoa assessed as sperm motility at 1 % drug solution%,Other,19906466.0,
1424,467902,7,1,,103189534,4173,Active,,,,,Antitrichomonal activity against Trichomonas vaginalis after 48 hrs by trypan blue exclusion assay,Other,19906466.0,
1425,467909,3,4,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HeLa cells at 200 ug/ml after 24 hrs by MTT assay,Other,19906466.0,
1426,472376,5,2,,103189534,4173,Unspecified,,,500.0,IC50,Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry,Confirmatory,19748781.0,
1427,472379,5,2,,103189534,4173,Active,,,2.7,IC50,Antitrichomonal activity against Trichomonas vaginalis TVR79 after 48 hrs by optical microscopy,Confirmatory,19748781.0,
1428,477784,5,2,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution technique,Confirmatory,20122767.0,
1429,477785,7,1,,103189534,4173,Active,,,,,Antigiardial activity against Giardia intestinalis Thai trophozoites after 24 hrs by inverted microscopic analysis,Other,20122767.0,
1430,477786,5,2,,103189534,4173,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by SRB assay,Confirmatory,20122767.0,
1431,477787,3,4,,103189534,4173,Inconclusive,,,,,"Safety index, ratio of IC50 for african green monkey Vero cells to IC50 for Entamoeba histolytica HM-1:IMSS",Other,20122767.0,
1432,484209,5,2,,103189534,4173,Active,,,2.5,IC50,Antiprotozoal activity against Entamoeba histolytica after 24 hrs by trypan blue assay,Confirmatory,20478706.0,
1433,484210,5,2,,103189534,4173,Active,,,3.0,IC50,Antiprotozoal activity against Entamoeba invadens after 24 hrs by trypan blue assay,Confirmatory,20478706.0,
1434,485270,1,1,,855672,4173,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1435,485272,1,1,,855672,4173,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1436,485273,2,1,,855672,4173,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1437,485275,1,3,,855672,4173,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1438,485281,1,1,,855672,4173,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1439,485281,1,1,,11112343,4173,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1440,485281,1,1,,26719631,4173,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1441,485290,1,1,,855672,4173,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1442,485290,1,1,,11112343,4173,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1443,485290,1,1,,17389815,4173,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1444,485290,1,1,,26719631,4173,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1445,485290,1,1,,26746949,4173,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1446,485294,1,1,,855672,4173,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1447,485294,1,1,,26719631,4173,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1448,485297,1,1,,855672,4173,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1449,485297,1,1,,26719631,4173,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1450,485298,1,1,,855672,4173,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1451,485298,1,1,,26719631,4173,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1452,485313,1,2,,855672,4173,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1453,485313,1,2,,26719631,4173,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1454,485314,1,1,,855672,4173,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1455,485314,1,1,,26719631,4173,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1456,485317,1,2,,855672,4173,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1457,485341,1,1,,855672,4173,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1458,485341,1,1,,26719631,4173,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1459,485344,1,1,,855672,4173,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1460,485344,1,1,,26719631,4173,Active,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1461,485346,1,1,,855672,4173,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1462,485346,1,1,,855672,4173,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1463,485347,1,2,,855672,4173,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1464,485347,1,2,,26719631,4173,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1465,485349,1,1,,855672,4173,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1466,485350,1,2,,92124203,4173,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1467,485350,1,2,,92124968,4173,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1468,485353,2,1,,855672,4173,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1469,485353,2,1,,26719631,4173,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1470,485358,1,1,,855672,4173,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1471,485358,1,1,,26719631,4173,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1472,485360,1,1,,855672,4173,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1473,485364,1,1,,855672,4173,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1474,485364,1,1,,26719631,4173,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1475,485367,1,2,,855672,4173,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1476,485367,1,2,,26719631,4173,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1477,488806,1,2,,855672,4173,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1478,488837,1,1,,855672,4173,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1479,488837,1,1,,26719631,4173,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1480,488839,1,1,,855672,4173,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1481,488839,1,1,,855672,4173,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1482,488847,1,3,,855672,4173,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1483,488862,1,1,,855672,4173,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1484,488890,1,2,,855672,4173,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1485,488895,1,2,,855672,4173,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1486,488896,1,1,,855672,4173,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1487,488899,1,1,,855672,4173,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1488,488922,1,2,,855672,4173,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1489,488965,1,2,,855672,4173,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1490,488966,1,1,,855672,4173,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1491,488975,1,2,,855672,4173,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1492,488977,1,2,,855672,4173,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1493,489030,2,1,,855672,4173,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1494,489031,2,1,,855672,4173,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1495,490816,5,2,,103189534,4173,Active,,,1.228,IC50,Antiprotozoal activity against Giardia intestinalis IMSS:0989:1 after 48 hrs,Confirmatory,20430484.0,
1496,490817,5,2,,103189534,4173,Active,,,0.35,IC50,Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS after 48 hrs,Confirmatory,20430484.0,
1497,490818,5,2,,103189534,4173,Active,,,0.21600000000000003,IC50,Antiprotozoal activity against Trichomonas vaginalis G3 after 48 hrs,Confirmatory,20430484.0,
1498,490819,5,2,,103189534,4173,Inconclusive,,,,IC50,Antileishmanial activity against Leishmania mexicana MHOM/MX92/UAY68 after 48 hrs,Confirmatory,20430484.0,
1499,490820,3,3,,103189534,4173,Inconclusive,,,,,Antitrichinellosis activity against Trichinella spiralis ML assessed as reduction of parasites viability at 0.18 uM after 3 days by MTT assay,Other,20430484.0,
1500,490821,3,3,,103189534,4173,Inconclusive,,,,,Antitrichinellosis activity against Trichinella spiralis ML assessed as reduction of parasites viability at 0 37 uM after 3 days by MTT assay,Other,20430484.0,
1501,490822,3,3,,103189534,4173,Inconclusive,,,,,Antitrichinellosis activity against Trichinella spiralis ML assessed as reduction of parasites viability at 1.8 uM after 3 days by MTT assay,Other,20430484.0,
1502,492947,1,1,,855672,4173,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1503,492947,1,1,,26719631,4173,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1504,492953,1,1,,855672,4173,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1505,492956,1,1,,855672,4173,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1506,492967,1,2,,92124968,4173,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1507,492967,1,2,,92254470,4173,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1508,492967,1,2,,99301095,4173,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1509,492972,1,1,,855672,4173,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1510,493005,1,1,,855672,4173,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1511,493008,1,1,,855672,4173,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1512,493008,1,1,,855672,4173,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1513,493008,1,1,,855672,4173,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1514,493008,1,1,,855672,4173,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1515,493011,1,1,,855672,4173,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1516,493012,1,1,,855672,4173,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1517,493014,1,1,,855672,4173,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1518,493014,1,1,,26719631,4173,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1519,493027,1,2,,855672,4173,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1520,493027,1,2,,855672,4173,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1521,493033,1,2,,92124203,4173,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1522,493033,1,2,,92124968,4173,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1523,493035,1,2,,855672,4173,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1524,493035,1,2,,855672,4173,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1525,493036,1,2,,855672,4173,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1526,493056,1,1,,855672,4173,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1527,493056,1,1,,26719631,4173,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1528,493084,1,1,,855672,4173,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1529,493084,1,1,,26719631,4173,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1530,493087,1,1,,855672,4173,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1531,493091,1,1,,855672,4173,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1532,493098,1,1,,855672,4173,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1533,493131,1,1,,855672,4173,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1534,493140,1,1,,103913888,4173,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1535,493160,1,1,,855672,4173,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1536,493162,1,2,,99301095,4173,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1537,493187,1,2,,855672,4173,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1538,493244,1,1,,855672,4173,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1539,493244,1,1,,855672,4173,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1540,493244,1,1,,855672,4173,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1541,493244,1,1,,855672,4173,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1542,494129,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori ATCC 43504 clinical isolates after 72 hrs by agar dilution method,Other,20630755.0,
1543,494130,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-resistant Helicobacter pylori NCTC 11637 after 72 hrs by agar dilution method,Other,20630755.0,
1544,494131,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-resistant Helicobacter pylori isolate 1 after 72 hrs by agar dilution method,Other,20630755.0,
1545,494132,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-resistant Helicobacter pylori isolate 8 after 72 hrs by agar dilution method,Other,20630755.0,
1546,494134,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-resistant Helicobacter pylori isolate 18 after 72 hrs by agar dilution method,Other,20630755.0,
1547,494135,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against metronidazole-resistant Helicobacter pylori isolate 20 after 72 hrs by agar dilution method,Other,20630755.0,
1548,496823,4,2,,103189534,4173,Active,,,3.0,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
1549,498307,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae DSM 16972T expressing nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1550,498308,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 427 expressing nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1551,498309,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 430 expressing nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1552,498310,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 432 expressing nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1553,498311,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 466 expressing nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1554,498312,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 475 expressing nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1555,498313,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBP 9 expressing nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1556,498314,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBP 19 expressing nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1557,498315,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 330 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1558,498316,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 331 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1559,498317,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 332 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1560,498318,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 333 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1561,498319,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 334 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1562,498320,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 336 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1563,498321,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 339 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1564,498322,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 343 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1565,498323,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 346 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1566,498324,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 350 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1567,498325,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 361 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1568,498326,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 365 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1569,498327,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 371 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1570,498328,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 374 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1571,498329,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 445 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1572,498330,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 464 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1573,498331,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 467 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1574,498332,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 478 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1575,498333,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBP 4 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1576,498334,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBP 38 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1577,498335,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBP 51 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1578,498336,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBP 52 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1579,498337,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBP 65 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1580,498338,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBP 69 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1581,498339,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBP 78 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1582,498340,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nanceiensis LBN 293b deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1583,498341,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nanceiensis LBN 297 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1584,498342,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nanceiensis LBN 298 deficient in nim gene assessed as inhibition of growth at 48 hrs by Etest method,Other,19805556.0,
1585,498343,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nanceiensis LBN 410 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1586,498344,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nanceiensis LBP 66 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1587,498345,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 330 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1588,498346,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 331 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1589,498347,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 332 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1590,498348,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 333 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1591,498349,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 334 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1592,498350,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 336 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1593,498351,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 339 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1594,498352,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 343 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1595,498538,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 346 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1596,498539,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 350 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1597,498540,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 361 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1598,498541,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 365 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1599,498542,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 371 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1600,498543,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 374 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1601,498544,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 445 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1602,498545,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 464 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1603,498546,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 467 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1604,498547,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBN 478 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1605,498548,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBP 4 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1606,498549,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBP 38 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1607,498550,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBP 51 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1608,498551,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBP 52 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1609,498552,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBP 65 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1610,498553,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBP 69 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1611,498554,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella bivia LBP 78 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1612,498555,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella nanceiensis LBN 293b deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1613,498556,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella nanceiensis LBN 297 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1614,498557,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella nanceiensis LBN 298 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1615,498558,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella nanceiensis LBN 410 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1616,498559,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against slow growing colonies of Prevotella nanceiensis LBP 66 deficient in nim gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1617,498560,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella buccae LBN 465 deficient in nimI gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1618,498561,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis ATCC 25285T deficient in nimI gene assessed as inhibition of growth at 48 hrs by agar dilution method,Other,19805556.0,
1619,498562,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae DSM 16972T expressing nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentrations of compound by agar dilution method,Other,19805556.0,
1620,498563,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 427 expressing nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentrations of compound by agar dilution method,Other,19805556.0,
1621,498564,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 430 expressing nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentrations of compound by agar dilution method,Other,19805556.0,
1622,498565,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 432 expressing nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentration of compound by agar dilution method,Other,19805556.0,
1623,498566,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 475 expressing nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentration of compound by agar dilution method,Other,19805556.0,
1624,498567,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBP19 expressing nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentration of compound by agar dilution method,Other,19805556.0,
1625,498568,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 332 deficient in nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentration of compound by agar dilution method,Other,19805556.0,
1626,498569,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 371 deficient in nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentration of compound by agar dilution method,Other,19805556.0,
1627,498570,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 467 deficient in nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentration of compound by agar dilution method,Other,19805556.0,
1628,498571,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella buccae LBN 465 deficient in nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentration of compound by agar dilution method,Other,19805556.0,
1629,498572,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nanceiensis LBN 293b deficient in nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentration of compound by agar dilution method,Other,19805556.0,
1630,498573,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nanceiensis LBN 410 deficient in nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentration of compound by agar dilution method,Other,19805556.0,
1631,498574,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis ATCC 25285T deficient in nimI gene assessed as inhibition of growth after several passages on plates containing increasing concentration of compound by agar dilution method,Other,19805556.0,
1632,498575,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae DSM 16972T expressing nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1633,498576,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 427 expressing nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1634,498577,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 430 expressing nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1635,498578,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 432 expressing nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1636,498579,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBN 475 expressing nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1637,498580,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella baroniae LBP19 expressing nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1638,498581,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 332 deficient in nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1639,498582,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 371 deficient in nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1640,498583,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia LBN 467 deficient in nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1641,498584,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella buccae LBN 465 deficient in nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1642,498585,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nanceiensis LBN 293b deficient in nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1643,498586,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nanceiensis LBN 410 deficient in nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1644,498587,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis ATCC 25285T deficient in nimI gene assessed as inhibition of growth after three consecutive subcultures on compound free medium by agar dilution method,Other,19805556.0,
1645,501583,4,2,,103189534,4173,Active,,,0.72,IC50,Antiparasitic activity against Trichomonas vaginalis T1 after 24 hrs by hemocytometric analysis,Confirmatory,20667728.0,
1646,501584,4,2,,103189534,4173,Active,,,0.77,IC50,Antiparasitic activity against Trichomonas vaginalis G3 after 24 hrs by hemocytometric analysis,Confirmatory,20667728.0,
1647,502038,4,2,,103189534,4173,Active,,,5.36,IC50,Antimicrobial activity against Giardia intestinalis IMSS:0696:1 after 48 hrs,Confirmatory,20674375.0,
1648,502039,4,2,,103189534,4173,Active,,,0.29,IC50,Antimicrobial activity against Trichomonas vaginalis GT3 after 48 hrs,Confirmatory,20674375.0,
1649,502040,4,4,,103189534,4173,Active,,,0.77,IC50,Antimicrobial activity against Entamoeba histolytica HM-1:IMSS after 48 hrs,Confirmatory,20674375.0,
1650,502520,3,4,,103189534,4173,Unspecified,,,,,Inhibition of Helicobacter pylori invasion into human AGS cells at 2.5 uM after 6 hrs,Other,20705463.0,
1651,502523,3,4,,103189534,4173,Inactive,,,,,Inhibition of Helicobacter pylori-induced inflammation in human AGS cells assessed as reduction of NF-kappaB activity at 2.5 uM after 6 hrs by luciferase reporter gene assay relative to control,Other,20705463.0,
1652,502656,4,4,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM1:IMSS after 72 hrs by microplate method,Confirmatory,20719524.0,
1653,502657,5,2,,103189534,4173,Inconclusive,,,,,Cytotoxicity against BALB/c mouse splenocyte by [3H]thymidine incorporation assay,Other,20719524.0,
1654,502777,2,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori ATCC 700392 at 0.8 ug/ml by disk agar diffusion method,Other,20705463.0,
1655,502779,2,3,,103189534,4173,Active,,,,,Antibacterial activity against Helicobacter pylori Hp 26695,Other,20705463.0,
1656,502780,2,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against multidrug-resistant Helicobacter pylori v1254,Other,20705463.0,
1657,502781,2,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against multidrug-resistant Helicobacter pylori v1354,Other,20705463.0,
1658,502782,2,4,,103189534,4173,Unspecified,,,,,Inhibition of Helicobacter pylori-induced inflammation in human AGS cells assessed as reduction of IL-8 production at 10 uM by ELISA,Other,20705463.0,
1659,504326,1,2,,855672,4173,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1660,504326,1,2,,855672,4173,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1661,504327,1,1,,855672,4173,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1662,504327,1,1,,11112343,4173,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1663,504327,1,1,,26719631,4173,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1664,504329,1,1,,855672,4173,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1665,504332,1,1,,855672,4173,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1666,504332,1,1,,11112343,4173,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1667,504332,1,1,,26719631,4173,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1668,504333,1,1,,855672,4173,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1669,504333,1,1,,26719631,4173,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1670,504339,1,1,,855672,4173,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1671,504357,1,1,,855672,4173,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1672,504357,1,1,,855672,4173,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1673,504406,1,1,,855672,4173,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1674,504408,2,1,,855672,4173,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1675,504411,1,1,,855672,4173,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1676,504414,1,1,,855672,4173,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1677,504414,1,1,,855672,4173,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1678,504423,1,1,,855672,4173,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1679,504441,1,1,,855672,4173,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1680,504444,1,1,,855672,4173,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1681,504454,1,3,,855672,4173,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1682,504462,1,1,,855672,4173,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1683,504466,1,1,,855672,4173,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1684,504467,1,1,,855672,4173,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1685,504490,1,2,,855672,4173,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1686,504523,1,1,,855672,4173,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1687,504523,1,1,,855672,4173,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1688,504541,1,1,,855672,4173,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
1689,504558,1,1,,855672,4173,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1690,504577,2,2,,855672,4173,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1691,504582,2,1,,855672,4173,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1692,504594,1,1,,855672,4173,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1693,504600,1,2,,855672,4173,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1694,504621,1,1,,855672,4173,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1695,504634,1,1,,855672,4173,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1696,504648,1,1,,855672,4173,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1697,504651,1,1,,855672,4173,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1698,504651,1,1,,26719631,4173,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1699,504652,1,1,,855672,4173,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1700,504652,1,1,,26719631,4173,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1701,504660,1,1,,855672,4173,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1702,504660,1,1,,26719631,4173,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1703,504690,1,3,,855672,4173,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1704,504692,2,2,,855672,4173,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1705,504700,1,1,,855672,4173,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1706,504700,1,1,,855672,4173,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1707,504706,1,1,,855672,4173,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1708,504707,1,1,,855672,4173,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1709,504707,1,1,,855672,4173,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1710,504720,1,1,,855672,4173,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1711,504734,1,1,,855672,4173,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1712,504749,1,3,,26746949,4173,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1713,504749,1,3,,104171304,4173,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1714,504749,1,3,1.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1715,504749,1,3,2.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1716,504749,1,3,3.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1717,504749,1,3,4.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1718,504749,1,3,5.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1719,504749,1,3,6.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1720,504749,1,3,7.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1721,504749,1,3,8.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1722,504749,1,3,9.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1723,504749,1,3,10.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1724,504749,1,3,11.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1725,504749,1,3,12.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1726,504749,1,3,13.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1727,504749,1,3,14.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1728,504749,1,3,15.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1729,504749,1,3,16.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1730,504749,1,3,17.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1731,504749,1,3,18.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1732,504749,1,3,19.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1733,504749,1,3,20.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1734,504749,1,3,21.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1735,504749,1,3,22.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1736,504749,1,3,23.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1737,504749,1,3,24.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1738,504749,1,3,25.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1739,504749,1,3,26.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1740,504749,1,3,27.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1741,504749,1,3,28.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1742,504749,1,3,29.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1743,504749,1,3,30.0,104171304,4173,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1744,504749,1,3,31.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1745,504749,1,3,32.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1746,504749,1,3,33.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1747,504749,1,3,34.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1748,504749,1,3,35.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1749,504749,1,3,36.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1750,504749,1,3,37.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1751,504749,1,3,38.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1752,504749,1,3,39.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1753,504749,1,3,40.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1754,504749,1,3,41.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1755,504749,1,3,42.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1756,504749,1,3,43.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1757,504749,1,3,44.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1758,504749,1,3,45.0,104171304,4173,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1759,504749,1,3,46.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1760,504749,1,3,47.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1761,504749,1,3,48.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1762,504749,1,3,49.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1763,504749,1,3,50.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1764,504749,1,3,51.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1765,504749,1,3,52.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1766,504749,1,3,53.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1767,504749,1,3,54.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1768,504749,1,3,55.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1769,504749,1,3,56.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1770,504749,1,3,57.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1771,504749,1,3,58.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1772,504749,1,3,59.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1773,504749,1,3,60.0,104171304,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1774,504749,1,3,61.0,26746949,4173,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1775,504766,2,1,,855672,4173,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1776,504770,1,2,,92124203,4173,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1777,504775,1,1,,855672,4173,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1778,504803,1,1,,855672,4173,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1779,504810,1,2,,855672,4173,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1780,504810,1,2,,26719631,4173,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1781,504812,1,2,,855672,4173,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1782,504812,1,2,,26719631,4173,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1783,504832,1,1,,855672,4173,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1784,504832,1,1,,104171304,4173,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1785,504834,1,1,,855672,4173,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1786,504834,1,1,,104171304,4173,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1787,504842,1,1,,855672,4173,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1788,504842,1,1,,26719631,4173,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1789,504845,1,1,,855672,4173,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1790,504847,1,1,,855672,4173,Inconclusive,63054845.0,7421.0,63.0957,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1791,504847,1,1,,11112343,4173,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1792,504847,1,1,,104171304,4173,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1793,504865,1,1,,11112343,4173,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1794,504865,1,1,,104171304,4173,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1795,504884,1,2,,855672,4173,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1796,504891,1,1,,855672,4173,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1797,504894,1,1,,855672,4173,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1798,504937,1,2,,855672,4173,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1799,510488,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in biovolume at 12.5 uM after 18 hrs,Other,20038616.0,
1800,510489,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in thickness of biofilm at 12.5 uM after 18 hrs,Other,20038616.0,
1801,510490,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis assessed as surface area/biovolume ratio at 12.5 uM after 18 hrs,Other,20038616.0,
1802,510491,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in surface area of substratum occupied by cells at 12.5 uM after 18 hrs,Other,20038616.0,
1803,510492,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in average number of microcolonies at 12.5 uM after 18 hrs,Other,20038616.0,
1804,510493,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in average number of microcolony area at 12.5 uM after 18 hrs,Other,20038616.0,
1805,515153,4,4,,103189534,4173,Active,,,1.84,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution method,Confirmatory,20696501.0,
1806,515156,4,2,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,20696501.0,
1807,520108,2,4,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv at assessed as growth inhibition at 10 mg/kg following 24 days oxygen depletion by Wayne method relative to control,Other,18268091.0,
1808,521805,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas asaccharolyticus isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1809,521806,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas circumdentaria isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1810,521807,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1811,521808,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas levii isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1812,521809,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas macacae isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1813,521810,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas salivosa isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1814,521811,4,2,,103189534,4173,Inconclusive,,,,,Antimicrobial activity against Prevotella buccae isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1815,521812,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella corporis isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1816,521813,5,2,,103189534,4173,Inconclusive,,,,,Antimicrobial activity against Prevotella denticola isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1817,521814,5,2,,103189534,4173,Inconclusive,,,,,Antimicrobial activity against Prevotella disiens isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1818,521815,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides heparinolyticus isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1819,521816,5,2,,103189534,4173,Inconclusive,,,,,Antimicrobial activity against Prevotella intermedia isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1820,521817,4,2,,103189534,4173,Inconclusive,,,,,Antimicrobial activity against Prevotella loescheii isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1821,521818,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nigrescens isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1822,521819,5,2,,103189534,4173,Inconclusive,,,,,Antimicrobial activity against Prevotella oralis isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1823,521820,6,2,,103189534,4173,Inconclusive,,,,,Antimicrobial activity against Prevotella oris isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1824,521821,5,2,,103189534,4173,Inconclusive,,,,,Antimicrobial activity against Prevotella oulorum isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1825,521822,5,2,,103189534,4173,Inconclusive,,,,,Antimicrobial activity against Bacteroides zoogleoformans isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1826,521823,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella sp. isolated from canine periodontal pockets after 48 hrs by agar dilution method,Other,18411326.0,
1827,522131,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1828,522132,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides thetaiotaomicron under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1829,522133,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis spp. under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1830,522134,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides caccae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1831,522135,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides distasonis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1832,522136,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides merdae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1833,522137,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides ovatus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1834,522138,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides uniformis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1835,522139,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides vulgatus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1836,522140,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1837,522141,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella buccae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1838,522142,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella melaninogenica under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1839,522143,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella intermedia under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1840,522144,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bergensis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1841,522145,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella corporis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1842,522146,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella denticola under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1843,522147,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella disiens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1844,522148,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella loescheii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1845,522149,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella nanceiensis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1846,522150,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella oris under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1847,522151,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella tannerae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1848,522152,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas asaccharolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1849,522153,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas somerae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1850,522154,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium nucleatum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1851,522155,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium necrophorum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1852,522156,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium mortiferum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1853,522157,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium varium under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1854,522158,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Veillonella spp. under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1855,522159,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus prevotii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1856,522160,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus tetradius under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1857,522161,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Finegoldia magna under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1858,522162,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Parvimonas micra under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1859,522163,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus asaccharolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1860,522164,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus anaerobius under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1861,522165,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus stomatis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1862,522166,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus lactolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1863,522167,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus murdochii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1864,522168,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus octavius under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1865,522169,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus vaginalis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1866,522170,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus sp. under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1867,522171,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Gemella morbillorum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1868,522172,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Gemella sanguinis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1869,522173,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus harei under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1870,522174,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus lacrimalis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1871,522175,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces israelii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1872,522176,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces meyeri under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1873,522177,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces neuii subsp. anitratus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1874,522178,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces odontolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1875,522179,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces turicensis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1876,522180,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Propionibacterium acnes under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1877,522181,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Propionibacterium avidum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1878,522182,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eggerthella lenta under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1879,522183,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Atopobium parvulum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1880,522184,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Colinsella aerofaciens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1881,522185,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium contortum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1882,522186,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium cylindroides under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1883,522188,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium saburreum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1884,522189,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Mogibacterium timidum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1885,522190,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Slackia exigua under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1886,522191,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Solobacterium moorei under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1887,522192,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Lactobacillus casei under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1888,522193,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Lactobacillus rhamnosus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1889,522194,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1890,522195,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium ramosum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1891,522196,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium inoculum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1892,522197,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium clostridioforme under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1893,522198,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium aldenense under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1894,522199,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium bolteae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1895,522200,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium citroniae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1896,522201,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium hathewayi under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1897,522202,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium baratii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1898,522203,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium bifermentans under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1899,522204,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium butyricum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1900,522205,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium cadaveris under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1901,522206,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium celerecrescens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1902,522207,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1903,522208,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium glycolicum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1904,522209,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium hylemonae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1905,522210,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium paraputrificum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1906,522211,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium sordellii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1907,522212,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium sphenoides under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1908,522213,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium subterminale under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1909,522214,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium symbiosum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1910,522215,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium tertium under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1911,522375,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium limosum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method,Other,20100877.0,
1912,531510,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides stercoris assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1913,531511,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides merdae assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1914,531512,2,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides eggerthii assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1915,531513,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides spp. assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1916,531514,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides ovatus assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1917,531515,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides distasonis assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1918,531516,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides caccae assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1919,531517,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides vulgatus assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1920,531518,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides uniformis assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1921,531519,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1922,531520,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis assessed as percent resistant isolates by agar dilution method,Other,18474575.0,
1923,531521,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides stercoris isolate by agar dilution method,Other,18474575.0,
1924,531522,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides merdae isolate by agar dilution method,Other,18474575.0,
1925,531523,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides eggerthii isolate by agar dilution method,Other,18474575.0,
1926,531524,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides spp. isolate by agar dilution method,Other,18474575.0,
1927,531525,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides ovatus isolate by agar dilution method,Other,18474575.0,
1928,531526,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides distasonis isolate by agar dilution method,Other,18474575.0,
1929,531527,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides vulgatus isolate by agar dilution method,Other,18474575.0,
1930,531528,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides caccae isolate by agar dilution method,Other,18474575.0,
1931,531529,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides uniformis isolate by agar dilution method,Other,18474575.0,
1932,531530,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides thetaiotaomicron isolate by agar dilution method,Other,18474575.0,
1933,531719,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis isolate by agar dilution method,Other,18474575.0,
1934,531784,4,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis obtained from complicated skin and skin structure infections by agar dilution method,Other,18591277.0,
1935,531785,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella spp. obtained from complicated skin and skin structure infections by agar dilution method,Other,18591277.0,
1936,531786,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Veillonella spp. obtained from complicated skin and skin structure infections by agar dilution method,Other,18591277.0,
1937,533385,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile by agar dilution method,Other,18838581.0,
1938,533388,1,3,,103189534,4173,Inconclusive,,,,,Antimicrobial activity against Clostridium difficile assessed as resistant isolates by agar dilution method,Other,18838581.0,
1939,533389,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens by agar dilution method,Other,18838581.0,
1940,533392,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens assessed as resistant isolates by agar dilution method,Other,18838581.0,
1941,533393,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium innocuum by agar dilution method,Other,18838581.0,
1942,533396,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium innocuum assessed as resistant isolates by agar dilution method,Other,18838581.0,
1943,533397,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium paraputrificum by agar dilution method,Other,18838581.0,
1944,533400,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium paraputrificum assessed as resistant isolates by agar dilution method,Other,18838581.0,
1945,533401,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium subterminale by agar dilution method,Other,18838581.0,
1946,533404,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium subterminale assessed as resistant isolates by agar dilution method,Other,18838581.0,
1947,533405,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium tertium by agar dilution method,Other,18838581.0,
1948,533408,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium tertium assessed as resistant isolates by agar dilution method,Other,18838581.0,
1949,533409,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Finegoldia magna by agar dilution method,Other,18838581.0,
1950,533412,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Finegoldia magna assessed as resistant isolates by agar dilution method,Other,18838581.0,
1951,533413,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method,Other,18838581.0,
1952,533416,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as resistant isolates by agar dilution method,Other,18838581.0,
1953,533417,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Micromonas micros by agar dilution method,Other,18838581.0,
1954,533420,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Micromonas micros assessed as resistant isolates by agar dilution method,Other,18838581.0,
1955,533421,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus prevotii by agar dilution method,Other,18838581.0,
1956,533424,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus prevotii assessed as resistant isolates by agar dilution method,Other,18838581.0,
1957,533425,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus sp. by agar dilution method,Other,18838581.0,
1958,533428,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus sp. assessed as resistant isolates by agar dilution method,Other,18838581.0,
1959,533631,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Propionibacterium acnes by agar dilution method,Other,18838581.0,
1960,533634,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Propionibacterium acnes assessed as resistant isolates by agar dilution method,Other,18838581.0,
1961,533635,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Propionibacterium sp. by agar dilution method,Other,18838581.0,
1962,533638,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Propionibacterium sp. assessed as resistant isolates by agar dilution method,Other,18838581.0,
1963,533863,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against toxin-positive Clostridium difficile clinical isolate by agar dilution method,Other,18725442.0,
1964,534427,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus prevotii ATCC 9321 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1965,534428,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Atopobium parvulum VPI 0546 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1966,534429,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Finegoldia magna ATCC 29328 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1967,534430,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Parvimonas micra VPI 5464-1 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1968,534431,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus asaccharolyticus WAL 3218 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1969,534432,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus indolicus GAI 0915 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1970,534433,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus anaerobius ATCC 27337 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1971,534434,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Gemella morbillorum ATCC 27824 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1972,534435,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Staphylococcus saccharolyticus ATCC 14953 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1973,534436,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Streptococcus constellatus ATCC 27923 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1974,534437,5,4,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Streptococcus intermedius ATCC 27335 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1975,534438,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium clostridioforme NCTC 11224 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1976,534439,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile GAI 10029 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1977,534440,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens ATCC 13124 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1978,534441,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium septicum ATCC 12464 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1979,534442,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium sordellii ATCC 9714 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1980,534443,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium ramosum ATCC 25582 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1981,534444,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces odontolyticus GAI 91002 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1982,534445,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium adolescentis ATCC 15703 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1983,534446,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium bifidum JCM 1255 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1984,534447,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium breve ATCC 15700 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1985,534448,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium longum subsp. longum ATCC 15707 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1986,534449,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium pseudolongum ATCC 25526 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1987,534450,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eggerthella lenta ATCC 25559 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1988,534451,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Propionibacterium acnes ATCC 11828 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1989,534452,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Propionibacterium granulosum ATCC 25564 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1990,534453,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Lactobacillus acidophilus JCM 1132 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1991,534454,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Lactobacillus brevis subsp. brevis JCM 1059 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1992,534455,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Lactobacillus casei subsp. casei JCM 1134 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1993,534456,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Lactobacillus fermentum JCM 1173 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1994,534457,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Lactobacillus plantarum JCM 1149 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1995,534458,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Lactobacillus reuteri JCM 1112 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1996,534459,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Lactobacillus salivarius subsp. salivarius JCM 1231 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1997,534460,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis GAI 5562 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1998,534461,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis ATCC 25285 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
1999,534462,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis NCTC 10581 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2000,534463,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis GAI 0558 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2001,534464,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis GAI 7955 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2002,534465,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis GAI 10150 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2003,534466,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against carbapenemase-producing Bacteroides fragilis GAI 30079 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2004,534467,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against carbapenemase-producing Bacteroides fragilis GAI 30144 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2005,534468,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides vulgatus GAI 0673 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2006,534469,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Parabacteroides distasonis ATCC 8503 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2007,534470,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides ovatus ATCC 8483 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2008,534471,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides thetaiotaomicron ATCC 29741 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2009,534472,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides uniformis ATCC 8492 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2010,534473,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides eggerthii ATCC 27754 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2011,534474,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides ureolyticus NCTC 10941 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2012,534475,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Campylobacter gracilis JCM 8538 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2013,534476,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Sutterella wadsworthensis ATCC 51579 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2014,534477,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia ATCC 29303 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2015,534478,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella buccae ATCC 33574 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2016,534479,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella corporis GAI 91000 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2017,534480,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella heparinolytica ATCC 35895 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2018,534667,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella intermedia ATCC 25611 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2019,534668,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella melaninogenica JCM 6325 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2020,534669,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella denticola GAI 5490 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2021,534670,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella oralis ATCC 33269 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2022,534671,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella oris ATCC 33573 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2023,534672,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas asaccharolyticus ATCC 25260 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2024,534673,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2025,534674,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium nucleatum ATCC 25586 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2026,534675,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium varium ATCC 8501 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2027,534676,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium necrophorum ATCC 25286 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2028,534677,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bilophila wadsworthia WAL 7959 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2029,534678,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Desulfovibrio desulfuricans ATCC 29577 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2030,534679,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Desulfovibrio piger DSM 749 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2031,534680,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Capnocytophaga ochracea GAI 5586 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2032,534681,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Veillonella parvula ATCC 10790 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2033,534682,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Veillonella dispar ATCC 17748 by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2034,534683,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2035,534684,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2036,534685,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Parabacteroides distasonis by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2037,534686,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides uniformis by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2038,534687,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides vulgatus by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2039,534688,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides caccae by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2040,534689,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides stercoris by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2041,534690,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Odoribacter splanchnicus by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2042,534691,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella intermedia by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2043,534692,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella sp. by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2044,534693,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella melaninogenica by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2045,534694,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas asaccharolyticus by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2046,534695,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2047,534696,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas uenonis by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2048,534697,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium nucleatum by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2049,534698,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium necrophorum by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2050,534699,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium varium by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2051,534700,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium mortiferum by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2052,534701,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium sp. by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2053,534702,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Desulfovibrio desulfuricans by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2054,534703,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Finegoldia magna by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2055,534704,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Parvimonas micra by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2056,534705,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus anaerobius by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2057,534706,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2058,534707,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eggerthella lenta by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2059,534708,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium limosum by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2060,534709,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2061,534710,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens by agar dilution method in presence of 5% laked sheep blood,Other,18955522.0,
2062,535822,2,2,,103189534,4173,Unspecified,,,,,AUC (0 to 24 hrs) in guinea pig at 100 mg/kg,Other,18694944.0,
2063,535823,1,3,,103189534,4173,Inactive,,,,,Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig lung assessed as reduction in bacterial load at 100 mg/kg,Other,18694944.0,
2064,535824,1,4,,103189534,4173,Inactive,,,,,Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig spleen assessed as reduction in bacterial load at 100 mg/kg,Other,18694944.0,
2065,535829,1,3,,103189534,4173,Inactive,,,,,Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig lung assessed as reduction in bacteria induced progression of inflammation at 100 mg/kg after 4 weeks by histological analysis relative to control,Other,18694944.0,
2066,535830,1,3,,103189534,4173,Inactive,,,,,Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig lung assessed as reduction in development of new secondary lesions at 100 mg/kg after 4 weeks by histological analysis relative to control,Other,18694944.0,
2067,535831,2,5,,103189534,4173,Unspecified,,,,,Toxicity in Hartley guinea pig lung assessed as formation of TB lesions by histological analysis,Other,18694944.0,
2068,536453,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Chrysosporium keratinophilum at 100 ug/mL after 72 hrs by well plate method,Other,20813436.0,
2069,536456,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Chrysosporium keratinophilum at 50 ug/mL after 72 hrs by well plate method,Other,20813436.0,
2070,536457,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Candida albicans at 100 ug/mL after 72 hrs by well plate method,Other,20813436.0,
2071,536458,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Candida albicans at 50 ug/mL after 72 hrs by well plate method,Other,20813436.0,
2072,536459,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Microsporum gypseum at 100 ug/mL after 72 hrs by well plate method,Other,20813436.0,
2073,536460,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Microsporum gypseum at 50 ug/mL after 72 hrs by well plate method,Other,20813436.0,
2074,536461,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Aspergillus flavus at 100 ug/mL after 72 hrs by well plate method,Other,20813436.0,
2075,536462,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Aspergillus flavus at 50 ug/mL after 72 hrs by well plate method,Other,20813436.0,
2076,538979,7,1,,103189534,4173,Active,,,0.72,IC50,Antitrypanosomal activity against Trichomonas vaginalis T1,Confirmatory,21044841.0,
2077,540195,4,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori SS1 assessed as inhibition of visible growth after 96 hrs by agar dilution method,Other,20832915.0,
2078,540209,4,3,,103189534,4173,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2079,540210,4,3,,103189534,4173,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2080,540211,2,5,,103189534,4173,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2081,540212,4,3,,103189534,4173,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2082,540213,4,3,,103189534,4173,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2083,540253,1,1,,855672,4173,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2084,540253,1,1,,855672,4173,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2085,540253,1,1,,855672,4173,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2086,540256,1,2,,855672,4173,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2087,540263,1,1,,855672,4173,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2088,540263,1,1,,855672,4173,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2089,540267,1,1,,855672,4173,Inconclusive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2090,540275,1,1,,855672,4173,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2091,540275,1,1,,26719631,4173,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2092,540276,1,2,,855672,4173,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2093,540277,1,1,,855672,4173,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2094,540277,1,1,,26719631,4173,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2095,540295,1,1,,855672,4173,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2096,540299,1,2,,92124203,4173,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2097,540299,1,2,,92124968,4173,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2098,540303,1,1,,855672,4173,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2099,540303,1,1,,855672,4173,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2100,540303,1,1,,855672,4173,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2101,540308,1,1,,855672,4173,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2102,540317,1,1,,855672,4173,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2103,540336,1,1,,855672,4173,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2104,540336,1,1,,855672,4173,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2105,540364,1,2,,855672,4173,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2106,543648,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile,Other,18955525.0,
2107,545981,4,4,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution assay,Confirmatory,20961670.0,
2108,545982,4,2,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,20961670.0,
2109,545983,1,4,,103189534,4173,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell viability up to 100 uM after 48 hrs by MTT assay,Other,20961670.0,
2110,548280,6,1,,103189534,4173,Unspecified,,,500.0,EC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20439607.0,
2111,548281,5,2,,103189534,4173,Unspecified,,,500.0,EC50,Antimicrobial activity against Trypanosoma brucei NfxR1,Confirmatory,20439607.0,
2112,548282,7,1,,103189534,4173,Unspecified,,,500.0,EC50,Antimicrobial activity against Trypanosoma brucei NfxR2,Confirmatory,20439607.0,
2113,548283,2,3,,103189534,4173,Inconclusive,,,,,Selectivity ratio of EC50 for Trypanosoma brucei NfxR1 to EC50 for Trypanosoma brucei,Other,20439607.0,
2114,548284,2,3,,103189534,4173,Inconclusive,,,,,Selectivity ratio of EC50 for Trypanosoma brucei NfxR2 to EC50 for Trypanosoma brucei,Other,20439607.0,
2115,550085,4,2,,103189534,4173,Unspecified,,,,,Antitrichomonas activity against Trichomonas vaginalis after 48 hrs by trypan blue exclusion assay,Other,21130651.0,
2116,554602,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori 10593/2 by Etest,Other,19223619.0,
2117,554603,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori RIG 117 J0 by Etest,Other,19223619.0,
2118,554604,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori CAS 015 J0 by Etest,Other,19223619.0,
2119,554605,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori HER 126 V1 by Etest,Other,19223619.0,
2120,554606,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against compound-resistant Helicobacter pylori 10593a/2 harboring rdxA C177stop mutant gene by Etest,Other,19223619.0,
2121,554607,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against compound-resistant Helicobacter pylori RIG 117 J56 harboring rdxA R16C and frxA A40stop mutant genes by Etest,Other,19223619.0,
2122,554608,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against compound-resistant Helicobacter pylori CAS 015 J56 harboring rdxA L132stop and frxA L39stop mutant genes by Etest,Other,19223619.0,
2123,554609,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against compound-resistant Helicobacter pylori HER 126 V4 by Etest,Other,19223619.0,
2124,554610,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori 10593/2 lysate assessed as compound reduction under oxygenated microaerobic condition per mg of protein,Other,19223619.0,
2125,554611,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori 10593/2 lysate assessed as compound reduction under argonized microaerobic condition per mg of protein,Other,19223619.0,
2126,554612,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori 10593/2 lysate assessed as compound reduction under oxygenated aerobic condition per mg of protein,Other,19223619.0,
2127,554613,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori 10593/2 lysate assessed as compound reduction under argonized aerobic condition per mg of protein,Other,19223619.0,
2128,554614,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori RIG 117 J0 lysate assessed as compound reduction under oxygenated microaerobic condition per mg of protein,Other,19223619.0,
2129,554615,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori RIG 117 J0 lysate assessed as compound reduction under argonized microaerobic condition per mg of protein,Other,19223619.0,
2130,554616,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori RIG 117 J0 lysate assessed as compound reduction under oxygenated aerobic condition per mg of protein,Other,19223619.0,
2131,554617,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori RIG 117 J0 lysate assessed as compound reduction under argonized aerobic condition per mg of protein,Other,19223619.0,
2132,554618,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori CAS 015 J0 lysate assessed as compound reduction under oxygenated microaerobic condition per mg of protein,Other,19223619.0,
2133,554619,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori CAS 015 J0 lysate assessed as compound reduction under argonized microaerobic condition per mg of protein,Other,19223619.0,
2134,554620,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori CAS 015 J0 lysate assessed as compound reduction under oxygenated aerobic condition per mg of protein,Other,19223619.0,
2135,554621,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori CAS 015 J0 lysate assessed as compound reduction under argonized aerobic condition per mg of protein,Other,19223619.0,
2136,554690,2,3,,103189534,4173,Active,,,0.067,Km,Activity of Entamoeba histolytica NTR1 at 50 uM,Confirmatory,19015349.0,
2137,554691,2,3,,103189534,4173,Active,,,0.081,Km,Activity of Entamoeba histolytica NTR2 at 50 uM,Confirmatory,19015349.0,
2138,554692,2,3,,103189534,4173,Active,,,0.083,Km,Activity of Entamoeba histolytica NTR3 at 50 uM,Confirmatory,19015349.0,
2139,554693,2,3,,103189534,4173,Active,,,0.20600000000000002,Km,Activity of Giardia lamblia NTR at 50 uM,Confirmatory,19015349.0,
2140,554694,2,3,,103189534,4173,Active,,,0.078,Km,Activity of Trichomonas vaginalis NTR8 at 50 uM,Confirmatory,19015349.0,
2141,554695,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Escherichia coli JM109 transformed with empty vector PQE30 after 16 hrs,Other,19015349.0,
2142,554696,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Escherichia coli JM109 transformed with Entamoeba histolytica NTR1 after 16 hrs,Other,19015349.0,
2143,554697,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Escherichia coli JM109 transformed with Entamoeba histolytica NTR2 after 16 hrs,Other,19015349.0,
2144,554698,2,3,,103189534,4173,Unspecified,,,,,Ratio of EC50 for Escherichia coli JM109 transformed with empty vector PQE30 to EC50 for Escherichia coli JM109 transformed with Entamoeba histolytica NTR1,Other,19015349.0,
2145,554699,2,3,,103189534,4173,Unspecified,,,,,Ratio of EC50 for Escherichia coli JM109 transformed with empty vector PQE30 to EC50 for Escherichia coli JM109 transformed with Entamoeba histolytica NTR2,Other,19015349.0,
2146,554700,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Escherichia coli JM109 transformed with Entamoeba histolytica nim1 after 16 hrs,Other,19015349.0,
2147,554701,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Escherichia coli JM109 transformed with Trichomonas vaginalis nim1 after 16 hrs,Other,19015349.0,
2148,554702,2,3,,103189534,4173,Unspecified,,,,,Ratio of EC50 for Escherichia coli JM109 transformed with empty vector PQE30 to EC50 for Escherichia coli JM109 transformed with Entamoeba histolytica nim1,Other,19015349.0,
2149,554703,2,3,,103189534,4173,Unspecified,,,,,Ratio of EC50 for Escherichia coli JM109 transformed with empty vector PQE30 to EC50 for Escherichia coli JM109 transformed with Trichomonas vaginalis nim1,Other,19015349.0,
2150,554704,3,2,,103189534,4173,Active,,,0.008,Km,Activity of Entamoeba histolytica NIM1,Confirmatory,19015349.0,
2151,554794,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori HER 126 V1 lysate assessed as compound reduction under oxygenated microaerobic condition per mg of protein,Other,19223619.0,
2152,554795,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori HER 126 V1 lysate assessed as compound reduction under argonized microaerobic condition per mg of protein,Other,19223619.0,
2153,554796,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori HER 126 V1 lysate assessed as compound reduction under oxygenated aerobic condition per mg of protein,Other,19223619.0,
2154,554797,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori HER 126 V1 lysate assessed as compound reduction under argonized aerobic condition per mg of protein,Other,19223619.0,
2155,554798,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in Helicobacter pylori 10593a/2 lysate harboring rdxA C177stop mutant gene assessed as compound reduction under oxygenated microaerobic condition per mg of protein,Other,19223619.0,
2156,554799,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori 10593a/2 lysate harboring rdxA C177stop mutant gene assessed as compound reduction under argonized microaerobic condition per mg of protein,Other,19223619.0,
2157,554800,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori 10593a/2 lysate harboring rdxA C177stop mutant gene assessed as compound reduction under oxygenated aerobic condition per mg of protein,Other,19223619.0,
2158,554801,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori 10593a/2 lysate harboring rdxA C177stop mutant gene assessed as compound reduction under argonized aerobic condition per mg of protein,Other,19223619.0,
2159,554802,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori RIG 117 J56 lysate harboring rdxA R16C and frxA A40stop mutant genes assessed as compound reduction under oxygenated microaerobic condition per mg of protein,Other,19223619.0,
2160,554803,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori RIG 117 J56 lysate harboring rdxA R16C and frxA A40stop mutant genes assessed as compound reduction under argonized microaerobic condition per mg of protein,Other,19223619.0,
2161,554804,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori RIG 117 J56 lysate harboring rdxA R16C and frxA A40stop mutant genes assessed as compound reduction under oxygenated aerobic condition per mg of protein,Other,19223619.0,
2162,554805,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori RIG 117 J56 lysate harboring rdxA R16C and frxA A40stop mutant genes assessed as compound reduction under argonized aerobic condition per mg of protein,Other,19223619.0,
2163,554806,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori CAS 015 J56 lysate harboring rdxA L132stop and frxA L39stop mutant genes assessed as compound reduction under oxygenated microaerobic condition per mg of protein,Other,19223619.0,
2164,554807,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori CAS 015 J56 lysate harboring rdxA L132stop and frxA L39stop mutant genes assessed as compound reduction under argonized microaerobic condition per mg of protein,Other,19223619.0,
2165,554808,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori CAS 015 J56 lysate harboring rdxA L132stop and frxA L39stop mutant genes assessed as compound reduction under oxygenated aerobic condition per mg of protein,Other,19223619.0,
2166,554809,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori CAS 015 J56 lysate harboring rdxA L132stop and frxA L39stop mutant genes assessed as compound reduction under argonized aerobic condition per mg of protein,Other,19223619.0,
2167,554810,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori HER 126 V4 lysate assessed as compound reduction under oxygenated microaerobic condition per mg of protein,Other,19223619.0,
2168,554811,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori HER 126 V4 lysate assessed as compound reduction under argonized microaerobic condition per mg of protein,Other,19223619.0,
2169,554812,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori HER 126 V4 lysate assessed as compound reduction under oxygenated aerobic condition per mg of protein,Other,19223619.0,
2170,554813,2,3,,103189534,4173,Unspecified,,,,,Prodrug activation in compound-resistant Helicobacter pylori HER 126 V4 lysate assessed as compound reduction under argonized aerobic condition per mg of protein,Other,19223619.0,
2171,557408,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Bacteroides fragilis by CLSI agar dilution method,Other,19223615.0,
2172,557412,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Bacteroides thetaiotaomicron by CLSI agar dilution method,Other,19223615.0,
2173,557416,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Bacteroides ovatus by CLSI agar dilution method,Other,19223615.0,
2174,557420,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Bacteroides vulgatus by CLSI agar dilution method,Other,19223615.0,
2175,557424,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Bacteroides distasonis by CLSI agar dilution method,Other,19223615.0,
2176,557428,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Bacteroides uniformis by CLSI agar dilution method,Other,19223615.0,
2177,557432,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Bacteroides stercoris by CLSI agar dilution method,Other,19223615.0,
2178,557436,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella bivia by CLSI agar dilution method,Other,19223615.0,
2179,557440,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella buccae by CLSI agar dilution method,Other,19223615.0,
2180,557444,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella melaninogenica by CLSI agar dilution method,Other,19223615.0,
2181,557448,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella denticola by CLSI agar dilution method,Other,19223615.0,
2182,557452,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella intermedia by CLSI agar dilution method,Other,19223615.0,
2183,557456,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella nigrescens by CLSI agar dilution method,Other,19223615.0,
2184,557460,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella corporis by CLSI agar dilution method,Other,19223615.0,
2185,557464,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella disiens by CLSI agar dilution method,Other,19223615.0,
2186,557678,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella baroniae by CLSI agar dilution method,Other,19223615.0,
2187,557682,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella oralis group by CLSI agar dilution method,Other,19223615.0,
2188,557686,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella veroralis by CLSI agar dilution method,Other,19223615.0,
2189,557690,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella bergensis by CLSI agar dilution method,Other,19223615.0,
2190,557694,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella salivae by CLSI agar dilution method,Other,19223615.0,
2191,557698,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella loescheii by CLSI agar dilution method,Other,19223615.0,
2192,557702,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Prevotella sp.by CLSI agar dilution method,Other,19223615.0,
2193,557706,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Porphyromonas asaccharolytica by CLSI agar dilution method,Other,19223615.0,
2194,557710,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Fusobacterium nucleatum by CLSI agar dilution method,Other,19223615.0,
2195,557714,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Fusobacterium necrophorum by CLSI agar dilution method,Other,19223615.0,
2196,557718,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Fusobacterium mortiferum by CLSI agar dilution method,Other,19223615.0,
2197,557722,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Fusobacterium varium by CLSI agar dilution method,Other,19223615.0,
2198,557726,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Finegoldia magna by CLSI agar dilution method,Other,19223615.0,
2199,557730,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Micromonas micros by CLSI agar dilution method,Other,19223615.0,
2200,557734,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Peptostreptococcus anaerobius by CLSI agar dilution method,Other,19223615.0,
2201,557738,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Peptoniphilus asaccharolyticus by CLSI agar dilution method,Other,19223615.0,
2202,557742,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Anaerococcus tetradius by CLSI agar dilution method,Other,19223615.0,
2203,557746,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Anaerococcus prevotii by CLSI agar dilution method,Other,19223615.0,
2204,557750,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Lactobacillus by CLSI agar dilution method,Other,19223615.0,
2205,557944,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Bifidobacterium by CLSI agar dilution method,Other,19223615.0,
2206,557948,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Propionibacterium acnes by CLSI agar dilution method,Other,19223615.0,
2207,557952,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Actinomyces by CLSI agar dilution method,Other,19223615.0,
2208,557956,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Eggerthella lenta by CLSI agar dilution method,Other,19223615.0,
2209,557960,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium perfringens by CLSI agar dilution method,Other,19223615.0,
2210,557964,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium difficile by CLSI agar dilution method,Other,19223615.0,
2211,557968,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium sp. by CLSI agar dilution method,Other,19223615.0,
2212,557972,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium tertium by CLSI agar dilution method,Other,19223615.0,
2213,557976,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium ramosum by CLSI agar dilution method,Other,19223615.0,
2214,557980,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium cadaveris by CLSI agar dilution method,Other,19223615.0,
2215,557984,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium bifermentans by CLSI agar dilution method,Other,19223615.0,
2216,557988,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium innocuum by CLSI agar dilution method,Other,19223615.0,
2217,557992,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium sordellii by CLSI agar dilution method,Other,19223615.0,
2218,557996,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium butyricum by CLSI agar dilution method,Other,19223615.0,
2219,558000,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium clostridioforme by CLSI agar dilution method,Other,19223615.0,
2220,558004,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Clostridium hastiforme by CLSI agar dilution method,Other,19223615.0,
2221,558014,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity in Porphyromonas gingivalis by CLSI agar dilution method,Other,19223615.0,
2222,559485,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis by CLSI M11-A7 method,Other,19506065.0,
2223,559486,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium perfringens by CLSI M11-A7 method,Other,19506065.0,
2224,559487,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium sp. by CLSI M11-A7 method,Other,19506065.0,
2225,559488,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus sp. by CLSI M11-A7 method,Other,19506065.0,
2226,559489,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella sp. by CLSI M11-A7 method,Other,19506065.0,
2227,559490,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Propionibacterium acnes by CLSI M11-A7 method,Other,19506065.0,
2228,559491,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis assessed as percent susceptible isolates by CLSI M11-A7 method,Other,19506065.0,
2229,559492,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium perfringens assessed as percent susceptible isolates by CLSI M11-A7 method,Other,19506065.0,
2230,559493,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium sp. assessed as percent susceptible isolates by CLSI M11-A7 method,Other,19506065.0,
2231,559494,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus sp. assessed as percent susceptible isolates by CLSI M11-A7 method,Other,19506065.0,
2232,559495,2,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella sp. assessed as percent susceptible isolates by CLSI M11-A7 method,Other,19506065.0,
2233,559496,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Propionibacterium acnes assessed as percent susceptible isolates by CLSI M11-A7 method,Other,19506065.0,
2234,561090,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis by CLSI M11-A7 agar dilution method,Other,19528279.0,
2235,561091,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides vulgatus by CLSI M11-A7 agar dilution method,Other,19528279.0,
2236,561092,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides thetaiotaomicron by CLSI M11-A7 agar dilution method,Other,19528279.0,
2237,561093,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides ovatus by CLSI M11-A7 agar dilution method,Other,19528279.0,
2238,561094,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium perfringens by CLSI M11-A7 agar dilution method,Other,19528279.0,
2239,561095,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus anaerobius by CLSI M11-A7 agar dilution method,Other,19528279.0,
2240,561096,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus micros by CLSI M11-A7 agar dilution method,Other,19528279.0,
2241,561097,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Porphyromonas asaccharolytica by CLSI M11-A7 agar dilution method,Other,19528279.0,
2242,561098,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella sp. by CLSI M11-A7 agar dilution method,Other,19528279.0,
2243,562220,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Desulfovibrio sp. by Etest method,Other,19786606.0,
2244,562221,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Desulfovibrio fairfieldensis by Etest method,Other,19786606.0,
2245,562222,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Desulfovibrio desulfuricans Essex 6 by Etest method,Other,19786606.0,
2246,562223,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Desulfovibrio desulfuricans MB by Etest method,Other,19786606.0,
2247,562224,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Desulfovibrio piger by Etest method,Other,19786606.0,
2248,566971,2,3,,103189534,4173,Unspecified,,,,,Cytotoxicity against Trichomonas vaginalis TV-VP60 at 50 uM after 24 hrs by trypan blue exclusion assay,Other,21105684.0,
2249,571172,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile harboring ribotype 027 by CLSI agar dilution method,Other,18573937.0,
2250,571173,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile harboring ribotype 001 by CLSI agar dilution method,Other,18573937.0,
2251,571174,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile harboring other ribotypes by CLSI agar dilution method,Other,18573937.0,
2252,571789,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium bolteae by CLSI M11-A6 agar dilution method,Other,19581457.0,
2253,571790,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium clostridioforme by CLSI M11-A6 agar dilution method,Other,19581457.0,
2254,571791,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium difficile by CLSI M11-A6 agar dilution method,Other,19581457.0,
2255,571792,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium hathewayi by CLSI M11-A6 agar dilution method,Other,19581457.0,
2256,571793,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium innocuum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2257,571794,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium perfringens by CLSI M11-A6 agar dilution method,Other,19581457.0,
2258,571795,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium ramosum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2259,571796,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium subterminale by CLSI M11-A6 agar dilution method,Other,19581457.0,
2260,571797,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium bartlettii by CLSI M11-A6 agar dilution method,Other,19581457.0,
2261,571798,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium beijerinckii by CLSI M11-A6 agar dilution method,Other,19581457.0,
2262,571799,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium bifermentans by CLSI M11-A6 agar dilution method,Other,19581457.0,
2263,571800,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium butyricum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2264,571801,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium celerecrescens by CLSI M11-A6 agar dilution method,Other,19581457.0,
2265,571802,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium disporicum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2266,571803,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium glycolicum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2267,571804,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium hypermegas by CLSI M11-A6 agar dilution method,Other,19581457.0,
2268,571805,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium leptum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2269,571806,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium orbiscindens by CLSI M11-A6 agar dilution method,Other,19581457.0,
2270,571807,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium paraputrificum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2271,571808,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium scindens by CLSI M11-A6 agar dilution method,Other,19581457.0,
2272,571809,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium sordellii by CLSI M11-A6 agar dilution method,Other,19581457.0,
2273,571810,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium spiroforme by CLSI M11-A6 agar dilution method,Other,19581457.0,
2274,571811,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium sporogenes by CLSI M11-A6 agar dilution method,Other,19581457.0,
2275,571812,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium sporosphaeroides by CLSI M11-A6 agar dilution method,Other,19581457.0,
2276,571813,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium tertium by CLSI M11-A6 agar dilution method,Other,19581457.0,
2277,571814,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium sp. by CLSI M11-A6 agar dilution method,Other,19581457.0,
2278,571815,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Actinomyces naeslundii by CLSI M11-A6 agar dilution method,Other,19581457.0,
2279,571816,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bifidobacterium adolescentis by CLSI M11-A6 agar dilution method,Other,19581457.0,
2280,571817,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bifidobacterium bifidum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2281,571818,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bifidobacterium breve by CLSI M11-A6 agar dilution method,Other,19581457.0,
2282,571819,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bifidobacterium dentium by CLSI M11-A6 agar dilution method,Other,19581457.0,
2283,571820,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bifidobacterium infantis by CLSI M11-A6 agar dilution method,Other,19581457.0,
2284,571821,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bifidobacterium longum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2285,571822,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bifidobacterium pseudolongum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2286,571823,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Catenibacterium mitsuokai by CLSI M11-A6 agar dilution method,Other,19581457.0,
2287,571824,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Colinsella aerofaciens by CLSI M11-A6 agar dilution method,Other,19581457.0,
2288,571825,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Coprobacillus cateniformis by CLSI M11-A6 agar dilution method,Other,19581457.0,
2289,571826,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Coriobacteriumecies by CLSI M11-A6 agar dilution method,Other,19581457.0,
2290,571827,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Eggerthella lenta by CLSI M11-A6 agar dilution method,Other,19581457.0,
2291,571828,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Holdemania filiformis by CLSI M11-A6 agar dilution method,Other,19581457.0,
2292,571829,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Propionibacterium propionicus by CLSI M11-A6 agar dilution method,Other,19581457.0,
2293,571830,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Ruminococcus gnavus by CLSI M11-A6 agar dilution method,Other,19581457.0,
2294,571831,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Ruminococcus obeum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2295,571832,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Ruminococcus albus by CLSI M11-A6 agar dilution method,Other,19581457.0,
2296,571833,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Ruminococcus flavefaciens by CLSI M11-A6 agar dilution method,Other,19581457.0,
2297,571834,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Ruminococcus luti by CLSI M11-A6 agar dilution method,Other,19581457.0,
2298,571988,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Ruminococcus lactaris by CLSI M11-A6 agar dilution method,Other,19581457.0,
2299,571989,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Ruminococcus productus by CLSI M11-A6 agar dilution method,Other,19581457.0,
2300,571990,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Ruminococcus torques by CLSI M11-A6 agar dilution method,Other,19581457.0,
2301,571991,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Ruminococcus sp. by CLSI M11-A6 agar dilution method,Other,19581457.0,
2302,571992,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Anaerococcus prevotii by CLSI M11-A6 agar dilution method,Other,19581457.0,
2303,571993,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Anaerococcus tetradius by CLSI M11-A6 agar dilution method,Other,19581457.0,
2304,571994,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Finegoldia magna by CLSI M11-A6 agar dilution method,Other,19581457.0,
2305,571995,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptoniphilus asaccharolyticus by CLSI M11-A6 agar dilution method,Other,19581457.0,
2306,571996,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus anaerobius by CLSI M11-A6 agar dilution method,Other,19581457.0,
2307,571997,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Peptostreptococcus micros by CLSI M11-A6 agar dilution method,Other,19581457.0,
2308,571998,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Streptococcus anginosus by CLSI M11-A6 agar dilution method,Other,19581457.0,
2309,571999,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Streptococcus constellatus by CLSI M11-A6 agar dilution method,Other,19581457.0,
2310,572000,6,4,,103189534,4173,Unspecified,,,,,Antibacterial activity against Streptococcus intermedius by CLSI M11-A6 agar dilution method,Other,19581457.0,
2311,572001,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Parabacteroides distasonis by CLSI M11-A6 agar dilution method,Other,19581457.0,
2312,572002,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Parabacteroides merdae by CLSI M11-A6 agar dilution method,Other,19581457.0,
2313,572003,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis by CLSI M11-A6 agar dilution method,Other,19581457.0,
2314,572004,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides ovatus by CLSI M11-A6 agar dilution method,Other,19581457.0,
2315,572005,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides thetaiotaomicron by CLSI M11-A6 agar dilution method,Other,19581457.0,
2316,572006,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides vulgatus by CLSI M11-A6 agar dilution method,Other,19581457.0,
2317,572007,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides splanchnicus by CLSI M11-A6 agar dilution method,Other,19581457.0,
2318,572008,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bilophila wadsworthia by CLSI M11-A6 agar dilution method,Other,19581457.0,
2319,572009,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium mortiferum by CLSI M11-A6 agar dilution method,Other,19581457.0,
2320,572010,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium varium by CLSI M11-A6 agar dilution method,Other,19581457.0,
2321,572011,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella bivia by CLSI M11-A6 agar dilution method,Other,19581457.0,
2322,572012,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella buccae by CLSI M11-A6 agar dilution method,Other,19581457.0,
2323,572013,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella corporis by CLSI M11-A6 agar dilution method,Other,19581457.0,
2324,572014,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella P denticola by CLSI M11-A6 agar dilution method,Other,19581457.0,
2325,572015,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella P disiens by CLSI M11-A6 agar dilution method,Other,19581457.0,
2326,572016,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella P intermedia by CLSI M11-A6 agar dilution method,Other,19581457.0,
2327,572017,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella intermedia by CLSI M11-A6 agar dilution method,Other,19581457.0,
2328,572018,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella nigrescens by CLSI M11-A6 agar dilution method,Other,19581457.0,
2329,572019,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella loescheii by CLSI M11-A6 agar dilution method,Other,19581457.0,
2330,572020,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella melaninogenica by CLSI M11-A6 agar dilution method,Other,19581457.0,
2331,572021,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella oralis by CLSI M11-A6 agar dilution method,Other,19581457.0,
2332,572022,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella oris by CLSI M11-A6 agar dilution method,Other,19581457.0,
2333,572023,6,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Sutterella wadsworthensis by CLSI M11-A6 agar dilution method,Other,19581457.0,
2334,573394,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis by by CLSI agar dilution method,Other,18625771.0,
2335,573397,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron by by CLSI agar dilution method,Other,18625771.0,
2336,573551,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2337,573552,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2338,573557,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2339,573558,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2340,573563,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides vulgatus by CLSI agar dilution method,Other,18625771.0,
2341,573564,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2342,573565,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2343,573572,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides uniformis by CLSI agar dilution method,Other,18625771.0,
2344,573573,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2345,573574,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2346,573581,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides caccae by CLSI agar dilution method,Other,18625771.0,
2347,573582,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2348,573583,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2349,573590,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium varium by by CLSI agar dilution method,Other,18625771.0,
2350,573591,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium nucleatum by CLSI agar dilution method,Other,18625771.0,
2351,573592,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium mortiferum by CLSI agar dilution method,Other,18625771.0,
2352,573593,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium necrophorum by CLSI agar dilution method,Other,18625771.0,
2353,573594,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium varium assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2354,573595,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium nucleatum assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2355,573596,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium mortiferum assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2356,573597,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium necrophorum assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2357,573598,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium varium assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2358,573599,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium nucleatum assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2359,573600,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium mortiferum assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2360,573601,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Fusobacterium necrophorum assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2361,573783,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella buccae by by CLSI agar dilution method,Other,18625771.0,
2362,573784,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella bivia by by CLSI agar dilution method,Other,18625771.0,
2363,573785,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella intermedia by by CLSI agar dilution method,Other,18625771.0,
2364,573786,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella melaninogenica by by CLSI agar dilution method,Other,18625771.0,
2365,573795,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella buccae assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2366,573796,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella bivia assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2367,573797,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella intermedia assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2368,573798,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella melaninogenica assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2369,573799,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella buccae assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2370,573800,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella bivia assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2371,573801,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella intermedia assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2372,573802,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against Prevotella melaninogenica assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2373,573819,4,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Veillonella parvula by by CLSI agar dilution method,Other,18625771.0,
2374,573822,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium perfringens by CLSI agar dilution method,Other,18625771.0,
2375,573823,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium paraputrificum by CLSI agar dilution method,Other,18625771.0,
2376,573824,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium septicum by CLSI agar dilution method,Other,18625771.0,
2377,573825,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium tertium by CLSI agar dilution method,Other,18625771.0,
2378,573834,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2379,573835,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2380,573836,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2381,573837,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2382,574003,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2383,574004,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2384,574005,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2385,574006,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2386,574023,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius by CLSI agar dilution method,Other,18625771.0,
2387,574026,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2388,574027,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2389,574032,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Micromonas micros by CLSI agar dilution method,Other,18625771.0,
2390,574033,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Micromonas micros assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2391,574034,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Micromonas micros assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2392,574041,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus by CLSI agar dilution method,Other,18625771.0,
2393,574042,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2394,574043,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2395,574050,5,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Finegoldia magna by CLSI agar dilution method,Other,18625771.0,
2396,574051,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as susceptible isolates by CLSI agar dilution method,Other,18625771.0,
2397,574052,1,3,,103189534,4173,Unspecified,,,,,Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as resistant isolates by CLSI agar dilution method,Other,18625771.0,
2398,574482,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis after 48 hrs by agar dilution method,Other,20585132.0,
2399,574484,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides thetaiotaomicron after 48 hrs by agar dilution method,Other,20585132.0,
2400,574486,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides caccae after 48 hrs by agar dilution method,Other,20585132.0,
2401,574488,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides distasonis after 48 hrs by agar dilution method,Other,20585132.0,
2402,574490,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides vulgatus after 48 hrs by agar dilution method,Other,20585132.0,
2403,574492,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides ovatus after 48 hrs by agar dilution method,Other,20585132.0,
2404,574494,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2405,574496,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2406,574498,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2407,574500,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2408,574502,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides caccae assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2409,574504,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2410,574506,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides distasonis assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2411,574508,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2412,574510,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides vulgatus assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2413,574512,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2414,574514,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides ovatus assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2415,574516,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2416,574518,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella intermedia after 48 hrs by agar dilution method,Other,20585132.0,
2417,574520,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia after 48 hrs by agar dilution method,Other,20585132.0,
2418,574522,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella buccae after 48 hrs by agar dilution method,Other,20585132.0,
2419,574524,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella oralis after 48 hrs by agar dilution method,Other,20585132.0,
2420,574526,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella intermedia assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2421,574528,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella intermedia assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2422,574530,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2423,574532,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella bivia assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2424,574534,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella buccae assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2425,574724,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella buccae assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2426,574726,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella oralis assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2427,574728,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Prevotella oralis assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2428,574730,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Porphyromonas asaccharolytica after 48 hrs by agar dilution method,Other,20585132.0,
2429,574732,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium varium after 48 hrs by agar dilution method,Other,20585132.0,
2430,574734,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium necrogenes after 48 hrs by agar dilution method,Other,20585132.0,
2431,574736,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium nucleatum after 48 hrs by agar dilution method,Other,20585132.0,
2432,574738,4,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Fusobacterium mortiferum after 48 hrs by agar dilution method,Other,20585132.0,
2433,574740,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus anaerobius after 48 hrs by agar dilution method,Other,20585132.0,
2434,574742,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus micros after 48 hrs by agar dilution method,Other,20585132.0,
2435,574744,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2436,574746,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2437,574748,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus micros assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2438,574750,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptostreptococcus micros assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2439,574752,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus prevotii after 48 hrs by agar dilution method,Other,20585132.0,
2440,574754,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus prevotii assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2441,574756,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Anaerococcus prevotii assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2442,574758,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus asaccharolyticus after 48 hrs by agar dilution method,Other,20585132.0,
2443,574760,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2444,574762,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2445,574764,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Finegoldia magna after 48 hrs by agar dilution method,Other,20585132.0,
2446,574766,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Finegoldia magna assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2447,574768,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Finegoldia magna assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2448,574770,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens after 48 hrs by agar dilution method,Other,20585132.0,
2449,574772,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2450,574774,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2451,574776,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile after 48 hrs by agar dilution method,Other,20585132.0,
2452,574778,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2453,574780,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2454,574782,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces odontolyticus after 48 hrs by agar dilution method,Other,20585132.0,
2455,574965,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces odontolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2456,574967,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces odontolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2457,574969,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces israelii after 48 hrs by agar dilution method,Other,20585132.0,
2458,574971,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces israelii assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2459,574973,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces israelii assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2460,574975,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces meyeri after 48 hrs by agar dilution method,Other,20585132.0,
2461,574977,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces meyeri assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2462,574979,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces meyeri assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2463,574981,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces naeslundii after 48 hrs by agar dilution method,Other,20585132.0,
2464,574983,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces naeslundii assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2465,574985,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Actinomyces naeslundii assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2466,574987,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium adolescentis after 48 hrs by agar dilution method,Other,20585132.0,
2467,574989,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium adolescentis assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2468,574991,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium adolescentis assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2469,574993,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium sp. after 48 hrs by agar dilution method,Other,20585132.0,
2470,574995,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2471,574997,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Bifidobacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2472,574999,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium lentum after 48 hrs by agar dilution method,Other,20585132.0,
2473,575001,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium lentum assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2474,575003,1,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium lentum assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2475,575005,6,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium sp. after 48 hrs by agar dilution method,Other,20585132.0,
2476,575007,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method,Other,20585132.0,
2477,575009,2,3,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Eubacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method,Other,20585132.0,
2478,575275,5,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium difficile by broth microdilution method,Other,20625154.0,
2479,588209,2,3,,103189534,4173,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
2480,588210,2,4,,103189534,4173,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
2481,588211,2,3,,103189534,4173,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2482,588212,2,3,,103189534,4173,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2483,588213,2,3,,103189534,4173,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2484,588214,2,3,,103189534,4173,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2485,588215,2,3,,103189534,4173,Active,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2486,588216,2,3,,103189534,4173,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2487,588217,2,3,,103189534,4173,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2488,588218,2,3,,103189534,4173,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2489,588219,2,3,,103189534,4173,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2490,588220,2,3,,103189534,4173,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
2491,588334,1,1,,855672,4173,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2492,588335,1,1,,855672,4173,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2493,588342,1,1,,855672,4173,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2494,588342,1,1,,26719631,4173,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2495,588352,1,2,,855672,4173,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2496,588354,1,1,,855672,4173,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2497,588358,1,2,,855672,4173,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2498,588368,1,2,,855672,4173,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
2499,588382,1,2,,855672,4173,Inactive,,,,Potency,qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation in HepG2 cytotox,Confirmatory,,
2500,588382,1,2,,104171304,4173,Inactive,,,,Potency,qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation in HepG2 cytotox,Confirmatory,,
2501,588391,1,1,,855672,4173,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2502,588397,1,1,,855672,4173,Active,,,4.5997,Potency,qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation.,Confirmatory,,
2503,588397,1,1,,104171304,4173,Active,,,4.0995,Potency,qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation.,Confirmatory,,
2504,588405,1,1,,855672,4173,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2505,588413,1,2,,855672,4173,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2506,588436,1,1,,855672,4173,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2507,588453,1,1,,855672,4173,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2508,588456,1,1,,855672,4173,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2509,588458,1,1,,855672,4173,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2510,588459,1,2,,855672,4173,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
2511,588459,1,2,,855672,4173,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
2512,588459,1,2,,855672,4173,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
2513,588460,1,2,,855672,4173,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
2514,588460,1,2,,855672,4173,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
2515,588460,1,2,,855672,4173,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
2516,588461,1,2,,855672,4173,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
2517,588461,1,2,,855672,4173,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
2518,588461,1,2,,855672,4173,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
2519,588473,1,1,,855672,4173,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2520,588473,1,1,,855672,4173,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2521,588475,1,2,,855672,4173,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2522,588475,1,2,,855672,4173,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2523,588478,1,2,,124799733,4173,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2524,588489,1,1,,855672,4173,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2525,588492,1,1,,855672,4173,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2526,588493,1,2,,855672,4173,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2527,588497,1,2,,855672,4173,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2528,588497,1,2,,855672,4173,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2529,588497,1,2,,855672,4173,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2530,588499,1,3,,855672,4173,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2531,588499,1,3,,855672,4173,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2532,588499,1,3,,855672,4173,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2533,588501,1,2,,855672,4173,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2534,588501,1,2,,855672,4173,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2535,588501,1,2,,855672,4173,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2536,588506,1,2,,855672,4173,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
2537,588511,1,2,,855672,4173,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2538,588513,1,1,,17389815,4173,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2539,588514,1,1,,17389815,4173,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2540,588515,1,1,,17389815,4173,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2541,588516,1,1,,17389815,4173,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2542,588519,1,2,,92124203,4173,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2543,588519,1,2,,92124968,4173,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2544,588526,1,1,,17389815,4173,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2545,588527,1,1,,17389815,4173,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2546,588532,1,1,,17389815,4173,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2547,588533,1,1,,17389815,4173,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2548,588534,1,1,,17389815,4173,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2549,588535,1,1,,17389815,4173,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2550,588536,1,1,,17389815,4173,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2551,588537,1,1,,17389815,4173,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2552,588541,1,1,,17389815,4173,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2553,588543,1,1,,17389815,4173,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2554,588544,1,1,,17389815,4173,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2555,588545,1,1,,17389815,4173,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2556,588546,1,1,,17389815,4173,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2557,588547,1,1,,17389815,4173,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2558,588549,1,1,,855672,4173,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2559,588550,1,1,,855672,4173,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
2560,588579,1,1,,855672,4173,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2561,588579,1,1,,11112343,4173,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2562,588579,1,1,,104171304,4173,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2563,588590,1,1,,855672,4173,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2564,588591,1,1,,855672,4173,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2565,588621,1,1,,855672,4173,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2566,588627,1,1,,855672,4173,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2567,588664,1,2,,855672,4173,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2568,588664,1,2,,855672,4173,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2569,588674,1,2,,855672,4173,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2570,588675,1,1,,855672,4173,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2571,588676,1,1,,855672,4173,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2572,588685,1,1,,855672,4173,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
2573,588689,1,1,,855672,4173,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2574,588692,2,1,,855672,4173,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2575,588726,1,2,,855672,4173,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2576,588727,1,1,,855672,4173,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2577,588795,1,1,,855672,4173,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2578,588814,1,3,,855672,4173,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2579,588819,1,4,,855672,4173,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2580,588834,2,1,,17389815,4173,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2581,588834,2,1,,26746949,4173,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2582,588850,1,1,,855672,4173,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2583,588852,1,3,,855672,4173,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2584,588855,1,1,,855672,4173,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2585,588856,1,1,,855672,4173,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2586,592682,1,4,,103189534,4173,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis,Other,21458999.0,
2587,592683,1,4,,103189534,4173,Unspecified,,,,,Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis,Other,21458999.0,
2588,598281,3,2,,103189534,4173,Active,,,5.36,IC50,Antiprotozoan activity against Giardia intestinalis IMSS:0696:1 trophozoites after 48 hrs,Confirmatory,21397502.0,
2589,598282,3,2,,103189534,4173,Active,,,0.29,IC50,Antiprotozoan activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs,Confirmatory,21397502.0,
2590,598283,3,2,,103189534,4173,Active,,,0.77,IC50,Antiprotozoan activity against Entamoeba histolytica HM1-IMSS trophozoites after 48 hrs,Confirmatory,21397502.0,
2591,598284,3,2,,103189534,4173,Unspecified,,,50.0,IC50,Antileishmanial activity against Leishmania mexicana MHOM/MX/ISETGS promastigotes after 72 hrs by neubauer chamber,Confirmatory,21397502.0,
2592,598285,3,2,,103189534,4173,Unspecified,,,50.0,IC50,Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa epimastigotes after 72 hrs by neubauer chamber,Confirmatory,21397502.0,
2593,598286,3,2,,103189534,4173,Unspecified,,,50.0,IC50,Antimalarial activity against Plasmodium berghei schizonts isolated from parasitized erythrocytes infected Wistar rat measured 16 hrs post compound exposure,Confirmatory,21397502.0,
2594,598287,3,2,,103189534,4173,Unspecified,,,387.0,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,21397502.0,
2595,600469,3,4,,103189534,4173,Active,,,1.46,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution method,Confirmatory,21377771.0,
2596,600470,3,2,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,21377771.0,
2597,602123,1,1,,855672,4173,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2598,602141,1,1,,855672,4173,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2599,602162,1,1,,855672,4173,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2600,602163,1,1,,855672,4173,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2601,602179,1,2,,855672,4173,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2602,602229,1,1,,855672,4173,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2603,602233,1,1,,855672,4173,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2604,602244,1,2,,855672,4173,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2605,602247,1,2,,855672,4173,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2606,602248,1,2,,855672,4173,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2607,602250,1,2,,855672,4173,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2608,602252,1,1,,855672,4173,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2609,602252,1,1,,855672,4173,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2610,602261,1,1,,855672,4173,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2611,602274,1,2,,855672,4173,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2612,602276,1,1,,855672,4173,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
2613,602277,1,1,,855672,4173,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
2614,602281,1,1,,855672,4173,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2615,602281,1,1,,855672,4173,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2616,602310,1,2,,855672,4173,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2617,602313,1,1,,855672,4173,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2618,602314,1,2,,92124203,4173,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2619,602314,1,2,,92124968,4173,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2620,602314,1,2,,92254470,4173,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2621,602329,1,1,,855672,4173,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2622,602332,1,1,,855672,4173,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2623,602332,1,1,,11112343,4173,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2624,602332,1,1,,104171304,4173,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2625,602340,1,2,,855672,4173,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2626,602342,2,1,,855672,4173,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2627,602346,1,1,,855672,4173,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2628,602363,1,1,,855672,4173,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2629,602393,1,1,,855672,4173,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2630,602396,1,2,,855672,4173,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2631,602399,1,2,,855672,4173,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2632,602405,1,1,,855672,4173,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2633,602410,1,1,,855672,4173,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2634,602429,1,1,,855672,4173,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2635,602438,1,1,,855672,4173,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2636,602440,1,1,,855672,4173,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2637,602449,1,2,,855672,4173,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2638,602481,1,1,,855672,4173,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2639,618295,3,4,,103189534,4173,Active,,,1.45,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS by microdilution method,Confirmatory,21715066.0,
2640,618296,1,4,,103189534,4173,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as cell viability at 3.13 uM after 48 hrs by MTT assay,Other,21715066.0,
2641,618298,1,4,,103189534,4173,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as cell viability at 50 uM after 48 hrs by MTT assay,Other,21715066.0,
2642,618299,1,4,,103189534,4173,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as cell viability at 100 uM after 48 hrs by MTT assay,Other,21715066.0,
2643,618300,1,4,,103189534,4173,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as cell viability at 200 uM after 48 hrs by MTT assay,Other,21715066.0,
2644,618301,3,2,,103189534,4173,Unspecified,,,200.0,IC50,Cytotoxicity against rat H9c2 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21715066.0,
2645,618302,1,4,,103189534,4173,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat H9c2 cells to IC50 for Entamoeba histolytica HM-1:IMSS",Other,21715066.0,
2646,623870,1,1,,855672,4173,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2647,623870,1,1,,855672,4173,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2648,623877,1,1,,855672,4173,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2649,623901,1,1,,855672,4173,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2650,624030,1,2,,104171304,4173,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2651,624031,1,2,,104171304,4173,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
2652,624032,1,2,,104171304,4173,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
2653,624037,1,3,,855672,4173,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2654,624038,1,3,,855672,4173,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2655,624040,1,3,,855672,4173,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2656,624044,1,2,,104171304,4173,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
2657,624101,1,2,,85789474,4173,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2658,624125,1,4,,855672,4173,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2659,624126,1,3,,855672,4173,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2660,624127,1,2,,855672,4173,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2661,624151,1,1,,85789474,4173,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
2662,624168,1,1,,855672,4173,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2663,624169,1,1,,855672,4173,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2664,624170,1,1,,855672,4173,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2665,624170,1,1,,104171304,4173,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2666,624171,1,1,,855672,4173,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2667,624172,1,1,,855672,4173,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2668,624172,1,1,,104171304,4173,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2669,624173,1,3,,855672,4173,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2670,624173,1,3,,104171304,4173,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2671,624178,1,1,,855672,4173,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2672,624202,1,1,,855672,4173,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2673,624204,1,2,,855672,4173,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2674,624246,1,1,,855672,4173,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2675,624256,1,2,,855672,4173,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2676,624263,1,1,,855672,4173,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2677,624263,1,1,,855672,4173,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2678,624267,1,2,,855672,4173,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2679,624267,1,2,,855672,4173,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2680,624268,1,3,,855672,4173,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2681,624288,1,1,,855672,4173,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2682,624296,1,1,,855672,4173,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2683,624296,1,1,,26746949,4173,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2684,624296,1,1,,104171304,4173,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2685,624297,1,1,,855672,4173,Inactive,7705682.0,51053.0,0.631,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2686,624297,1,1,,26746949,4173,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2687,624297,1,1,,104171304,4173,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2688,624304,1,2,,855672,4173,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2689,624330,1,2,,855672,4173,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2690,624349,1,2,,92124203,4173,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2691,624349,1,2,,92124968,4173,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2692,624349,1,2,,92307304,4173,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2693,624349,1,2,,92308357,4173,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2694,624349,1,2,,92309035,4173,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2695,624349,1,2,,121362639,4173,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2696,624352,1,1,,855672,4173,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2697,624354,1,1,,855672,4173,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2698,624377,1,1,,855672,4173,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2699,624414,1,1,,855672,4173,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2700,624415,1,2,,855672,4173,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2701,624416,1,1,,855672,4173,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2702,624417,1,1,,855672,4173,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2703,624418,1,1,,855672,4173,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2704,624463,1,1,,855672,4173,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2705,624464,1,1,,855672,4173,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2706,624465,1,1,,855672,4173,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2707,624466,1,3,,855672,4173,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2708,624467,1,1,,855672,4173,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2709,624483,1,1,,855672,4173,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2710,625144,5,5,,103189534,4173,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2711,625145,4,7,,103189534,4173,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2712,625146,5,5,,103189534,4173,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2713,625147,4,7,,103189534,4173,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2714,625148,4,7,,103189534,4173,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2715,625149,4,7,,103189534,4173,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2716,625150,5,5,,103189534,4173,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2717,625151,4,7,,103189534,4173,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2718,625152,4,7,,103189534,4173,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2719,625153,4,7,,103189534,4173,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2720,625154,4,7,,103189534,4173,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2721,625155,4,7,,103189534,4173,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2722,625156,1,9,,103189534,4173,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
2723,625157,6,2,,103189534,4173,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
2724,625158,3,4,,103189534,4173,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
2725,625159,5,5,,103189534,4173,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
2726,625160,1,9,,103189534,4173,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
2727,625161,4,7,,103189534,4173,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
2728,625162,4,7,,103189534,4173,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2729,625163,4,7,,103189534,4173,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2730,625164,1,6,,103189534,4173,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
2731,625165,3,4,,103189534,4173,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2732,625166,3,4,,103189534,4173,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2733,625167,5,5,,103189534,4173,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
2734,625168,4,7,,103189534,4173,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
2735,625169,1,6,,103189534,4173,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
2736,625170,3,4,,103189534,4173,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
2737,625171,4,7,,103189534,4173,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
2738,625172,4,7,,103189534,4173,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
2739,625173,5,5,,103189534,4173,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
2740,625174,5,5,,103189534,4173,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
2741,625175,5,5,,103189534,4173,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
2742,625176,1,9,,103189534,4173,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
2743,625177,5,5,,103189534,4173,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2744,625178,5,5,,103189534,4173,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2745,625179,1,9,,103189534,4173,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
2746,625180,5,5,,103189534,4173,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2747,625181,5,5,,103189534,4173,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2748,625182,5,5,,103189534,4173,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2749,625183,5,5,,103189534,4173,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
2750,625184,5,5,,103189534,4173,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2751,625185,5,5,,103189534,4173,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2752,625186,5,5,,103189534,4173,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2753,625187,5,5,,103189534,4173,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2754,625188,1,9,,103189534,4173,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
2755,625189,1,7,,103189534,4173,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
2756,625190,4,5,,103189534,4173,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
2757,625191,4,7,,103189534,4173,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2758,625192,4,7,,103189534,4173,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
2759,625193,5,5,,103189534,4173,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
2760,625194,4,7,,103189534,4173,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
2761,625195,4,7,,103189534,4173,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
2762,625196,5,6,,103189534,4173,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
2763,625197,3,4,,103189534,4173,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
2764,625198,4,7,,103189534,4173,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2765,625199,4,7,,103189534,4173,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2766,625200,4,7,,103189534,4173,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2767,625201,4,7,,103189534,4173,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
2768,625202,4,7,,103189534,4173,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
2769,625203,4,7,,103189534,4173,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
2770,625204,4,7,,103189534,4173,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2771,625205,4,7,,103189534,4173,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
2772,625206,4,7,,103189534,4173,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2773,625207,4,7,,103189534,4173,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2774,625208,5,5,,103189534,4173,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2775,625209,4,7,,103189534,4173,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2776,625210,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2777,625211,1,6,,103189534,4173,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2778,625212,3,4,,103189534,4173,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2779,625213,4,7,,103189534,4173,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2780,625214,1,9,,103189534,4173,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2781,625215,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2782,625216,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2783,625217,4,7,,103189534,4173,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2784,625218,4,7,,103189534,4173,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2785,625219,3,4,,103189534,4173,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2786,625220,4,7,,103189534,4173,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2787,625221,4,7,,103189534,4173,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2788,625222,4,7,,103189534,4173,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2789,625223,4,7,,103189534,4173,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2790,625224,3,4,,103189534,4173,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2791,625225,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2792,625226,4,7,,103189534,4173,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2793,625227,4,7,,103189534,4173,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2794,625228,4,7,,103189534,4173,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2795,625229,5,5,,103189534,4173,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2796,625230,1,6,,103189534,4173,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2797,625231,4,7,,103189534,4173,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2798,625232,1,9,,103189534,4173,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2799,625233,4,7,,103189534,4173,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2800,625234,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2801,625235,4,7,,103189534,4173,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2802,625236,5,5,,103189534,4173,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2803,625237,4,7,,103189534,4173,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2804,625238,4,7,,103189534,4173,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2805,625239,4,7,,103189534,4173,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2806,625240,1,9,,103189534,4173,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2807,625241,4,7,,103189534,4173,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2808,625242,4,7,,103189534,4173,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2809,625243,5,5,,103189534,4173,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2810,625244,5,5,,103189534,4173,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2811,625245,5,5,,103189534,4173,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2812,625246,1,9,,103189534,4173,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2813,625247,5,5,,103189534,4173,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2814,625248,5,5,,103189534,4173,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2815,625249,5,5,,103189534,4173,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2816,625250,5,5,,103189534,4173,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2817,625251,5,5,,103189534,4173,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2818,625252,4,7,,103189534,4173,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2819,625253,4,7,,103189534,4173,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2820,625254,4,7,,103189534,4173,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2821,625255,4,7,,103189534,4173,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2822,625256,4,7,,103189534,4173,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2823,625257,4,7,,103189534,4173,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2824,625258,4,7,,103189534,4173,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2825,625259,4,7,,103189534,4173,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2826,625260,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2827,625261,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2828,625262,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2829,625263,4,7,,103189534,4173,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2830,625264,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2831,625265,1,6,,103189534,4173,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2832,625266,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2833,625267,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2834,625268,4,2,,103189534,4173,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2835,625268,4,2,,103189534,4173,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2836,625268,4,2,,103189534,4173,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2837,625268,4,2,,103189534,4173,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2838,625269,4,7,,103189534,4173,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2839,625270,4,7,,103189534,4173,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2840,625271,5,5,,103189534,4173,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2841,625272,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2842,625273,4,6,,103189534,4173,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2843,625274,1,6,,103189534,4173,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2844,625275,3,4,,103189534,4173,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2845,625278,1,3,,103189534,4173,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI,Other,21624500.0,
2846,625279,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2847,625280,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2848,625281,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2849,625282,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2850,625283,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2851,625284,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2852,625285,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2853,625286,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2854,625287,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2855,625288,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2856,625289,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2857,625290,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2858,625291,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2859,625292,1,3,,103189534,4173,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2860,631763,3,2,,103189534,4173,Active,,,0.23600000000000002,IC50,Antiprotozoan activity against Trichomonas vaginalis GT3 trophozoites compound treated for 48 hrs measured after 48 hrs washout period,Confirmatory,22047694.0,
2861,631764,3,2,,103189534,4173,Active,,,1.226,IC50,Antiprotozoan activity against Giardia intestinalis IMSS:0989:1 trophozoites compound treated for 48 hrs measured after 48 hrs washout period,Confirmatory,22047694.0,
2862,631830,5,1,,103189534,4173,Active,,,0.35,IC50,Antiprotozoan activity against Entamoeba histolytica HM1-IMSS trophozoites compound treated for 48 hrs measured after 48 hrs washout period,Confirmatory,22047694.0,
2863,635850,3,3,,103189534,4173,Active,,,1.56,IC50,Antiprotozoal activity against Giardia intestinalis G1 after 70 hrs by resazurin-based spectrophotometric assay,Confirmatory,22061825.0,
2864,635851,3,3,,103189534,4173,Active,,,5.82,IC50,Antiprotozoal activity against Entamoeba histolytica Hk-9 trophozoites after 70 hrs by resazurin-based spectrophotometric assay,Confirmatory,22061825.0,
2865,637014,3,4,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution method,Confirmatory,22236470.0,
2866,637015,3,2,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22236470.0,
2867,637018,1,4,,103189534,4173,Unspecified,,,,,"Safety index, ratio of IC50 for human HepG2 cells to IC50 for Entamoeba histolytica HM-1:IMSS",Other,22236470.0,
2868,637060,1,4,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as viable cells at 3.13 uM after 48 hrs by MTT assay,Other,22236470.0,
2869,644763,3,4,,103189534,4173,Active,,,1.81,IC50,Antiameobic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs using trypan blue staining method,Confirmatory,22309914.0,
2870,644764,3,2,,103189534,4173,Unspecified,,,250.0,IC50,Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,22309914.0,
2871,651550,1,1,,855672,4173,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2872,651560,1,1,,855672,4173,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2873,651572,1,2,,855672,4173,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2874,651582,1,1,,855672,4173,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2875,651602,1,1,,855672,4173,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2876,651602,1,1,,855672,4173,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2877,651602,1,1,,855672,4173,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2878,651610,2,1,,855672,4173,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2879,651631,4,1,,144203992,4173,Inconclusive,269849759.0,7157.0,3.3491,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2880,651631,4,1,,144209611,4173,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2881,651631,4,1,,144213111,4173,Inconclusive,269849759.0,7157.0,61.1306,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2882,651632,4,1,,144203992,4173,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2883,651632,4,1,,144209611,4173,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2884,651632,4,1,,144213111,4173,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2885,651633,4,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2886,651633,4,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2887,651633,4,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2888,651634,4,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2889,651634,4,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2890,651634,4,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2891,651635,1,3,,855672,4173,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2892,651635,1,3,,11112343,4173,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2893,651636,1,1,,855672,4173,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2894,651640,1,1,,855672,4173,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2895,651644,1,1,,855672,4173,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2896,651647,1,1,,855672,4173,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2897,651654,1,1,,855672,4173,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2898,651658,1,1,,855672,4173,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2899,651660,1,1,,855672,4173,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2900,651661,2,1,,855672,4173,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2901,651687,1,1,,855672,4173,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2902,651699,1,1,,855672,4173,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2903,651699,1,1,,855672,4173,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2904,651702,1,2,,855672,4173,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2905,651704,2,1,,855672,4173,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2906,651710,1,1,,855672,4173,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2907,651711,2,1,,855672,4173,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2908,651718,1,2,,855672,4173,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2909,651723,1,1,,855672,4173,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2910,651724,1,1,,855672,4173,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2911,651725,1,1,,855672,4173,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2912,651741,1,1,,17389815,4173,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2913,651743,1,1,,17389815,4173,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2914,651749,1,1,,17389815,4173,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2915,651751,1,1,,17389815,4173,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2916,651754,1,1,,17389815,4173,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
2917,651755,1,1,,17389815,4173,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
2918,651757,1,1,,17389815,4173,Inconclusive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
2919,651758,1,1,,17389815,4173,Inactive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
2920,651768,1,2,,855672,4173,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2921,651777,1,1,,17389815,4173,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2922,651778,1,1,,17389815,4173,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2923,651800,1,1,,855672,4173,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2924,651802,1,1,,17389815,4173,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2925,651819,1,1,,855672,4173,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2926,651820,1,1,,855672,4173,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2927,651821,2,4,,855672,4173,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2928,651828,1,2,,92308357,4173,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2929,651828,1,2,,92309035,4173,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2930,651838,1,1,,17389815,4173,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2931,651838,1,1,1.0,17389815,4173,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2932,651838,1,1,2.0,17389815,4173,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2933,651838,1,1,3.0,17389815,4173,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2934,651838,1,1,4.0,17389815,4173,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2935,651838,1,1,5.0,17389815,4173,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2936,651838,1,1,6.0,17389815,4173,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2937,651838,1,1,7.0,17389815,4173,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2938,651838,1,1,8.0,17389815,4173,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2939,651957,1,1,,855672,4173,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2940,651958,1,1,,855672,4173,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2941,651965,1,1,,855672,4173,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2942,651999,1,1,,855672,4173,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2943,652010,1,1,,855672,4173,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2944,652017,1,1,,855672,4173,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2945,652025,1,1,,855672,4173,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2946,652039,1,1,,855672,4173,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2947,652048,1,2,,855672,4173,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2948,652048,1,2,,144203992,4173,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2949,652051,1,1,,855672,4173,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2950,652051,1,1,,144203992,4173,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2951,652054,1,1,,855672,4173,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2952,652067,1,4,,855672,4173,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2953,652104,1,1,,855672,4173,Inconclusive,20140568.0,23435.0,7.9433,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2954,652105,1,1,,855672,4173,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2955,652106,1,1,,855672,4173,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2956,652115,1,1,,855672,4173,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2957,652126,1,3,,855672,4173,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2958,652154,1,1,,855672,4173,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2959,652162,2,1,,855672,4173,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2960,652163,1,1,,855672,4173,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2961,652197,1,1,,855672,4173,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2962,652257,1,1,,855672,4173,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2963,656870,2,4,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution method,Confirmatory,22444681.0,
2964,656871,3,1,,103189534,4173,Unspecified,,,250.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22444681.0,
2965,656872,1,3,,103189534,4173,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell viability at 250 uM after 48 hrs by MTT assay,Other,22444681.0,
2966,656873,1,3,,103189534,4173,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell viability at 2.5 to 100 uM after 48 hrs by MTT assay,Other,22444681.0,
2967,658931,2,2,,103189534,4173,Active,,,1.22,IC50,Antiparasitic activity against Giardia duodenalis IMSS:0989 after 48 hrs,Confirmatory,22464423.0,
2968,662566,2,2,,103189534,4173,Active,,,0.72,IC50,Growth inhibition of Trichomonas vaginalis T1 after 24 hrs by hemocytometry,Confirmatory,22579483.0,
2969,662568,4,1,,103189534,4173,Active,,,0.21,IC50,Growth inhibition of mtronidazole-resistant Trichomonas vaginalis after 24 hrs by hemocytometry,Confirmatory,22579483.0,
2970,662997,1,3,,103189534,4173,Unspecified,,,,,Growth inhibition of Mycobacterium tuberculosis H37Rv at >256 ug/mL,Other,22607678.0,
2971,664680,3,2,,103189534,4173,Active,,,,,Antitrichomonas activity against metronidazole-susceptible Trichomonas vaginalis,Other,24900434.0,
2972,664681,3,2,,103189534,4173,Unspecified,,,,,Antitrichomonas activity against metronidazole-resistant Trichomonas vaginalis ATCC 50143,Other,24900434.0,
2973,664682,1,4,,103189534,4173,Unspecified,,,,,Spermicidal activity against human spermatozoa assessed as immobilization measured for 60 seconds,Other,24900434.0,
2974,664683,2,3,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HeLa cells,Other,24900434.0,
2975,664684,2,3,,103189534,4173,Unspecified,,,,,Toxicity against Lactobacillus jensenii ATCC 25258,Other,24900434.0,
2976,665066,1,3,,103189534,4173,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at > 256 ug/mL,Other,22560587.0,
2977,666990,2,4,,103189534,4173,Active,,,1.8,IC50,Antiamnesic activity against Entamoeba histolytica HM1:IMSS after 72 hrs by microdilution method,Confirmatory,22658085.0,
2978,666991,2,2,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22658085.0,
2979,666992,1,3,,103189534,4173,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for Entamoeba histolytica HM1:IMSS",Other,22658085.0,
2980,666993,1,3,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as cell viability at 3.13 uM after 48 hrs by MTT assay,Other,22658085.0,
2981,674905,2,4,,103189534,4173,Active,,,1.46,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by eosin-staining method,Confirmatory,22832309.0,
2982,674906,2,2,,103189534,4173,Unspecified,,,250.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22832309.0,
2983,675034,2,4,,103189534,4173,Active,,,1.64,IC50,Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution method,Confirmatory,22840694.0,
2984,675035,2,2,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22840694.0,
2985,675036,1,3,,103189534,4173,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,22840694.0,
2986,677410,1,3,,103189534,4173,Inactive,,,,,Spermicidal activity against human spermatozoa at 10 mg/ml by modified sander-cramer assay,Other,22846917.0,
2987,677470,2,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against clinical isolate of Trichomonas vaginalis,Other,22846917.0,
2988,677471,2,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Trichomonas vaginalis ATCC 25258,Other,22846917.0,
2989,677472,2,2,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HeLa cells by MTT assay,Other,22846917.0,
2990,677473,2,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Lactobacillus jensenii,Other,22846917.0,
2991,686940,1,1,,855672,4173,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2992,686964,1,1,,855672,4173,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2993,686970,1,2,,855672,4173,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2994,686971,1,2,,855672,4173,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2995,686977,2,1,,49698715,4173,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2996,686978,1,1,,855672,4173,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2997,686978,1,1,,144203992,4173,Inconclusive,79154014.0,55775.0,9.4411,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2998,686979,1,1,,855672,4173,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2999,686979,1,1,,144203992,4173,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3000,686992,2,1,,855672,4173,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
3001,686996,1,1,,855672,4173,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3002,687014,1,1,,855672,4173,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
3003,687016,1,1,,855672,4173,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
3004,689770,2,2,,103189534,4173,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv isolate SRI after 5 days by resazurin-based microplate assay,Other,22691154.0,
3005,689771,2,2,,103189534,4173,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv isolate ITR after 7 days by luminescence spectrometry,Other,22691154.0,
3006,689772,2,2,,103189534,4173,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv incubated for 10 days in anaerobic condition followed by 48 hrs incubation in aerobic condition by LORA assay,Other,22691154.0,
3007,689773,2,2,,103189534,4173,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay,Other,22691154.0,
3008,693076,1,2,,103189534,4173,Unspecified,,,,,Redox potential of the compound assessed as one electron redox potential by pulse radiolysis method,Other,21353728.0,
3009,697912,3,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori 26695 ATCC 700392 at pH 7 by microdilution method,Other,22217866.0,
3010,697913,3,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori 26695 ATCC 700392 at pH 5 by microdilution method,Other,22217866.0,
3011,698041,3,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v1254 at pH 8 by microdilution method,Other,22217866.0,
3012,698042,3,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v1254 at pH 7 by microdilution method,Other,22217866.0,
3013,698043,1,2,,103189534,4173,Unspecified,,,,,Inhibition of Helicobacter pylori invasion to human AGS cells at 20 ug/ml after 6 hrs by gentamicin assay relative to control,Other,22217866.0,
3014,698045,3,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v1254 at pH 5 by microdilution method,Other,22217866.0,
3015,698047,3,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v633 at pH 8 by microdilution method,Other,22217866.0,
3016,698048,1,2,,103189534,4173,Unspecified,,,,,Inhibition of Helicobacter pylori adhesion to human AGS cells at 20 ug/ml after 6 hrs by gentamicin assay relative to control,Other,22217866.0,
3017,698051,3,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v633 at pH 5 by microdilution method,Other,22217866.0,
3018,698052,3,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v633 at pH 7 by microdilution method,Other,22217866.0,
3019,698053,3,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori 26695 ATCC 700392 at pH 8 by microdilution method,Other,22217866.0,
3020,698055,1,2,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori 26695 ATCC 700392 at 800 ug/ml by disk agar diffusion method,Other,22217866.0,
3021,720504,1,1,,855672,4173,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
3022,720508,1,1,,855672,4173,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3023,720509,1,1,,855672,4173,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3024,720511,1,1,,855672,4173,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
3025,720516,2,1,,144203992,4173,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3026,720516,2,1,,144209611,4173,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3027,720516,2,1,,144213111,4173,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3028,720532,1,1,,11112343,4173,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3029,720532,1,1,,144203992,4173,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3030,720533,1,1,,11112343,4173,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3031,720533,1,1,,144203992,4173,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3032,720542,1,2,,855672,4173,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
3033,720543,1,1,,855672,4173,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
3034,720551,1,2,,855672,4173,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
3035,720552,2,1,,144203992,4173,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3036,720552,2,1,,144209611,4173,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3037,720552,2,1,,144213111,4173,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3038,720553,1,2,,855672,4173,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
3039,720554,1,3,,92308357,4173,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
3040,720579,2,1,,855672,4173,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3041,720579,2,1,,144203992,4173,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3042,720580,1,1,,855672,4173,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3043,720580,1,1,,144203992,4173,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3044,720582,1,1,,855672,4173,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
3045,720596,1,1,,855672,4173,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
3046,720634,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3047,720634,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3048,720634,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3049,720635,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3050,720635,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3051,720635,2,1,,144213111,4173,Inconclusive,,,6.1131,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3052,720636,1,1,,17389815,4173,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
3053,720637,2,1,,144203992,4173,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3054,720637,2,1,,144209611,4173,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3055,720637,2,1,,144213111,4173,Inconclusive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3056,720641,1,2,,92307304,4173,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3057,720641,1,2,,92308357,4173,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3058,720641,1,2,,92309035,4173,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3059,720648,1,1,,855672,4173,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
3060,720652,1,1,,17389815,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3061,720653,1,1,,17389815,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
3062,720659,1,1,,17389815,4173,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
3063,720674,2,2,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3064,720674,2,2,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3065,720674,2,2,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3066,720675,2,2,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3067,720675,2,2,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3068,720675,2,2,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3069,720678,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3070,720678,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3071,720678,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3072,720679,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3073,720679,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3074,720679,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3075,720680,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3076,720680,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3077,720680,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3078,720681,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3079,720681,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3080,720681,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3081,720682,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3082,720682,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3083,720682,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3084,720683,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3085,720683,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3086,720683,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3087,720684,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3088,720684,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3089,720684,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3090,720685,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3091,720685,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3092,720685,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3093,720686,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3094,720686,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3095,720686,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3096,720687,2,2,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3097,720687,2,2,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3098,720687,2,2,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3099,720691,4,1,,144203992,4173,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3100,720691,4,1,,144209611,4173,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3101,720691,4,1,,144213111,4173,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3102,720692,3,1,,144203992,4173,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3103,720692,3,1,,144209611,4173,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3104,720692,3,1,,144213111,4173,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3105,720693,3,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3106,720693,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3107,720693,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3108,720700,1,4,,855672,4173,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
3109,720702,1,1,,855672,4173,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
3110,720704,1,4,,855672,4173,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
3111,720706,1,2,,855672,4173,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3112,720707,1,2,,855672,4173,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3113,720708,1,2,,855672,4173,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
3114,720709,1,2,,855672,4173,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3115,720711,1,2,,855672,4173,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
3116,720717,1,3,,92124203,4173,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3117,720717,1,3,,92124968,4173,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3118,720717,1,3,,92307304,4173,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3119,720717,1,3,,92308357,4173,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3120,720717,1,3,,92309035,4173,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3121,720719,2,1,,144203992,4173,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3122,720719,2,1,,144209611,4173,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3123,720719,2,1,,144213111,4173,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3124,720725,2,1,,144203992,4173,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3125,720725,2,1,,144209611,4173,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3126,720725,2,1,,144213111,4173,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3127,743012,3,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3128,743012,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3129,743012,3,1,,144213111,4173,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3130,743014,3,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3131,743014,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3132,743014,3,1,,144213111,4173,Inconclusive,,,76.9588,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3133,743015,3,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3134,743015,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3135,743015,3,1,,144213111,4173,Active,,,61.1306,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3136,743033,3,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3137,743033,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3138,743033,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3139,743035,2,1,,144203992,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3140,743035,2,1,,144209611,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3141,743035,2,1,,144213111,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3142,743036,2,1,,144203992,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3143,743036,2,1,,144209611,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3144,743036,2,1,,144213111,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3145,743040,3,1,,144203992,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3146,743040,3,1,,144209611,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3147,743040,3,1,,144213111,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3148,743041,3,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3149,743041,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3150,743041,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3151,743042,3,1,,144203992,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3152,743042,3,1,,144209611,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3153,743042,3,1,,144213111,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3154,743053,2,1,,144203992,4173,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3155,743053,2,1,,144209611,4173,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3156,743053,2,1,,144213111,4173,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3157,743054,2,1,,144203992,4173,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3158,743054,2,1,,144209611,4173,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3159,743054,2,1,,144213111,4173,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3160,743063,2,1,,144203992,4173,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3161,743063,2,1,,144209611,4173,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3162,743063,2,1,,144213111,4173,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3163,743064,3,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3164,743064,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3165,743064,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3166,743065,3,1,,144203992,4173,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3167,743065,3,1,,144209611,4173,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3168,743065,3,1,,144213111,4173,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3169,743066,3,1,,144203992,4173,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3170,743066,3,1,,144209611,4173,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3171,743066,3,1,,144213111,4173,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3172,743067,2,1,,144203992,4173,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3173,743067,2,1,,144209611,4173,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3174,743067,2,1,,144213111,4173,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3175,743069,2,1,,144203992,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3176,743069,2,1,,144209611,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3177,743069,2,1,,144213111,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3178,743074,2,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3179,743074,2,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3180,743074,2,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3181,743075,2,1,,144203992,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3182,743075,2,1,,144209611,4173,Inconclusive,348019627.0,2099.0,0.0898,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3183,743075,2,1,,144213111,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3184,743077,2,1,,144203992,4173,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3185,743077,2,1,,144209611,4173,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3186,743077,2,1,,144213111,4173,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3187,743078,2,1,,144203992,4173,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3188,743078,2,1,,144209611,4173,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3189,743078,2,1,,144213111,4173,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3190,743079,3,1,,144203992,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3191,743079,3,1,,144209611,4173,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3192,743079,3,1,,144213111,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3193,743080,3,1,,144203992,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3194,743080,3,1,,144209611,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3195,743080,3,1,,144213111,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3196,743081,3,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3197,743081,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3198,743081,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3199,743083,3,1,,144203992,4173,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3200,743083,3,1,,144209611,4173,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3201,743083,3,1,,144213111,4173,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3202,743084,3,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3203,743084,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3204,743084,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3205,743085,3,1,,144203992,4173,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3206,743085,3,1,,144209611,4173,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3207,743085,3,1,,144213111,4173,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3208,743086,3,1,,144203992,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3209,743086,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3210,743086,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3211,743091,2,1,,144203992,4173,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3212,743091,2,1,,144209611,4173,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3213,743091,2,1,,144213111,4173,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3214,743094,3,1,,144203992,4173,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3215,743094,3,1,,144209611,4173,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3216,743094,3,1,,144213111,4173,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3217,743122,2,1,,144203992,4173,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3218,743122,2,1,,144209611,4173,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3219,743122,2,1,,144213111,4173,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3220,743126,1,1,,855672,4173,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
3221,743139,2,1,,144203992,4173,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3222,743139,2,1,,144209611,4173,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3223,743139,2,1,,144213111,4173,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3224,743140,2,1,,144203992,4173,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3225,743140,2,1,,144209611,4173,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3226,743140,2,1,,144213111,4173,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3227,743191,3,1,,144209611,4173,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3228,743191,3,1,,144213111,4173,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3229,743191,3,1,,170464948,4173,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3230,743194,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3231,743194,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3232,743194,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3233,743199,2,1,,144209611,4173,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3234,743199,2,1,,144213111,4173,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3235,743199,2,1,,170464948,4173,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3236,743202,4,1,,144209611,4173,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3237,743202,4,1,,144213111,4173,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3238,743202,4,1,,170464948,4173,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3239,743203,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3240,743203,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3241,743203,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3242,743209,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3243,743209,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3244,743209,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3245,743210,4,1,,144209611,4173,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3246,743210,4,1,,144213111,4173,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3247,743210,4,1,,170464948,4173,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3248,743211,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3249,743211,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3250,743211,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3251,743212,3,1,,144209611,4173,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3252,743212,3,1,,144213111,4173,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3253,743212,3,1,,170464948,4173,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3254,743213,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3255,743213,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3256,743213,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3257,743215,3,1,,144209611,4173,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3258,743215,3,1,,144213111,4173,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3259,743215,3,1,,170464948,4173,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3260,743217,3,1,,144209611,4173,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3261,743217,3,1,,144213111,4173,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3262,743217,3,1,,170464948,4173,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3263,743218,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3264,743218,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3265,743218,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3266,743219,3,1,,144209611,4173,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3267,743219,3,1,,144213111,4173,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3268,743219,3,1,,170464948,4173,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3269,743220,3,1,,144209611,4173,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3270,743220,3,1,,144213111,4173,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3271,743220,3,1,,170464948,4173,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3272,743221,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3273,743221,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3274,743221,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3275,743222,3,1,,144209611,4173,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3276,743222,3,1,,144213111,4173,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3277,743222,3,1,,170464948,4173,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3278,743223,3,1,,144209611,4173,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3279,743223,3,1,,144213111,4173,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3280,743223,3,1,,170464948,4173,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3281,743224,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3282,743224,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3283,743224,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3284,743225,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3285,743225,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3286,743225,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3287,743226,2,1,,144209611,4173,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3288,743226,2,1,,144213111,4173,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3289,743226,2,1,,170464948,4173,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3290,743227,2,1,,144209611,4173,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3291,743227,2,1,,144213111,4173,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3292,743227,2,1,,170464948,4173,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3293,743228,3,1,,144209611,4173,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3294,743228,3,1,,144213111,4173,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3295,743228,3,1,,170464948,4173,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3296,743238,1,1,,855672,4173,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
3297,743239,2,1,,144209611,4173,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3298,743239,2,1,,144213111,4173,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3299,743239,2,1,,170464948,4173,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3300,743240,2,1,,144209611,4173,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3301,743240,2,1,,144213111,4173,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3302,743240,2,1,,170464948,4173,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3303,743241,2,1,,144209611,4173,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3304,743241,2,1,,144213111,4173,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3305,743241,2,1,,170464948,4173,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3306,743242,2,1,,144209611,4173,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3307,743242,2,1,,144213111,4173,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3308,743242,2,1,,170464948,4173,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3309,743244,1,1,,144203992,4173,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3310,743247,1,2,,855672,4173,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3311,743255,1,1,,855672,4173,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
3312,743266,1,2,,855672,4173,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
3313,743268,1,1,,172080143,4173,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
3314,743269,1,1,,855672,4173,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3315,743269,1,1,,855672,4173,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3316,743270,1,1,,172080143,4173,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3317,743271,1,1,,172080143,4173,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
3318,743272,1,1,,172080143,4173,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
3319,743279,1,2,,855672,4173,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
3320,743281,1,1,,46386860,4173,Inactive,1778357.0,22341.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
3321,743281,1,1,,46386860,4173,Inactive,219520294.0,8828.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
3322,743288,1,1,,17389815,4173,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3323,743292,1,1,,17389815,4173,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3324,743344,1,1,,174006204,4173,Inactive,,,0.0006,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
3325,743345,1,1,,174006204,4173,Inactive,,,0.0237,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
3326,743346,1,1,,174006204,4173,Inactive,,,0.7493,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
3327,743347,1,1,,174006204,4173,Inactive,,,4.7277,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
3328,743397,1,1,,855672,4173,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3329,743398,1,1,,855672,4173,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3330,745656,1,1,,103189534,4173,Active,,,0.72,IC50,Antibacterial activity against Trichomonas vaginalis G3 after 24 hrs by hemocytometry,Confirmatory,23631874.0,
3331,749415,1,3,,103189534,4173,Active,,,1.45,IC50,Antiamoebic activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS assessed as growth inhibition after 72 hrs by microdilution method,Confirmatory,23602620.0,
3332,750266,1,1,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM after 48 hrs by MTT assay,Other,23644202.0,
3333,750267,1,1,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as cell viability at 50 to 100 uM after 48 hrs by MTT assay,Other,23644202.0,
3334,750268,1,1,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as cell viability up to 25 uM after 48 hrs by MTT assay,Other,23644202.0,
3335,750269,1,1,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as cell viability at 3.13 uM after 48 hrs by MTT assay,Other,23644202.0,
3336,750270,1,1,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,23644202.0,
3337,750271,1,1,,103189534,4173,Unspecified,,,,,"Safety index, ratio of IC50 for human HepG2 cells to IC50 for Entamoeba histolytica HM-1:IMSS trophozoites",Other,23644202.0,
3338,750272,3,2,,103189534,4173,Active,,,1.8,IC50,Antiamoebic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution method,Confirmatory,23644202.0,
3339,757805,1,3,,103189534,4173,Active,,,0.3798,IC50,Antiprotozoal activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS assessed as growth inhibition after 48 hrs by haemocytometric analysis,Confirmatory,23731944.0,
3340,757806,1,1,,103189534,4173,Active,,,1.226,IC50,Antiprotozoal activity against trophozoite stage of Giardia intestinalis IMSS:0981:1 assessed as growth inhibition after 48 hrs by haemocytometric analysis,Confirmatory,23731944.0,
3341,757807,1,1,,103189534,4173,Active,,,0.23600000000000002,IC50,Antiprotozoal activity against trophozoite stage of Trichomonas vaginalis GT3 assessed as growth inhibition after 48 hrs by haemocytometric analysis,Confirmatory,23731944.0,
3342,763545,1,1,,103189534,4173,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for trophozoite stage of Entamoeba histolytica HM-1:IMSS",Other,23787289.0,
3343,763546,1,1,,103189534,4173,Unspecified,,,100.0,IC50,Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by WST-1 assay,Confirmatory,23787289.0,
3344,763547,1,3,,103189534,4173,Active,,,4.5,IC50,Antiamoebic activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS assessed as growth inhibition after 48 hrs by microdilution method,Confirmatory,23787289.0,
3345,774309,1,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against clinical isolates of Giardia lamblia IMSS:8901:1,Other,24099364.0,
3346,774310,1,3,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against clinical isolates of Entamoeba histolytica HM-1:IMSS,Other,24099364.0,
3347,774912,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Trichomonas vaginalis G3 assessed as growth inhibition at 10 uM after 24 hrs by hemocytometry,Other,24012713.0,
3348,925507,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020211,Other,,
3349,925508,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020211,Other,,
3350,925509,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020211,Other,,
3351,925510,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020211,Other,,
3352,925511,1,3,,103189534,4173,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020211",Other,,
3353,925512,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020211,Other,,
3354,925513,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020211,Other,,
3355,925514,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020211,Other,,
3356,925515,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020211,Other,,
3357,925516,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020211,Other,,
3358,925517,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020211,Other,,
3359,925518,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020211,Other,,
3360,925519,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020211,Other,,
3361,925520,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020211,Other,,
3362,925521,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020211,Other,,
3363,925522,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020211,Other,,
3364,925523,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020211,Other,,
3365,927524,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020211,Other,,
3366,927525,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020211,Other,,
3367,969197,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020211,Other,,
3368,969198,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020211,Other,,
3369,969199,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020211,Other,,
3370,969200,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020211,Other,,
3371,969201,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020211,Other,,
3372,969202,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020211,Other,,
3373,969203,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020211,Other,,
3374,969204,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020211,Other,,
3375,969205,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020211,Other,,
3376,969206,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020211,Other,,
3377,969207,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020211,Other,,
3378,969208,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020211,Other,,
3379,969209,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020211,Other,,
3380,969210,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020211,Other,,
3381,969211,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020211,Other,,
3382,969212,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020211,Other,,
3383,969213,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020211,Other,,
3384,969214,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020211,Other,,
3385,969215,1,3,,103189534,4173,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020211,Other,,
3386,977599,1,1,,103189534,4173,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3387,977602,1,2,,103189534,4173,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3388,1053175,2,1,,178127229,4173,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
3389,1053188,2,1,,855672,4173,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3390,1053197,1,1,,855672,4173,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3391,1053268,1,4,,103189534,4173,Unspecified,3915797.0,5743.0,,,Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control,Other,24088053.0,
3392,1054551,3,1,,103189534,4173,Unspecified,,,,,Trichomonacidal activity against Trichomonas vaginalis after 48 hrs by trypan blue exclusion assay,Other,24140949.0,
3393,1054552,1,1,,103189534,4173,Unspecified,,,,,Spermicidal activity in human semen assessed as sperm immobilization at 0.1 % w/v up to 30 seconds by phase contrast microscopy,Other,24140949.0,
3394,1054553,1,1,,103189534,4173,Unspecified,,,,,Spermicidal activity in human semen assessed as sperm immobilization at 1.0 % w/v up to 30 seconds by phase contrast microscopy,Other,24140949.0,
3395,1055935,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis harboring luxABCDE under hypoxic condition after 10 days by MABA assay in presence of 10% fetal bovine serum,Other,24224794.0,
3396,1055936,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis harboring luxABCDE under hypoxic condition after 10 days by MABA assay in presence of 4% bovine serum albumin,Other,24224794.0,
3397,1055937,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv under normoxic condition after 7 days by MABA assay in presence of 10% fetal bovine serum,Other,24224794.0,
3398,1055938,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv under normoxic condition after 7 days by MABA assay in presence of 4% bovine serum albumin,Other,24224794.0,
3399,1055954,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against capreomycin-resistant Mycobacterium tuberculosis under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3400,1055955,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against cycloserine-resistant Mycobacterium tuberculosis ATCC 35826 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3401,1055956,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis ATCC 35822 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3402,1055957,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against kanamycin-resistant Mycobacterium tuberculosis ATCC 35827 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3403,1055958,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against moxifloxacin-resistant Mycobacterium tuberculosis under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3404,1055959,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis ATCC 35838 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3405,1055960,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against streptomycin-resistant Mycobacterium tuberculosis ATCC 35820 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3406,1055961,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X005319 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3407,1055962,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X005282 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3408,1055963,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X004439 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3409,1055964,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X004244 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3410,1055965,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X003899 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3411,1055966,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate X001354 under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3412,1055967,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis harboring luxABCDE under hypoxic condition after 10 days by MABA assay,Other,24224794.0,
3413,1055969,3,1,,103189534,4173,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv under normoxic condition after 7 days by MABA assay,Other,24224794.0,
3414,1063463,3,1,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as concentration required to decrease cell viability incubated for 24 hrs followed by compound washout measured after 18 hrs by resazurin dye-based assay,Other,24360560.0,
3415,1063464,3,1,,103189534,4173,Unspecified,,,,,Cytotoxicity against human FADU cells assessed as concentration required to decrease cell viability incubated for 24 hrs followed by compound washout measured after 18 hrs by resazurin dye-based assay,Other,24360560.0,
3416,1063466,1,1,,103189534,4173,Inactive,,,,,Antibacterial activity against stationary phase of Clostridium difficile CD196 assessed as cell killing at 1 to 20 X MIC after 3 to 6 hrs,Other,24360560.0,
3417,1063468,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 47077 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3418,1063469,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 700927 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3419,1063470,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Streptococcus mutans ATCC 700610 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3420,1063471,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus 8325-4 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3421,1063472,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Lactobacillus reuteri ATCC 23272 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3422,1063473,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Lactobacillus casei ATCC 334 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3423,1063474,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bifidobacterium longum ATCC BAA-999 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3424,1063475,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides thetaiotaomicron ATCC 29148 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3425,1063476,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis ATCC 25285 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3426,1063477,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium perfringens ATCC 13124 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3427,1063478,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium difficile CD196 assessed as growth inhibition after 20 to 24 hrs,Other,24360560.0,
3428,1066689,1,1,,103189534,4173,Active,,,1.22,IC50,Antiprotozoal activity against Giardia lamblia IMSS:1090:1,Confirmatory,24502360.0,
3429,1066690,1,1,,103189534,4173,Active,,,0.23,IC50,Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS,Confirmatory,24502360.0,
3430,1067245,1,1,,103189534,4173,Unspecified,,,,,Trichomonacidal activity against Trichomonas vaginalis JH31A at 0.5 ug/ml after 48 hrs by Neubauer chamber analysis relative to control,Other,24513185.0,
3431,1067246,1,1,,103189534,4173,Unspecified,,,,,Trichomonacidal activity against Trichomonas vaginalis JH31A at 1 ug/ml after 48 hrs by Neubauer chamber analysis relative to control,Other,24513185.0,
3432,1067247,1,1,,103189534,4173,Unspecified,,,,,Trichomonacidal activity against Trichomonas vaginalis JH31A at 2 ug/ml after 48 hrs by Neubauer chamber analysis relative to control,Other,24513185.0,
3433,1067251,1,1,,103189534,4173,Unspecified,,,,,Trichomonacidal activity against Trichomonas vaginalis JH31A at 0.5 ug/ml after 24 hrs by Neubauer chamber analysis relative to control,Other,24513185.0,
3434,1067252,1,1,,103189534,4173,Unspecified,,,,,Trichomonacidal activity against Trichomonas vaginalis JH31A at 1 ug/ml after 24 hrs by Neubauer chamber analysis relative to control,Other,24513185.0,
3435,1067254,1,1,,103189534,4173,Unspecified,,,,,Trichomonacidal activity against Trichomonas vaginalis JH31A at 2 ug/ml after 24 hrs by Neubauer chamber analysis relative to control,Other,24513185.0,
3436,1067348,1,1,,103189534,4173,Unspecified,,,50.0,IC50,Antimicrobial activity against promastigote stage of Leishmania amazonensis IFLA/BR/67/PH-8 clinical isolate after 72 hrs by Neubauer chamber analysis,Confirmatory,24529307.0,
3437,1067349,3,1,,103189534,4173,Active,,,0.31623,IC50,Antimicrobial activity against Trichomonas vaginalis GT3 incubated for 48 hrs followed by compound washout measured after 48 hrs,Confirmatory,24529307.0,
3438,1067350,3,1,,103189534,4173,Active,,,5.3703199999999995,IC50,Antimicrobial activity against Giardia intestinalis IMSS:0696:1 incubated for 48 hrs followed by compound washout measured after 48 hrs,Confirmatory,24529307.0,
3439,1067357,1,2,,103189534,4173,Unspecified,,,387.0,CC50,Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,24529307.0,
3440,1067358,1,1,,103189534,4173,Unspecified,,,50.0,IC50,Antimicrobial activity against epimastigote stage of Trypanosoma cruzi MHOM/MX/1994/Ninoa clinical isolate after 72 hrs by Neubauer chamber analysis,Confirmatory,24529307.0,
3441,1070246,3,1,,103189534,4173,Unspecified,,,,IC50,Antiprotozoal activity against trophozoite stage of Trichomonas vaginalis GT3 assessed as growth inhibition,Confirmatory,24468633.0,
3442,1070247,3,1,,103189534,4173,Unspecified,,,,IC50,Antiprotozoal activity against trophozoite stage of Giardia lamblia IMSS:8909:1 assessed as growth inhibition after 48 hrs,Confirmatory,24468633.0,
3443,1070248,3,1,,103189534,4173,Unspecified,,,,IC50,Antiprotozoal activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS assessed as growth inhibition after 48 hrs,Confirmatory,24468633.0,
3444,1076163,1,1,,103189534,4173,Active,,,5.4,IC50,Cytotoxicity against BALB/c mouse splenocytes assessed as [3H]-thymidine incorporation after 24 hrs by beta-radiation counting analysis relative to control,Confirmatory,24530492.0,
3445,1076164,1,1,,103189534,4173,Active,,,1.5,IC50,Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution method,Confirmatory,24530492.0,
3446,1079931,1,1,,103189534,4173,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3447,1079932,1,1,,103189534,4173,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3448,1079933,1,1,,103189534,4173,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3449,1079934,1,1,,103189534,4173,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3450,1079935,1,1,,103189534,4173,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3451,1079936,1,1,,103189534,4173,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3452,1079937,1,1,,103189534,4173,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3453,1079938,1,1,,103189534,4173,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3454,1079939,1,1,,103189534,4173,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3455,1079940,1,1,,103189534,4173,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3456,1079941,1,1,,103189534,4173,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3457,1079942,1,1,,103189534,4173,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3458,1079943,1,1,,103189534,4173,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3459,1079944,1,1,,103189534,4173,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3460,1079945,1,1,,103189534,4173,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3461,1079946,1,1,,103189534,4173,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3462,1079947,1,1,,103189534,4173,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3463,1079948,1,1,,103189534,4173,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3464,1079949,1,1,,103189534,4173,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3465,1084255,1,2,,103189534,4173,Active,,,,,Antiparasitic activity against Trichomonas vaginalis GT3 after 24 hr by Alamar blue assay,Other,,
3466,1084256,1,2,,103189534,4173,Active,,,,EC50,Antiparasitic activity against Trichomonas vaginalis GT3 after 48 hr by Alamar blue assay,Confirmatory,,
3467,1084257,2,1,,103189534,4173,Unspecified,,,,,"Partition coefficient, log P of compound at 1:1 1-octanol/water volume ratio by spectrophotometer",Other,,
3468,1084258,2,1,,103189534,4173,Unspecified,,,,,"Partition coefficient, log P of compound at 1:2 1-octanol/water volume ratio by spectrophotometer",Other,,
3469,1084259,2,1,,103189534,4173,Unspecified,,,,,"Partition coefficient, log P of compound at 2:1 1-octanol/water volume ratio by spectrophotometer",Other,,
3470,1086105,1,2,,103189534,4173,Inactive,,,,,Antifungal activity against Candida albicans ATCC 10231 up to 1.25 mg/ml after 24 hr by broth microdilution method,Other,,
3471,1086110,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 6538P after 24 hr by broth microdilution method,Other,,
3472,1086111,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 8739 after 24 hr by broth microdilution method,Other,,
3473,1086112,1,2,,103189534,4173,Active,,,,,Antibacterial activity against Clostridium sporogenes ATCC 19404 after 24 hr by broth microdilution method,Other,,
3474,1086113,1,2,,103189534,4173,Active,,,3.74,IC50,Antigiardial activity against Giardia intestinalis WB by trypan blue assay,Confirmatory,,
3475,1094365,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori at 8 ug/disk after 3 to 5 days by paper disk diffusion method,Other,,
3476,1096888,1,2,,103189534,4173,Unspecified,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as concentration at which cell growth as in negative control after 48 hr by hemocytometer,Other,,
3477,1096889,1,2,,103189534,4173,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) Hep2 cells assessed as concentration at which cell growth as in negative control after 48 hr by hemocytometer,Other,,
3478,1096890,1,2,,103189534,4173,Active,,,5.17,IC50,Antiparasitic activity against Giardia intestinalis WB strain ATCC 30957 using trypan blue staining by hemocytometer,Confirmatory,,
3479,1096891,1,2,,103189534,4173,Active,,,4.4,IC50,Antiparasitic activity against Entamoeba histolytica HK-9 strain ATCC 30015 using trypan blue staining by hemocytometer,Confirmatory,,
3480,1106227,1,2,,103189534,4173,Unspecified,,,250.0,IC50,Cytotoxicity against Homo sapiens (human) MCF-7 cells assessed as decrease in number of viable cells after 48 hr by MTT assay,Confirmatory,,
3481,1106228,1,2,,103189534,4173,Active,,,1.8,IC50,Antiamoebic activity against Entamoeba histolytica HM-1:IMSS trophozoite assessed as growth inhibition after 72 hr by microdilution method,Confirmatory,,
3482,1106550,1,2,,103189534,4173,Unspecified,,,250.0,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay,Confirmatory,,
3483,1106551,1,2,,103189534,4173,Active,,,1.8,IC50,Antiamoebic activity against trophozoites of Entamoeba histolytica HM-1:IMSS after 72 hr by eosin stain-based spectrophotometric analysis,Confirmatory,,
3484,1113832,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori strain 3 assessed as diameter of growth inhibition zone at 16 ug/disk after 3-5 days by filter paper disk diffusion method,Other,,
3485,1113836,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori strain 2 assessed as diameter of growth inhibition zone at 16 ug/disk after 3-5 days by filter paper disk diffusion method,Other,,
3486,1113840,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori strain 1 assessed as diameter of growth inhibition zone at 16 ug/disk after 3-5 days by filter paper disk diffusion method,Other,,
3487,1116180,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3488,1116201,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 06-8 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3489,1116202,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 06-7 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3490,1116203,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 06-6 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3491,1116204,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 06-5 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3492,1116205,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 06-4 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3493,1116206,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 06-3 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3494,1116207,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 06-2 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3495,1116208,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 06-1 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3496,1116209,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 05-3 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3497,1116210,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 05-14 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3498,1116211,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 05-12 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3499,1116212,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 05-9 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3500,1116213,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 05-5 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3501,1116214,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 05-4 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3502,1116215,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 05-2 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3503,1116216,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori 05-1 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3504,1116217,1,2,,103189534,4173,Unspecified,,,,,Antibacterial activity against Helicobacter pylori ATCC 11637 assessed as growth inhibition after 16 to 18 hr NCCLS agar dilution method,Other,,
3505,1117298,1,2,,170464948,4173,Inactive,,,7.0795,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3506,1117301,1,2,,170464948,4173,Inactive,,,7.9433,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
3507,1117302,1,2,,170464948,4173,Inactive,,,0.3162,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
3508,1117303,1,2,,170464948,4173,Inactive,,,2.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
3509,1117304,1,2,,170464948,4173,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3510,1117305,1,2,,170464948,4173,Inactive,,,5.0119,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3511,1117310,1,1,,170464948,4173,Inactive,,,7.079460000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3512,1117311,1,1,,170464948,4173,Inactive,,,7.943280000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
3513,1117312,1,1,,170464948,4173,Inactive,,,5.01187,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3514,1117314,1,1,,170464948,4173,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3515,1117315,1,1,,170464948,4173,Inactive,,,0.316228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
3516,1117318,1,1,,170464948,4173,Inactive,,,1.9952599999999998,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
3517,1117319,1,2,,26719631,4173,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3518,1117319,1,2,,26719631,4173,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3519,1117326,1,1,,170464948,4173,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
3520,1117329,1,1,,170464948,4173,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
3521,1117336,1,1,,170464948,4173,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
3522,1117340,1,1,,170464948,4173,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
3523,1117341,1,1,,170464948,4173,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
3524,1117342,1,1,,170464948,4173,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
3525,1117343,1,1,,170464948,4173,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
3526,1117346,1,1,,170464948,4173,Active,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
3527,1121634,1,1,,103189534,4173,Active,,,0.72,IC50,Antimicrobial activity against Trichomonas vaginalis G3 assessed as growth inhibition after 24 hrs by hemocytometry,Confirmatory,,
3528,1125369,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus RN4220 assessed as growth inhibition at 300 ug/ml after 16 hrs by spectrophotometric analysis,Other,24641976.0,
3529,1125376,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus RN4220 assessed as growth inhibition at 150 ug/ml after 16 hrs by spectrophotometric analysis,Other,24641976.0,
3530,1125377,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus RN4220 assessed as growth inhibition at 75 ug/ml after 16 hrs by spectrophotometric analysis,Other,24641976.0,
3531,1125391,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5alpha assessed as growth inhibition at 100 ug/ml after 16 hrs by spectrophotometric method,Other,24641976.0,
3532,1125399,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5alpha assessed as growth inhibition at 75 ug/ml after 16 hrs by spectrophotometric method,Other,24641976.0,
3533,1125400,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5alpha assessed as growth inhibition at 50 ug/ml after 16 hrs by spectrophotometric method,Other,24641976.0,
3534,1127195,1,1,,103189534,4173,Unspecified,,,,,Antitrichomonal activity against metronidazole-susceptible Trichomonas vaginalis clinical isolate by trypan blue staining-based cell counting,Other,24727243.0,
3535,1127196,1,1,,103189534,4173,Unspecified,,,,,Antitrichomonal activity against metronidazole-resistant Trichomonas vaginalis ATCC 50143 by trypan blue staining-based cell counting,Other,24727243.0,
3536,1127198,1,1,,103189534,4173,Unspecified,,,,,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Other,24727243.0,
3537,1127199,1,1,,103189534,4173,Unspecified,,,,,Ratio of MIC for metronidazole-resistant Trichomonas vaginalis ATCC 50143 to metronidazole-susceptible Trichomonas vaginalis clinical isolate,Other,24727243.0,
3538,1135253,1,1,,103189534,4173,Unspecified,,,,,Trichomonastatic activity against Trichomonas vaginalis by tube dilution method,Other,16132.0,
3539,1135254,1,1,,103189534,4173,Unspecified,,,,,Trichomonacidal activity against Trichomonas vaginalis by tube dilution method,Other,16132.0,
3540,1135263,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Trichomonas vaginalis infected in sc dosed mouse,Other,16132.0,
3541,1135604,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Entamoeba histolytica NIH 200-mu cecal forms infected in Wistar albino rat assessed as cure rate administered qd for 5 days by microscopic analysis,Other,203694.0,
3542,1135605,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Entamoeba histolytica NIH 200-mu hepatic forms infected in golden hamster assessed as survival rate administered qd for 5 days measured up to 14 days by microscopic analysis,Other,203694.0,
3543,1136089,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium pasteurianum ATCC 6013 assessed as growth inhibition after 24 hrs under anaerobic conditions by microscopic analysis,Other,25969.0,
3544,1136090,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Trichomonas vaginalis ATCC 30001 assessed as growth inhibition after 48 hrs under anaerobic conditions by microscopic analysis,Other,25969.0,
3545,1136091,2,1,,103189534,4173,Unspecified,,,,,"1-Octanol-saturated McIlvaine buffer partition coefficient, log P of the compound at 80 uM at pH 6.01 by spectrophotometric analysis",Other,25969.0,
3546,1136095,1,1,,103189534,4173,Unspecified,,,,,Electroreduction potential of the compound assessed as alternating current reduction peak potential by polarographic technique,Other,25969.0,
3547,1142218,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori isolated from gastrointestinal disease patient after 72 hrs by Etest method,Other,24775303.0,
3548,1146159,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus Tour assessed as growth inhibition,Other,199729.0,
3549,1146160,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium perfringens ISS 30453 assessed as growth inhibition,Other,199729.0,
3550,1146161,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Escherichia coli SKF 12140 assessed as growth inhibition,Other,199729.0,
3551,1146162,1,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against Trichomonas vaginalis assessed as static effect,Other,199729.0,
3552,1146163,1,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against Trichomonas vaginalis assessed as cidal effect,Other,199729.0,
3553,1146164,1,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against Trichomonas vaginalis infected in po dosed mouse,Other,199729.0,
3554,1146165,1,1,,103189534,4173,Unspecified,,,,,Ratio of compound ED50 to metronidazole ED50 for Trichomonas vaginalis infected in po dosed mouse,Other,199729.0,
3555,1146166,1,1,,103189534,4173,Unspecified,,,,,Acute toxicity in po dosed mouse,Other,199729.0,
3556,1146193,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus Tour by microtitre method,Other,211235.0,
3557,1146194,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Streptococcus pyogenes C 203 by microtitre method,Other,211235.0,
3558,1146195,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens ISS 30543 by broth dilution method,Other,211235.0,
3559,1146196,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Mycoplasma gallisepticum S6 Weybridge by broth dilution method,Other,211235.0,
3560,1146197,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Trichomonas vaginalis by broth dilution method,Other,211235.0,
3561,1146198,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Trichomonas vaginalis infected in po dosed mouse,Other,211235.0,
3562,1146200,1,1,,103189534,4173,Unspecified,,,,,Acute toxicity in po dosed mouse,Other,211235.0,
3563,1146201,1,1,,103189534,4173,Unspecified,,,,,"Therapeutic index, ratio of LD50 for po dosed mouse to ED50 for Trichomonas vaginalis infected in po dosed mouse",Other,211235.0,
3564,1146210,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as reduction in curiosity at 10 to 600 mg/kg, po by Irwin test",Other,211235.0,
3565,1146211,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as reduction in spontaneous activity at 10 to 600 mg/kg, po by Irwin test",Other,211235.0,
3566,1146212,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as reduction in body tone at 10 to 600 mg/kg, po by Irwin test",Other,211235.0,
3567,1146213,1,2,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as reduction in heart rate at 10 to 600 mg/kg, po by Irwin test",Other,211235.0,
3568,1146214,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as reduction in respiratory rate at 10 to 600 mg/kg, po by Irwin test",Other,211235.0,
3569,1146215,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as reduction in opening of eyelid at 10 to 600 mg/kg, po by Irwin test",Other,211235.0,
3570,1146216,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as flaccid paralysis at 600 mg/kg, po by Irwin test",Other,211235.0,
3571,1146219,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as change in sleeping time at 300 mg/kg, po administered 30 mins prior to hexobarbital sodium challenge relative to vehicle-treated control",Other,211235.0,
3572,1146220,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as change in sleeping time at 600 mg/kg, po administered 30 mins prior to hexobarbital sodium challenge relative to vehicle-treated control",Other,211235.0,
3573,1146223,1,1,,103189534,4173,Active,,,,,"Inhibition of strychine sulfate/pentetrazole-induced death in CF1 mouse at 300 to 600 mg/kg, po administered 60 mins prior to strychine sulfate/pentetrazole challenge",Other,211235.0,
3574,1146226,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as ataxia at 10 to 600 mg/kg, po by Irwin test",Other,211235.0,
3575,1146227,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in CF1 mouse assessed as cyanosis at 10 to 600 mg/kg, po by Irwin test",Other,211235.0,
3576,1147712,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Clostridium perfringens ATCC 13124 after 24 hrs by ten-fold serial dilution method,Other,412966.0,
3577,1147713,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Bacteroides fragilis ATCC 23745 after 24 hrs by ten-fold serial dilution method,Other,412966.0,
3578,1147714,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Neisseria gonorrhoeae ATCC 19424 after 48 hrs by ten-fold serial dilution method,Other,412966.0,
3579,1147715,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Trichomonas vaginalis ATCC 30001 after 48 hrs by ten-fold serial dilution method,Other,412966.0,
3580,1147716,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Tritrichomonas foetus 1002-96-27 after 48 hrs by ten-fold serial dilution method,Other,412966.0,
3581,1147717,1,1,,103189534,4173,Unspecified,,,,,Antibacterial activity against Pentatrichomonas hominis ATCC 30000 after 48 hrs by ten-fold serial dilution method,Other,412966.0,
3582,1147718,1,1,,103189534,4173,Inactive,,,,,Antifungal activity against Candida albicans,Other,412966.0,
3583,1159386,1,2,,103189534,4173,Unspecified,,,,,ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
3584,1159387,1,2,,103189534,4173,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
3585,1159395,1,2,,103189534,4173,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
3586,1159396,1,2,,103189534,4173,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
3587,1159509,1,1,,144209611,4173,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3588,1159509,1,1,,144213111,4173,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3589,1159509,1,1,,170464948,4173,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3590,1159515,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3591,1159515,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3592,1159515,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3593,1159516,1,1,,144209611,4173,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3594,1159516,1,1,,144213111,4173,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3595,1159516,1,1,,170464948,4173,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3596,1159517,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3597,1159517,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3598,1159517,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3599,1159518,1,1,,144209611,4173,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3600,1159518,1,1,,144213111,4173,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3601,1159518,1,1,,170464948,4173,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3602,1159519,1,1,,144209611,4173,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3603,1159519,1,1,,144213111,4173,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3604,1159519,1,1,,170464948,4173,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3605,1159520,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3606,1159520,1,1,,144213111,4173,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3607,1159520,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3608,1159521,1,1,,144209611,4173,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3609,1159521,1,1,,144213111,4173,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3610,1159521,1,1,,170464948,4173,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3611,1159523,1,1,,144209611,4173,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3612,1159523,1,1,,144213111,4173,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3613,1159523,1,1,,170464948,4173,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3614,1159524,1,1,,855672,4173,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3615,1159524,1,1,,144203992,4173,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3616,1159525,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3617,1159525,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3618,1159525,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3619,1159526,1,1,,144209611,4173,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3620,1159526,1,1,,144213111,4173,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3621,1159526,1,1,,170464948,4173,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3622,1159527,1,1,,144209611,4173,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3623,1159527,1,1,,144213111,4173,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3624,1159527,1,1,,170464948,4173,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3625,1159528,1,1,,144209611,4173,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3626,1159528,1,1,,144213111,4173,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3627,1159528,1,1,,170464948,4173,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3628,1159529,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3629,1159529,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3630,1159529,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3631,1159531,1,1,,144209611,4173,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3632,1159531,1,1,,144213111,4173,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3633,1159531,1,1,,170464948,4173,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3634,1159550,3,1,,252402361,4173,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
3635,1159551,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3636,1159551,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3637,1159551,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3638,1159552,1,1,,144209611,4173,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3639,1159552,1,1,,144213111,4173,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3640,1159552,1,1,,170464948,4173,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3641,1159553,2,1,,144209611,4173,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3642,1159553,2,1,,144213111,4173,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3643,1159553,2,1,,170464948,4173,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3644,1159555,1,1,,144209611,4173,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3645,1159555,1,1,,144213111,4173,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3646,1159555,1,1,,170464948,4173,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3647,1159580,2,1,,268734625,4173,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3648,1159583,2,1,,178127229,4173,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
3649,1159606,1,1,,855672,4173,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3650,1159607,2,1,,312309649,4173,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3651,1159614,1,2,,170464948,4173,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
3652,1159620,1,1,,103189534,4173,Active,,,,,Summary of drug indications.,Other,,
3653,1160935,1,1,,103189534,4173,Unspecified,,,,,"Partition coefficient, log D of the compound at pH 7.4",Other,25148516.0,
3654,1176978,1,1,,103189534,4173,Active,,,0.58,IC50,Antiprotozoal activity against Giardia lamblia assessed as growth inhibition,Confirmatory,25547934.0,
3655,1177054,1,1,,103189534,4173,Active,,,0.58,IC50,Antiprotozoan activity against Giardia lamblia G1,Confirmatory,25563890.0,
3656,1181510,1,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS trophozoites assessed as growth inhibition compound treated for 48 hrs measured 48 hrs post wash-out by MTT assay,Other,24974343.0,
3657,1181511,1,1,,103189534,4173,Unspecified,,,,,Antiprotozoal activity against Giardia lamblia IMSS: 8909:1 trophozoites assessed as growth inhibition compound treated for 48 hrs measured 48 hrs post wash-out by MTT assay,Other,24974343.0,
3658,1189129,1,1,,103189534,4173,Unspecified,,,278.69,IC50,"DNDI: Chagas in Vitro, 96 hour",Confirmatory,,
3659,1189130,1,1,,103189534,4173,Unspecified,,,338.87,IC50,"DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells",Confirmatory,,
3660,1189131,1,1,,103189534,4173,Unspecified,,,175.28,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes)",Confirmatory,,
3661,1189133,1,1,,103189534,4173,Unspecified,,,337.7,IC50,"DNDI: HAT in Vitro, 72 hour",Confirmatory,,
3662,1189134,1,1,,103189534,4173,Unspecified,,,491.36,IC50,"DNDI: Leish (axenic) in Vitro, 72 hour",Confirmatory,,
3663,1189135,1,1,,103189534,4173,Unspecified,,,175.28,IC50,"DNDI: Leish (macro) in Vitro, 96 hour",Confirmatory,,
3664,1189136,1,1,,103189534,4173,Unspecified,,,276.94,IC50,"DNDI: Malaria in Vitro, 72 hour",Confirmatory,,
3665,1192646,1,1,,103189534,4173,Inactive,,,,IC50,Inhibition of Mycobacterium smegmatis TMC 607 ATP synthase incubated for 10 mins prior to NADH addition measured after 1 hr by luminescence assay,Confirmatory,25614114.0,
3666,1192659,1,1,,103189534,4173,Inactive,,,,,Bactericidal activity against non-replicating Mycobacterium tuberculosis H37Rv Wayne model under hypoxic/oxygen depleted conditions assessed as log reduction after 4 days by serial dilution assay,Other,25614114.0,
3667,1192663,1,1,,103189534,4173,Unspecified,,,,,Bactericidal activity against non-replicating Mycobacterium tuberculosis H37Rv Wayne model under hypoxic/oxygen depleted conditions assessed as log reduction at 50 ug/ml after 4 days by serial dilution assay,Other,25614114.0,
3668,1194389,1,1,,103189534,4173,Active,,,0.29,IC50,Trichomonicidal activity against Trichomonas vaginalis GT3 compound treated for 48 hrs followed by incubation for 48 hrs in compound-free medium by cell counting,Confirmatory,25801157.0,
3669,1194390,1,1,,103189534,4173,Active,,,5.36,IC50,Giardicidal activity against Giardia intestinalis IMSS:0696:1 compound treated for 48 hrs followed by incubation for 48 hrs in compound-free medium by cell counting,Confirmatory,25801157.0,
3670,1194391,1,1,,103189534,4173,Unspecified,,,367.0,CC50,Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay,Confirmatory,25801157.0,
3671,1194392,1,1,,103189534,4173,Inconclusive,,,,,"Inhibition of Giardia intestinalis fructose 1,6-bisphosphate aldolase at 400 nM after 2 hrs by spectrophotometry",Other,25801157.0,
3672,1196181,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori at 1 ug/disc,Other,25553540.0,
3673,1196182,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori by disc diffusion method,Other,25553540.0,
3674,1204222,1,1,,103189534,4173,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 1 hr relative to control",Other,25937011.0,
3675,1204224,1,1,,103189534,4173,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 2 hrs relative to control",Other,25937011.0,
3676,1204226,1,1,,103189534,4173,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 3 hrs relative to control",Other,25937011.0,
3677,1204228,1,1,,103189534,4173,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 4 hrs relative to control",Other,25937011.0,
3678,1204230,1,1,,103189534,4173,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 24 hrs relative to control",Other,25937011.0,
3679,1204231,1,1,,103189534,4173,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg indomethacin mol equivalent, ip administered 1 hr prior to carrageenan challenge measured at 3 hrs relative to indomethacin",Other,25937011.0,
3680,1204232,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in albino mouse assessed as appearance of toxic symptoms at 50 to 100 mg/kg indomethacin mol equivalent, ip measured after 24 hrs",Other,25937011.0,
3681,1204233,1,1,,103189534,4173,Unspecified,,,,,"Toxicity in albino mouse assessed as mortality at 50 to 100 mg/kg indomethacin mol equivalent, ip measured after 24 hrs",Other,25937011.0,
3682,1204234,1,1,,103189534,4173,Unspecified,,,,,"Ulcerogenic activity in Wistar rat assessed as ulcer index at 10 mg/kg indomethacin mol equivalent, po administered 3 days relative to control",Other,25937011.0,
3683,1207750,1,1,,103189534,4173,Unspecified,,,177.9,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
3684,1224824,1,1,,174006204,4173,Inactive,,,0.3317,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
3685,1224825,1,1,,174006204,4173,Inactive,,,33.1734,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
3686,1224834,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3687,1224834,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3688,1224834,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3689,1224835,1,1,,144209611,4173,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3690,1224835,1,1,,144213111,4173,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3691,1224835,1,1,,170464948,4173,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3692,1224836,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3693,1224836,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3694,1224836,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3695,1224837,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3696,1224837,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3697,1224837,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3698,1224838,1,1,,144209611,4173,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3699,1224838,1,1,,144213111,4173,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3700,1224838,1,1,,170464948,4173,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3701,1224839,1,1,,144209611,4173,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3702,1224839,1,1,,144213111,4173,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3703,1224839,1,1,,170464948,4173,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3704,1224840,3,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3705,1224840,3,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3706,1224840,3,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3707,1224841,3,1,,144209611,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3708,1224841,3,1,,144213111,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3709,1224841,3,1,,170464948,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3710,1224842,3,1,,144209611,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3711,1224842,3,1,,144213111,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3712,1224842,3,1,,170464948,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3713,1224843,1,1,,144209611,4173,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3714,1224843,1,1,,144213111,4173,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3715,1224843,1,1,,170464948,4173,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3716,1224844,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3717,1224844,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3718,1224844,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3719,1224845,1,1,,144209611,4173,Inconclusive,344243002.0,100757539.0,130.666,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3720,1224845,1,1,,144213111,4173,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3721,1224845,1,1,,170464948,4173,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3722,1224846,1,1,,144209611,4173,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3723,1224846,1,1,,144213111,4173,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3724,1224846,1,1,,170464948,4173,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3725,1224847,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3726,1224847,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3727,1224847,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3728,1224848,3,1,,144209611,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3729,1224848,3,1,,144213111,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3730,1224848,3,1,,170464948,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3731,1224849,3,1,,144209611,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3732,1224849,3,1,,144213111,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3733,1224849,3,1,,170464948,4173,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3734,1224857,2,1,,170464948,4173,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3735,1224857,2,1,,174006204,4173,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3736,1224859,2,1,,170464948,4173,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3737,1224859,2,1,,174006204,4173,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3738,1224863,1,1,,176484410,4173,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3739,1224863,1,1,,316920395,4173,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3740,1224864,1,2,,316935128,4173,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
3741,1224865,1,2,,855672,4173,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3742,1224867,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3743,1224867,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3744,1224867,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3745,1224868,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3746,1224868,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3747,1224868,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3748,1224869,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3749,1224869,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3750,1224869,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3751,1224870,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3752,1224870,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3753,1224870,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3754,1224871,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3755,1224871,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3756,1224871,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3757,1224872,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3758,1224872,1,1,,144213111,4173,Inconclusive,,,54.9477,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3759,1224872,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3760,1224873,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3761,1224873,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3762,1224873,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3763,1224874,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3764,1224874,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3765,1224874,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3766,1224875,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3767,1224875,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3768,1224875,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3769,1224876,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3770,1224876,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3771,1224876,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3772,1224877,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3773,1224877,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3774,1224877,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3775,1224878,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3776,1224878,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3777,1224878,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3778,1224879,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3779,1224879,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3780,1224879,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3781,1224880,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3782,1224880,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3783,1224880,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3784,1224881,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3785,1224881,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3786,1224881,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3787,1224882,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3788,1224882,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3789,1224882,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3790,1224883,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3791,1224883,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3792,1224883,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3793,1224884,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3794,1224884,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3795,1224884,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3796,1224885,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3797,1224885,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3798,1224885,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3799,1224886,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3800,1224886,1,1,,144213111,4173,Inconclusive,,,48.9722,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3801,1224886,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3802,1224887,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3803,1224887,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3804,1224887,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3805,1224888,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3806,1224888,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3807,1224888,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3808,1224889,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3809,1224889,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3810,1224889,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3811,1224890,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3812,1224890,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3813,1224890,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3814,1224892,1,1,,144209611,4173,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3815,1224892,1,1,,144213111,4173,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3816,1224892,1,1,,170464948,4173,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3817,1224893,1,1,,144209611,4173,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3818,1224893,1,1,,144213111,4173,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3819,1224893,1,1,,170464948,4173,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3820,1224894,1,1,,144209611,4173,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3821,1224894,1,1,,144213111,4173,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3822,1224894,1,1,,170464948,4173,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3823,1224895,1,1,,144209611,4173,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3824,1224895,1,1,,144213111,4173,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3825,1224895,1,1,,170464948,4173,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3826,1224896,1,1,,144209611,4173,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3827,1224896,1,1,,144213111,4173,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3828,1224896,1,1,,170464948,4173,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3829,1224905,2,1,,92309035,4173,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3830,1224905,2,1,,92309035,4173,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3831,1225671,1,1,,103189534,4173,Active,,,4.16,IC50,Trichomonicidal activity against Trichomonas vaginalis JH31A#4 trophozite assessed as inhibition of parasite growth after 24 hrs by resazurin redox dye based fluorimetric microtiter method,Confirmatory,25771033.0,
3832,1225673,1,1,,103189534,4173,Unspecified,,,,,Trichomonicidal activity against Trichomonas vaginalis JH31A#4 trophozite assessed as inhibition of parasite growth at 300 uM after 24 hrs by resazurin redox dye based fluorimetric microtiter method,Other,25771033.0,
3833,1225674,1,1,,103189534,4173,Unspecified,,,,,Trichomonicidal activity against Trichomonas vaginalis JH31A#4 trophozite assessed as inhibition of parasite growth at 150 uM after 24 hrs by resazurin redox dye based fluorimetric microtiter method,Other,25771033.0,
3834,1225675,1,1,,103189534,4173,Unspecified,,,,,Trichomonicidal activity against Trichomonas vaginalis JH31A#4 trophozite assessed as inhibition of parasite growth at 75 uM after 24 hrs by resazurin redox dye based fluorimetric microtiter method,Other,25771033.0,
3835,1225676,1,1,,103189534,4173,Unspecified,,,,,Trichomonicidal activity against Trichomonas vaginalis JH31A#4 trophozite assessed as inhibition of parasite growth at 37.5 uM after 24 hrs by resazurin redox dye based fluorimetric microtiter method,Other,25771033.0,
3836,1225677,1,1,,103189534,4173,Unspecified,,,,,Trichomonicidal activity against Trichomonas vaginalis JH31A#4 trophozite assessed as inhibition of parasite growth at 18.75 uM after 24 hrs by resazurin redox dye based fluorimetric microtiter method,Other,25771033.0,
3837,1225678,1,1,,103189534,4173,Unspecified,,,,,Trichomonicidal activity against Trichomonas vaginalis JH31A#4 trophozite assessed as inhibition of parasite growth at 9.37 uM after 24 hrs by resazurin redox dye based fluorimetric microtiter method,Other,25771033.0,
3838,1225679,1,1,,103189534,4173,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells at 300 uM after 24 hrs by resazurin redox dye based fluorimetric microtiter method,Other,25771033.0,
3839,1225680,1,1,,103189534,4173,Unspecified,,,600.0,CC50,Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth after 24 hrs by resazurin redox dye based fluorimetric microtiter method,Confirmatory,25771033.0,
3840,1225681,1,1,,103189534,4173,Unspecified,,,,,"Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Trichomonas vaginalis JH31A#4 trophozite",Other,25771033.0,
3841,1225684,1,1,,103189534,4173,Unspecified,,,,,"Trichomonicidal activity against Trichomonas vaginalis C-1:NIH trophozoites infected in NMRI mouse assessed as reduction of pathogenicity at 25 mg/kg/day, po administered for 7 days from day 3 to day 10 post-infection measured at day 15 post-infection",Other,25771033.0,
3842,1227231,1,1,,103189534,4173,Unspecified,,,,,Antimicrobial activity against metronidazole-resistant Clostridium difficile,Other,25993059.0,
3843,1231110,1,1,,103189534,4173,Active,,,6.8,IC50,Amoebicidal activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS assessed as growth inhibition after 72 hrs by carboxyfluorescein diacetate/propidium iodide staining-based fluorescence microscopic analysis,Confirmatory,,
3844,1240190,1,1,,103189534,4173,Active,,,1.81,IC50,Antiamoebic activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution method,Confirmatory,26174554.0,
3845,1244338,1,1,,103189534,4173,Inconclusive,,,,,Inhibition of HIV1 reverse transcriptase at 100 ug/ml incubated for 1 hr by ELISA method,Other,26209833.0,
3846,1244339,1,1,,103189534,4173,Inconclusive,,,,,Spermicidal activity in liquefied human semen assessed as reduction in motile spermatozoa incubated at 37 degC for 30 mins,Other,26209833.0,
3847,1244340,1,1,,103189534,4173,Active,,,,,Anti-trichomonas activity against MTZ-susceptible Trichomonas vaginalis incubated for 3 to 48 hrs by trypan blue exclusion assay,Other,26209833.0,
3848,1244341,1,1,,103189534,4173,Unspecified,,,,,Anti-trichomonas activity against MTZ-resistant Trichomonas vaginalis incubated for 3 to 48 hrs by trypan blue exclusion assay,Other,26209833.0,
3849,1244350,1,1,,103189534,4173,Unspecified,,,,,"Resistance index, ratio of MIC for MTZ-resistant Trichomonas vaginalis to MIC for MTZ-susceptible Trichomonas vaginalis",Other,26209833.0,
3850,1254732,1,1,,103189534,4173,Active,,,,,Antitrichomonal activity against Trichomonas vaginalis after 48 hrs by invert microscope analysis,Other,26099536.0,
3851,1259241,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3852,1259241,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3853,1259241,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3854,1259242,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3855,1259242,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3856,1259242,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3857,1259243,1,1,,144209611,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3858,1259243,1,1,,144213111,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3859,1259243,1,1,,170464948,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3860,1259244,1,1,,144209611,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3861,1259244,1,1,,144213111,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3862,1259244,1,1,,170464948,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3863,1259247,1,1,,144209611,4173,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3864,1259247,1,1,,144213111,4173,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3865,1259247,1,1,,170464948,4173,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3866,1259248,1,1,,144209611,4173,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3867,1259248,1,1,,144213111,4173,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3868,1259248,1,1,,170464948,4173,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3869,1259251,1,1,,46386860,4173,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of Unc-51 Like Autophagy Activating Kinase 1 (ULK1).,Screening,,
3870,1259252,1,1,,174006204,4173,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3871,1259253,1,1,,174006204,4173,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3872,1259255,1,1,,174006204,4173,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3873,1259256,1,1,,174006204,4173,Inactive,169655958.0,,0.1049,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3874,1259309,1,1,,178127229,4173,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3875,1259310,1,1,,46386860,4173,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3876,1259310,1,1,,332876141,4173,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3877,1259310,1,1,,332876142,4173,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3878,1259311,1,1,,178127229,4173,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3879,1259313,1,1,,855672,4173,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3880,1259318,1,1,,855672,4173,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3881,1259325,1,2,,336954321,4173,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3882,1259344,1,1,,144203992,4173,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3883,1259355,1,1,,26746949,4173,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3884,1259356,1,1,,144203992,4173,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3885,1259364,1,1,,144209611,4173,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3886,1259364,1,1,,144213111,4173,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3887,1259364,1,1,,170464948,4173,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3888,1259365,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3889,1259365,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3890,1259365,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3891,1259366,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3892,1259366,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3893,1259366,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3894,1259367,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3895,1259367,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3896,1259367,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3897,1259368,1,1,,144209611,4173,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3898,1259368,1,1,,144213111,4173,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3899,1259368,1,1,,170464948,4173,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3900,1259369,1,1,,144209611,4173,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3901,1259369,1,1,,144213111,4173,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3902,1259369,1,1,,170464948,4173,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3903,1259377,1,1,,144209611,4173,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3904,1259377,1,1,,144213111,4173,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3905,1259377,1,1,,170464948,4173,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3906,1259378,1,1,,144209611,4173,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3907,1259378,1,1,,144213111,4173,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3908,1259378,1,1,,170464948,4173,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3909,1259379,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3910,1259379,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3911,1259379,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3912,1259380,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3913,1259380,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3914,1259380,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3915,1259381,1,1,,144209611,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3916,1259381,1,1,,144213111,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3917,1259381,1,1,,170464948,4173,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3918,1259382,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3919,1259382,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3920,1259382,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3921,1259383,1,1,,144209611,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3922,1259383,1,1,,144213111,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3923,1259383,1,1,,170464948,4173,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3924,1259384,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3925,1259384,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3926,1259384,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3927,1259385,1,1,,144209611,4173,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3928,1259385,1,1,,144213111,4173,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3929,1259385,1,1,,170464948,4173,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3930,1259386,1,1,,144209611,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3931,1259386,1,1,,144213111,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3932,1259386,1,1,,170464948,4173,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3933,1259387,1,1,,144209611,4173,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3934,1259387,1,1,,144213111,4173,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3935,1259387,1,1,,170464948,4173,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3936,1259388,1,1,,144209611,4173,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3937,1259388,1,1,,144213111,4173,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3938,1259388,1,1,,170464948,4173,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3939,1259389,1,1,,124637836,4173,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3940,1259390,1,1,,144209611,4173,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3941,1259390,1,1,,144213111,4173,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3942,1259390,1,1,,170464948,4173,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3943,1259391,1,1,,144209611,4173,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3944,1259391,1,1,,144213111,4173,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3945,1259391,1,1,,170464948,4173,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3946,1259392,1,1,,144209611,4173,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3947,1259392,1,1,,144213111,4173,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3948,1259392,1,1,,170464948,4173,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3949,1259393,1,1,,144209611,4173,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3950,1259393,1,1,,144213111,4173,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3951,1259393,1,1,,170464948,4173,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3952,1259394,1,1,,144209611,4173,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3953,1259394,1,1,,144213111,4173,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3954,1259394,1,1,,170464948,4173,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3955,1259395,1,1,,144209611,4173,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3956,1259395,1,1,,144213111,4173,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3957,1259395,1,1,,170464948,4173,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3958,1259396,1,1,,144209611,4173,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3959,1259396,1,1,,144213111,4173,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3960,1259396,1,1,,170464948,4173,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3961,1259400,1,1,,170464948,4173,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3962,1259401,1,1,,144209611,4173,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3963,1259401,1,1,,144213111,4173,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3964,1259401,1,1,,170464948,4173,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3965,1259402,1,1,,144209611,4173,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3966,1259402,1,1,,144213111,4173,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3967,1259402,1,1,,170464948,4173,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3968,1259403,1,1,,144209611,4173,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3969,1259403,1,1,,144213111,4173,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3970,1259403,1,1,,170464948,4173,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3971,1259404,1,1,,144209611,4173,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3972,1259404,1,1,,144213111,4173,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3973,1259404,1,1,,170464948,4173,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3974,1259407,1,1,,363898360,4173,Active,,,,,CCRIS mutagenicity studies,Other,,
3975,1259408,1,1,,363895615,4173,Active,,,,,GENE-TOX mutagenicity studies,Other,,
3976,1259410,1,1,,363898360,4173,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
3977,1259411,1,1,,363898360,4173,Active,,,,,CCRIS carcinogenicity studies,Other,,
3978,1259413,1,2,,46386860,4173,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
3979,1259415,1,1,,855672,4173,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3980,1259416,1,2,,144089065,4173,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3981,1259416,1,2,,340080243,4173,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3982,1259416,1,2,,375174900,4173,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3983,1259421,1,1,,340080243,4173,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3984,1259421,1,1,,375174900,4173,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3985,1259423,1,2,,354765876,4173,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3986,1259423,1,2,,354768674,4173,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3987,1259423,1,2,,354921902,4173,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3988,1259423,1,2,,354927675,4173,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3989,1259423,1,2,,354978365,4173,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
